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ABSTRACT 
 
Katy M. Brown: Methods for Surveillance of Antimicrobial Resistant Bacteria in Environmental Water and 
Wastewater 
(Under the direction of Mark D. Sobsey) 
 
The rise of antibiotic resistant bacteria (ARB) exacerbates the global spread and burden of 
infectious disease. There are no harmonized efforts for ARB surveillance and response. This study 
investigated the development of a culture-based indicator system for the direct detection and 
quantification of Extended-spectrum-β-lactamase (ESBL) and carbapenemase (KPC) producing 
Enterobacteriaceae in exposure-relevant environmental sites including hospital and domestic sewage, 
treated effluent, and surface waters. This was done by performing parallel assays using agar media 
supplemented with antibiotics, then analyzing the clinical media’s performances via concentrations and 
proportions of ESBL-and KPC-producing target organisms found at all sample sites, and then confirming 
resistance profiles and identities of resulting isolates. The performance of the clinical medium was 
comparable to the gold standard for detection indicator organisms in all samples, excepting E. coli in raw 
sewage and surface waters. This indicator system shows promise, but more work must be done towards 
its iterative improvement.  
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CHAPTER 1: OVERVIEW 
 
Background 
Researchers have documented dramatic increases in the occurrence and types of antimicrobial 
resistance (AMR) worldwide. AMR is found globally, threatening the prevention and treatment of 
infectious diseases despite great advances in diagnostic and therapeutic interventions based on the use 
of antimicrobials (AMs). There are few new antimicrobial treatments in development and present use is, 
in many countries, excessive and indiscriminate. Without a coordinated response across the fields of 
medicine, agriculture, and environmental sciences, we may be on the brink of a “post-antibiotic” era1. 
Protecting the efficacy of present antibiotics is especially important, as their loss due to AMR may reverse 
seventy-five years of medical, agricultural, social, and economic progress made as a direct result of the 
advent of penicillin and subsequent antimicrobials2. However, strategic and effective interventions cannot 
be carried out until more is known about the magnitude, spread, and evolution of present AMR types, 
sources, and pathways. 
Antimicrobials can be naturally or synthetically derived and are divided into two main categories: 
(1) those used in vivo for chemotherapeutic purposes, and (2) those used externally or for the 
decontamination of non-living material, such as sterilants, disinfectants, sanitizers, and antiseptics. Before 
the application of the former, abatement of infectious disease depended on the latter. An established 
infection could be deadly, as chemicals designed for external use were often too toxic for internal use, 
limiting treatment to little more than a guessing game of poultices, herbs, and amputations.  
Modern antimicrobials are designed to target and hinder the intrinsic functionalities and persistence 
of an infectious agent without harming the host. Broadly, this can occur via inhibition or alteration of 
basic biological and biochemical processes that affect, and thereby deter, the development and 
replication of an infectious organism. Careful decisions must be made by the clinician prior to 
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administration of treatment, as the targets, formulation, and modality of many drugs is organism-
dependent 3. 
Chemotherapies for the treatment of parasitic, fungal, or viral infections are complex and difficult 
to develop, as eukaryotic pathogens have similar cell structure to humans and viruses utilize human cells 
for reproduction. Antibiotics tend to target the differences in prokaryotic cellular composition and 
function, such as the peptidoglycan wall found in bacteria and not in humans, as a mode of action to 
inhibit growth and trigger apoptosis. When the aforementioned drugs fail to eradicate the infection after 
being used at an established, optimal inhibitory levels, the causative microbe is considered to be resistant 
to treatment 4.  
The global emergence and spread of AMR hinders the prevention and treatment of many important 
infectious diseases. First-line chemotherapies for HIV are progressively becoming ineffective due to 
burgeoning anti-viral resistance 1. Increasing resistance to artemisinin-based combination antimalarial 
therapies may have “disastrous” impact on global malaria control and place 3.2 billion people at risk of 
infection, illness, and further transmission 5. Complications from invasive antifungal resistant infections 
are increasing sequelae and mortality rates in patients with serious underlying diseases 6. Multi-drug 
resistant tuberculosis infections have also risen, with 480,000 infections and 210,000 deaths in 2013 1. 
There are presently no globally coordinated efforts for AMR surveillance, response, and prevention. 
Surveillance is often relegated to academic research or accidental discovery, post-clinical analysis of 
specimens from critically ill patients, and healthcare based monitoring of patients and their antimicrobial 
resistant bacteria. This lack of coordinated surveillance globally perpetuates continued ignorance of the 
actual scope of AMR and hinders the development, application, and enforcement of strategic response 
and prevention efforts. In 2014, the World Health Organization (WHO) released a report calling for united 
action to combat AMR, with strong emphases on addressing the importance of antibiotic resistant 
bacteria (ARB)1.  
There is growing concern regarding the high levels of resistance in bacteria that cause common 
infections like pneumonia, gastroenteritis, uremia, and septicemia 7–9. Alexander Fleming observed and 
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noted resistance in Gram-negative bacteria during initial experiments with penicillin 10. Since then, there 
has been extensive documentation and research on resistance. However, little is actually known about 
the magnitude, global landscape, and trends of ABR due to the lack of harmonized and coordinated data 
on the complexity and multidimensionality of associated resistance mechanisms, selection pressures, 
transmission pathways, and spread. 
Resistance mechanisms can co-occur and are chromosomally or plasmid mediated, depending on 
both the antimicrobial agent and the organism. Bacterial strains that genetically encode a particular 
resistance trait are said to have intrinsic resistance. Acquired resistance occurs when a mutation or 
horizontal gene acquisition alters the genome of selected isolates or groups of bacteria11. Antibiotic 
resistance genes (ARG) can be transferred between species, genera, and even families by different 
mechanisms, such as R-plasmid transfer via conjugation 12. These common and widespread horizontal 
gene-transfer processes are instrumental in the emergence and spread of multi-drug resistance.  
Many antibiotics work by entering the cell and inhibiting essential processes via binding to the cell 
wall or to key enzymes and target sites on the ribosome. An example of intrinsic resistance would be 
natural impermeability to certain antibiotics (e.g. Gram-negative bacteria and penicillin) or lacking the 
structure that the antibiotic inhibits (e.g. the absence of a typical cell wall in mycoplasma bacteria). If a 
bacterial strain is usually susceptible to an antibiotic and a mutation occurs that alters a target site, the 
bacteria has acquired resistance that results in the decreased affinity for the antibiotic and thus, its 
inability to bind and act. 
Bacteria can also develop biochemical resistance pathways that overcome an antimicrobial’s action, 
such as circumventing a growth analog by utilizing an exogenous growth factor. Efflux pumps, or 
transport proteins that facilitate the excretion or elimination of toxic substrates from within the cell to the 
environment, can make an organism resistant by simply pumping the antibiotic out. An ever-evolving 
resistance mechanism is the production of enzymes capable of inactivating a drug, such as hydrolysis of 
the β-lactam ring of an antimicrobial by β-lactamases. Thousands of these enzymes have been identified, 
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many conferring multi-drug resistance 3,4,13. All of the above can co-occur, evolve and be transferred, 
depending on the organism and its environment.  
Selection pressures, both environmental and anthropogenic, significantly influence the emergence, 
spread, and transfer ARB and ARG 11. Environmental stressors, such as exposure to antibiotics and 
chemical pollutants, mobilize ARGs14. Excessive and indiscriminant use of antibiotics in medicine, 
agriculture (specifically, animal production and aquaponics), and households are significant 
anthropogenic selection pressures. Medical sectors are frequently blamed for the rise in antibiotic 
resistance, as health care facilities are, by nature, reservoirs of infectious disease and pharmaceutical use 
resulting in release11,15,16. However, agriculture and veterinary sectors are also to blame, as antibiotics are 
used extensively in food animal production and aquaculture for continued prevention of disease as well 
as for growth promotion 17.  
Antibiotics, ARB, and ARG are released into the environment and bacterial ecosystem via human 
sewage (treated and untreated), animal manure, and industrial wastes 18. A feedback loop is created that 
selects for and sustains ARB strains. If these strains are located in an exposure relevant reservoir, they 
can spread to humans and animals. Non-pathogenic bacteria can also serve a reservoir for ARG and 
contribute to transfer of resistance 11. ARB infections develop, spread to others, persist, and then are 
treated with broader spectra of antimicrobial medication. The ARB, ARG, and antibiotic residue are then 
re-introduced back into the environment once excreted. These strains are then spread via several 
different pathways, including exposures from water, sanitation, and hygiene (WaSH) pathways, food 
consumption, international travel, poor domestic waste water treatment, land application of manure, and 
so on 13,14,17. 
The large knowledge gaps about ARB hinder the development of comprehensive and strategic 
action plans. There are few actors with both the understanding and agency to implement such 
strategies19. Choosing and analyzing antimicrobial agents and the effects of their use in humans and 
animals on antimicrobial susceptibility as determined by testing are foundational to clinical diagnostic 
microbiology. If we are to approach this as a One Health problem, more work should be done to 
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integrate monitoring of exposure-relevant environmental sites for comprehensive surveillance. Extensive 
work has been done to standardize antimicrobial susceptibility testing methods for the selection of the 
most appropriate chemotherapeutic agent and to improve the clinical predictive value of the results 20,21. 
However, these thresholds are for the determination of optimal clinical treatment, not optimal treatment 
and management of waste waters or to determine the relative magnitude of ARB in the environment, 
especially in exposure-relevant pathways22. There are a wide range of monitoring and surveillance 
methods for the detection and quantification of antibiotic resistance in the environment23, but many are 
too capacity requiring, intensive, and complex for lower-resource areas, limiting their uptake for 
standardized and harmonized global surveillance19,24.  
In an effort to address this need, this Masters project focused on the evaluation of a prototype 
method for the direct, one-step, culture-based detection of ARB in representative waste waters and 
environmental samples of interest using an indicator system proposed by the World Health Organization. 
This was done by evaluating the direct detection and enumeration of standard chromogenic clinical 
agar media to determine the presence, concentration, and relative proportions of presumptive 
Extended Spectrum β-lactamase (ESBL) producing and presumptive carbapenemase producing 
(carbapenem resistant Enterobacteriaceae, CRE) E. coli and other coliforms in representative waste 
waters and environmental surface waters in Chapel Hill, NC. The identities and antimicrobial resistance 
properties of presumptive isolates of these target bacteria were further confirmed by further 
phenotypic and molecular analyses to determine the percentages of them correctly identified.  
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Project Objectives: 
The goal of this research was to evaluate candidate indicators and methods for surveillance of 
antibiotic resistant bacteria in water and wastewaters with an emphasis on a culture-based indicator 
system for the enumeration of ESBL and KPC (CRE) Escherichia coli and other coliform bacteria. This goal 
was achieved by conducting field and lab-based studies designed to accomplish the following five project 
objectives. 
Table 1.1 - Objective 1 
Objective 1: Evaluate the performance of a chromogenic substrate standard clinical agar medium 
for use in the direct detection and enumeration of E. coli and coliforms as fecal indicator bacteria in 
representative waste waters and surface waters by comparing it to the performance of a “gold 
standard” chromogenic substrate agar medium for the direct detection and enumeration of E. coli 
and coliforms in environmental water, wastewater and other matrices. 
Application 
Repeated, parallel assays of representative environmental and waste water 
samples were performed using procedures of EPA Method 1604 for membrane 
filtration followed by culturing on CHROMagar Orientation (clinical) agar medium 
and Bio-Rad Rapid'E.coli 2 (gold standard) agar medium. Following incubation, 
presumptive colonies of E. coli and coliforms detected by each medium were 
enumerated using manufactures’ guides. E. coli and coliform concentrations were 
calculated as CFU/100 mL 
Output 
Presumptive E. coli and coliform concentrations from repeated, parallel assays of 
the same representative waste water and surface water samples, one data set 
for CHROMagar Orientation agar and one data set for Bio-Rad Rapid’E. coli 2 
agar. 
Analysis 
Use a paired Wilcoxon signed-rank test to evaluate the performance of the 
clinical medium (Orientation) against the detection performance of the “gold 
standard”, environmental medium (Bio-Rad Rapid’E. coli 2 agar) by comparing 
concentrations that are paired by date, sample site, and organism. 
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Performance 
Criteria 
Null Hypothesis: The median difference between the two pairs of observations 
(CHROMagar Orientation agar concentration versus Bio-Rad Rapid’E. coli 2 agar 
concentrations) is close to or equal to zero. Alternative Hypothesis: The median 
difference between the two paired observations is significantly greater or less 
than 0 with significance at α = 0.05. 
 
P< 0.05 indicates, with 95% CI, that the performance of the clinical medium is 
not comparable to the “gold standard” medium and not appropriate for use in 
the direct detection and enumeration of E. coli and coliforms as fecal indicator 
bacteria in waste water and environmental surface water matrices.  
 
P>0.05 indicates, with a 95% confidence, that the performance of the clinical 
medium is comparable to the “gold standard” environmental medium and 
capable of use in the direct detection and enumeration of E. coli and coliforms as 
fecal indicator bacteria in waste water and environmental surface water 
matrices. 
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Table 1.2 - Objective 2 
Objective 2: Determine the presence, concentration, and relative proportion of presumptive 
Extended Spectrum β-lactamase (ESBL) producing E. coli and coliforms as well as presumptive 
carbapenemase (KPC) producing E. coli and coliforms (carbapenem resistant Enterobacteriaceae or 
CRE) in representative waste waters and environmental surface waters in Chapel Hill, NC, compared 
to the total number of E. coli and coliforms present in the samples analyzed. 
Application 
Repeated and often parallel assays of representative waste water and 
environmental surface water samples were performed using the procedures of 
EPA Method 1604 for membrane filtration followed by plating on CHROMagar 
ESBL and KPC agar media. These assays were done in parallel with plating the 
same samples on the aforementioned Bio-Rad Rapid’E. coli 2 agar/CHROMagar 
Orientation agar assays to determine percentages of totals that are resistant.  
 
Following incubation, presumptive colonies of E. coli and coliforms were 
enumerated using manufacturers’ guides for colony color and appearance. 
Presumptive positives on the ESBL and carbapenem (KPC) media are presumed 
to express the resistance property of the culture medium on which they were 
detected. Concentrations of E. coli and coliform presumed to be ESBL positive 
and concentrations of E. coli and coliforms presumed to be KPC positive were 
calculated and expressed as in CFU/100 mL. 
Output 
A dataset was obtained for presumptive ESBL positive E. coli and coliform 
concentrations from repeated, parallel assays of representative waste water and 
environmental surface water samples.  
 
A dataset was obtained for presumptive KPC positive E. coli and coliform 
concentrations from repeated, parallel assays of representative waste water and 
environmental surface water samples.  
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Analysis 
Proportions of presumptive ESBL and KPC producing bacteria relative to total E. coli 
and coliform concentrations were calculated for each resistance type, per sample, 
per target organism (E. coli and other coliforms) and per collection event relative 
to total E. coli and coliforms enumerated in the same samples. This was done by 
dividing the resulting concentrations of presumptive ESBL and KPC positive 
organisms (ESBL coliform, ESBL E. coli, KPC coliform, or KPC E. coli ) by the 
concentrations of the same organisms (E. coli and coliforms) plated in the parallel 
on Bio-Rad Rapid’E. coli 2 medium for total concentrations of E. coli and coliforms.  
 
Use a paired Wilcoxon signed-rank test to evaluate the difference in resistance 
profiles within each site and amongst other sites. This was performed by 
comparing the proportions of presumptive ESBL and KPC positive organisms within 
the same site. Then, average proportions of each resistance type and organism 
were evaluated between paired sites (e.g. Raw Sewage and Secondary Effluent 
proportions of ESBL or KPC positive E. coli). When three or more sites were 
compared, a Kruskal-Wallis one-way analysis of variance was performed.  
 
Performance 
Criteria 
Null Hypothesis: The median difference between the two pairs of observations is 
equal to zero. Alternative Hypothesis: The median difference between the two 
paired observations is greater or less than 0. (α = 0.05)   
 
For Wilcoxon signed ranked tests, a P< 0.05 indicates, with 95% CI, that there is 
a significant difference between the medians of the two paired observations. 
P>0.05 indicates, with a 95% CI, that there is not a significant difference 
between the observed proportions. With Kruskal-Wallis test, a P>0.05 indicates 
that there is not a significant difference between the group means. A P<0.05, 
indicates that there is a significant difference and necessitates a post-test, done 
using Dunn’s test, to evaluate which of the observations created the significant 
difference in the pooled rankings.  
 
 
 
 
10 
 
Table 1.3 - Objective 3 
Objective 3: Evaluate and attempt to validate the performance of CHROMagar ESBL agar medium 
for the direct detection and enumeration of Extended Spectrum β-lactam resistant E. coli and 
coliforms in representative waste water and environmental surface water sample as a component of 
a potential indicator system for the surveillance of ESBL production in presumptive E. coli and 
coliform isolates from samples of wastewater and environmental surface water matrices. 
Application 
Repeated assays of representative environmental and waste water samples were 
performed using the procedures of EPA Method 1604 for membrane filtration on 
CHROMagar ESBL medium. Following incubation, representative colonies of E. 
coli and coliforms were selected, purified, isolated and the then frozen for future 
analysis.  
 
Output 
A bank of over 300 presumptive ESBL isolates of E. coli and coliform colonies, 
prepared and stored in duplicate, from representative waste water and 
environmental surface water samples were obtained for further analysis to 
determine species and phenotypic antimicrobial resistance.   
Analysis 
Frozen isolates of presumptive ESBL E. coli and coliforms were revived and 
subjected to VITEK 2 automated antimicrobial susceptibility testing in order 
evaluate and confirm reduced susceptibility to Extended Spectrum β-lactam 
antibiotics. MALDI-TOF MS was performed on these isolates for speciation as the 
basis for confirming the identities of presumptive ESBL E. coli and coliform isolates. 
Performance 
Criteria 
Rates of confirmed antimicrobial susceptibility profiles and speciation results were 
evaluated. These results provide the basis for an overall evaluation of the 
performance of CHROMagar ESBL agar medium for the direct culture-based 
detection and enumeration of ESBL E. coli and coliforms as fecal indicator 
bacteria in waste water and environmental surface water matrices 
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Table 1.4 - Objective 4 
Objective 4: Evaluate and attempt to validate the performance of CHROMagar KPC agar medium 
for the direct detection and enumeration of carbapenem resistant E. coli and coliforms in 
representative waste water and environmental surface water samples as a component of a potential 
indicator system for the surveillance of presumptive carbapenem resistant E. coli and coliforms 
detected in wastewater and environmental surface water matrices. 
Application 
Repeated and parallel assays of representative waste water and environmental 
water samples were performed using the procedures of EPA Method 1604 for 
membrane filtration on CHROMagar KPC medium. Following incubation, 
representative colonies of presumptive KPC E. coli and coliforms were selected 
and purified as isolates and then frozen for future analysis to determine species 
and antimicrobial resistance properties.  
 
Output 
A bank of over 300 presumptive E. coli and coliform KPC isolates, prepared and 
stored in duplicate, were obtained from representative wastewater and 
environmental water samples as purified colony isolates presumed to have 
carbapenem resistance traits 
Analysis 
Frozen presumptive KPC isolates will be revived and subjected to the Modified 
Hodge Test for antimicrobial susceptibility testing to phenotypically evaluate 
resistance profiles and thereby confirm KPC resistance. MALDI-TOF MS was 
performed on these isolates for speciation in order to confirm their presumptive 
identity. 
Performance 
Criteria 
Antimicrobial susceptibility and speciation results were to provide the basis for 
quantifying the relative specificity, sensitivity, positive predictive value and 
negative predictive value of the detection and quantification methods for KPC E. 
coli and coliforms. These results provide the basis for an overall evaluation of the 
performance of CHROMagar KPC agar medium for the direct culture-based 
detection and enumeration of E. coli and coliforms as fecal indicator bacteria in 
waste water and environmental water matrices. 
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Study Rationale and Design 
A major gap exists in the availability of documented performance evidence for the suitability and 
effectiveness of simple and practical culture-based analytical methods for the direct detection and 
quantification of antibiotic resistant bacteria outside of clinical settings and in the environment in 
particular. The World Health Organization and others have proposed the development of an indicator 
system for the detection of ARB in water, wastewater, and other environmental media 22,25,26. E. coli and 
coliforms are already widely accepted and used as bacterial indicators of water and was tewater to assess 
water- and waste-borne presence and exposures as human health risks. Therefore, the direct detection 
and quantification of key antimicrobial resistant members of this fecal indicator group, and specifically 
those having resistance due to Extended Spectrum-β-Lactamase (ESBL) activity and carbapenem 
resistance (called carbapenem resistant Enterobacteriaceae or CRE and also called Klebsiella Pneumoniae 
Carbapenemase (KPC)) have been suggested as candidates for such ARB analyses using standard 
chromogenic clinical diagnostic culture media. 
To address this need, an initial collaboration was formed between members of the Sobsey 
Environmental Microbiology Laboratory at UNC, the School of Family Medicine at the UNC Medical School, 
and the Department of Microbiology at the United National Autonomous University of Nicaragua-León. 
The team worked together to develop, use and evaluate a simple, culture-based method for the detection 
and enumeration of target ARBs of concern in environmental samples. Later, the collaboration expanded 
to include the Department of Pathology and Laboratory Medicine at the UNC School of Medicine, the 
College of Veterinary Medicine at North Carolina State University, and The University of Colorado at Fort 
Collins.  
Repeated, parallel assays involving direct, one-step membrane filtration of environmental 
samples onto chromogenic bacteriologic culture media described in Table 2.1. After incubation, samples 
were characterized via visual identification and counting of presumptive target organism colonies on agar 
media used during membrane filtration. The resulting assay data was analyzed and a dataset was created 
that included site-, event-, and organism-specific calculations and statistical analysis concerning the 
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presence, concentration, and relative proportion of presumptive target organisms. To better evaluate the 
performance of the original protocol, colonies of presumptive ESBL and KPC positive target organisms 
were selected, streaked to purification, and isolated. The presumptive resistance profiles and identities of 
these isolates were later confirmed. The result is a proof-of-concept prototype of a simple but effective 
monitoring method for the direct detection and enumeration of target gram-negative fecal indicator 
bacteria resistant to extended-β-lactams as well as reduced susceptibility to carbapenems in hotspot 
environmental samples of wastewater and water impacted by wastewater.  
Literature Review 
Present Policies and Practice of Antimicrobial Susceptibility Testing: 
Antibiosis, or the antagonistic relationship between two or more organisms that is ultimately 
deleterious to one, is a cornerstone of the field of microbiology. Pasteur, Koch, and Ehrlich laid the 
groundwork for present-day antimicrobial susceptibility testing (AST) by contributing methodologies 
associated with the study of antibiosis27. Consequently, AST predates the introduction of antibiotics, 
including the 1874 paper by Roberts describing how liquid media containing Penicillium glaucum curiously 
inhibits contamination by other bacteria28. Fleming later contributed to AST by developing two broth 
dilution techniques, one with turbidity and the other with pH as the determinant endpoints. These 
methods were the forerunner to modern minimum inhibitory concentration (MIC) methodologies, 
including agar diffusion methods later described by Schmith and Reymann in 1940, Vincent and Vincent 
in 1944, Mohs in 1945, Bondi in 1947, and Frank et al in 195029–33. These agar diffusion and agar dilution 
methods were effective but prone to error and cumbersome. Determining the MIC, or the lowest 
antibiotic concentration that prevents bacterial growth, was also very time-intensive. In the 1960s, critical 
concentration methods that separated organisms into resistant and susceptible categories were 
introduced, eventually being described as “breakpoint” techniques by Ericsson and Sherris in the 1970s34.  
During these nascent stages of AST, several variables that impact the replicability and performance of 
these techniques were documented. The WHO published a report in 1961 calling for standardization of 
AST methodology which subsequently led Bauer, Kirby, and others to create a globally implemented, 
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phenotypic AST method35,36. The Kirby Bauer disk-diffusion method was the basis for the formation of the 
National Committee for Clinical Laboratory Standards (NCCLS) in 1975. The NCCLS lead to the initiation 
of several other governing bodies focused on ATS standardization, including the Clinical Laboratory 
Standards Institute for AST in the Americas (CLSI) and the European Committee on AST (EUCAST) 27. 
These organizations, and others like them, are responsible for the harmonization of MIC breakpoints 
across their associated geographic region. Breakpoint guidelines change in response to both the 
advancement of diagnostics as well as epidemiological information. The guidelines from CLSI and 
EUCAST, in particular, are not always in agreement, leading to discordant diagnosis and treatment, even 
within the same hospital and veterinary systems 37,38. 
AST changed with the advent of genotypic approaches, ushering in the use and development of DNA-
based assays for the detection of bacterial resistance genes39. Previous phenotypic methods sometimes 
required multiple days and other tests to truly characterize the resistance profile of the isolate. Genotypic 
techniques promised rapid results, but with ongoing verification and validation came a better 
understanding of the relationship of genetics to antimicrobial susceptibility and its limitations for use in 
routine diagnostics. For instance, the presence of a resistance gene many not be indicative of resistant 
bacteria because the gene may not be expressed. However, validation and implementation of genotypic 
methods lead to the discovery of a new realm of microbial ecology in the Resistome40,41. Present 
exploration of the determinants, abundance, and diversity of environmental antimicrobial resistance has 
led to a better understanding of non-clinical transmission and spread of AMR and also progress towards 
the development of much needed new antimicrobials. The incorporation of genotypic techniques into 
clinical diagnostic practice is still limited in many areas, potentially due to the required expertise and cost 
required for implementation19.  
Despite these advancements in AST, there are no standardized methodologies or coordinated efforts 
for the surveillance of AMR in non-clinical “hotspots,” specifically the detection of ARB and ARG in 
exposure relevant, environmental compartments like wastewater treatment plants, pharmaceutical 
manufacturing effluents, and aquaculture and animal husbandry facilities 13. There have been efforts by 
EUCAST to incorporate and build epidemiological cutoffs (ECOFFs), which utilize epidemiologically based 
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data to determine breakpoints and not therapeutic efficiency. ECOFFs separate clinically relevant bacterial 
populations into those with acquired resistance mechanisms (non-wild-type) from the wild-type 
populations that have no resistance21. These criteria do not include potentially emergent pathogens or 
ARG reservoir bacteria, limiting their full application for surveillance of known environmental hotspots.  An 
accessible methodology is needed to give a more complete overview of the prevalence of resistance in 
environmental AMR hotpots, as they are critical control points for the reduction in emergence, spread, 
and transmission of infectious disease1,13,19.  
The Need for Standardized ARB Surveillance Systems:  
Monitoring and evaluation of environmental hotspots that promote, sustain, or spread ARB and 
ARG are crucial for resistance control. There are no globally standardized surveillance methods for the 
detection and quantification of ARB in environmental samples. There are no agreed and widely 
implemented epidemiological or microbiological methods, protocols, and performance standards. 
Consequently, there is limited information and understanding of population-based ARB-associated 
morbidity and mortality which, in turn, hinders analysis of economic and societal impacts of ABR and 
interventions. 
The 2014 WHO Antimicrobial Resistance Global Report on Surveillance states that ARB 
monitoring and evaluation are being performed in some national and regional surveillance networks but 
are very disparate, both in methodology and quality. In addition, only a few of the surveillance networks 
use the One Health approach, e.g. performing harmonized integrated surveillance of AMR in humans, 
food-producing animals, and food. Higher-income countries seem to have implemented AMR stewardship 
policies; however, they have used antibiotics extensively in multiple sectors since their advent and now 
require more sophisticated drugs, with broader spectrum of activity to treat even the most common 
infections. Lower- to middle-income countries, on the other hand, have not had wide-spread saturation 
for as long but are similar in the magnitude of ABR. This is a result of growing income, inadequate access 
to WaSH, poor waste treatment and disposal, overcrowding, and limited health-care infrastructure, which 
supports widespread self-prescribed use of antibiotics and spread of ARB. All of these factors then 
heighten the spread and evolution of resistance14,19.  
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There are huge knowledge gaps and strategic evaluations of resistance trends and 
determinations of efficacy of resistance containment activities seem impossible1. High-income countries 
have long-established systems for routine surveillance (of which some are coordinated regionally), but all 
are limited geographically. Lower- to middle-income countries may have some coordinated efforts, but 
they are underfunded and often focus on specific diseases. To contend with the substantive divide in 
laboratory capacity, funding, and access to infrastructure, WHO recommended a cultured-based indicator 
system based on the detection of clinically significant ARB with resistance profiles appropriate for 
incorporation in harmonized surveillance of environmental samples1.  
Nine bacteria of international concern were identified along with reason for their urgency. E. coli 
is of concern because of its resistance to third-generation cephalosporins, including resistance conferred 
by ESBLs and to fluoroquinolones. Klebsiella pneumonia is of concern due to its resistance to third-
generation cephalosporins, including resistance conferred by ESBLs, and to carbapenems. Staphylococcus 
aureus is resistant to β-lactam antibacterial drugs (methicillin, methicillin-resistant S. aureus [MRSA]). 
Streptococcus pneumonia is resistant or not susceptible to penicillin. Nontyphoidal Salmonella (NTS) and 
Shigella species are both resistant to fluoroquinolones. Neisseria gonorrhea was listed due to decreased 
susceptibility to third-generation cephalosporins1. 
Though VRE and MRSA are of high clinical importance, resistance conferred by production of 
ESBLs and resistance to carbapenems were chosen as priorities. Effective drugs still exist for the 
treatment of multi-drug resistant Gram-positive bacterial infections like VRE and MRSA. On the other 
hand, there has been limited pharmaceutical progress in the treatment of multi-drug resistant Gram-
negative bacterial infections. β-lactams are considered to be the “workhorse” of antimicrobials due to 
their wide use and efficacy in clinical and veterinary settings. Carbapenems are considered to be the 
chemotherapeutic of last resort for the treatment of Gram-negative infections. Routine detection of ESBL 
producing organisms of clinical significance in human-impacted environments is relatively expected, given 
the known prevalence, but changes in its magnitude could elucidate overall resistance trends 12,13. Routine 
detection of carbapenem resistant organisms of clinical significance in human-impacted environments, 
specifically drinking water sources, illustrates more dire AMR conditions requiring an urgent response 42,43. 
17 
 
Members of the Enterobacteriaceae family were suggested as indicator organisms. They are 
clinically and agriculturally relevant and have the following characteristics: thermotolerance, facultative 
anaerobic respiration, rod-shaped, Gram-negative, non-spore forming, and some that are lactose 
fermenting. These shared factors have defined the above as “fecal indicator” organisms and their 
detection is a widely used and promoted proxy to detect the presence of fecal contamination44. The 
combined coliform group includes E. coli and other coliforms (Klebsiella, Enterobacter, Citrobacter, 
Serratia). E. coli is largely fecal in origin and considered to be instrumental in community acquired 
infections16,45,46. Klebsiella (specifically K. pneumoniae) is associated with nosocomial infections 47–49. Both 
of these organisms are priority ESBL and carbapenemase producers and their detection is potentially 
illustrative of overall AMR emergence, trends, and spread 1,12,50.  
β-Lactam Antibiotics 
In the early 1900s, Paul Ehrlich developed both the concept of selective toxicity as well as the first 
effective treatment for syphilis from synthesized arsphenamine. In 1928, Alexander Fleming isolated the 
parent compound for the antibiotic penicillin after observing a zone of inhibition on a bacteria culture 
plate contaminated by Penicillium notatum. In 1935, Gerhard Domagk developed the first sulfa-drug from 
a synthetically derived dye that was shown to protect mice against systemic streptococcal infections. In 
1942, spurred by World War II, Ernst Chain and Howard Florey stabilized and then mass manufactured 
penicillin to treat bacterial infections in the British troops, subsequently releasing it to the general public, 
ushering in modern medical, agricultural, veterinary practice based in antibiotic therapy3,4.  
β-lactam antibiotics are the most important clinical antibiotics, as they are very highly selective and 
non-toxic to animal or human host cells. β-lactam antibiotics bind to transpeptidase enzyme, inhibiting 
the transpeptidation reaction essential to cell wall synthesis21. The cell wall continues to form, but is 
weaker due to a defective peptidoglycan backbone that would have been catalyzed by the bound, 
regulatory enzymes. The complex of antibiotic penicillin binding proteins (PBP) also catalyze the release 
of autolysins which digest the cell wall, ultimately causing the existing cell to self-degrade 3,4 
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The basic formulation of penicillin is a thiazolidine ring, a β-lactam ring and an acyl (R) side chain. 
Over time, this natural product has become a semi-synthesized formula, undergoing several, iterative 
biological and chemical alterations to increase its antimicrobial spectrum, make it more stable, and to 
improve its pharmacokinetics 3. In the 1950s, the original penicillin G was improved in order to contend 
with and treat infections caused by newly emergent penicillinase-producing staphylococci. This formula, 
however, was still unable to penetrate, and thus treat infections of Gram-negative rod-shaped bacteria. 
Ampicillin was then developed by adding an α-amino group into the benzyl chain to enhance activity 
against organisms such as E. coli. Since then, multiple, semi-synthetic β-lactam antibiotics have been 
developed and introduced such as cephalosporin, monobactams, and carbapenems, each designed with a 
broader spectrum of activity to contend with growing ABR in Gram-negative bacteria 4,51. 
Extended Spectrum β-Lactamase and Carbapenem Resistant Enterobacteriaceae  
Bacteria can become resistant to β-lactams via three general mechanisms: (1) blocking the 
interaction between the antibiotic and the target PBP, (2) altering the way in which the antibiotic binds to 
the PBP, and (3) inactivation of the antibiotics via hydrolysis by β-lactamases 3. The first mechanism only 
occurs in Gram-negative bacteria, particularly species that have an outer membrane covering the 
peptidoglycan layer, such as Pseudomonas. Antibiotics must pass through pores in the outer membrane 
of Gram-negative bacteria rods and any alteration to these pores may preclude penetration of the 
antibiotic, resulting in its exclusion. The second mechanism is mediated by the overproduction or 
acquisition of new PBP as well as point mutation or recombination of existing PBP. The third mechanism 
occurs via the plasmid-mediated or chromosomally mediated production enzymes that hydrolyze the 
antibiotics, inactivating it by opening the β-lactam ring 3,4,43.  
Extended-spectrum β-lactamases (ESBLs) confer resistance to most β-lactam antibiotics, including 
penicillins, cephalosporins, and monobactam aztreonam. Since their discovery in Greece in the 1960s, 
close to 1000 chromosomal- and plasmid-encoded β-lactamases have been identified. ESBLs are found 
exclusively in Gram-negative organisms, but are very heterogeneous including TEM, TEM-1, SHV, SHV-2, 
CTX-M, and OXA ESBL families43. ESBLs do not inhibit cephamycins and carbapenems and are susceptible 
to β-lactamase inhibitors such as clavulanate, sulbactam, and tazobactam. Consequently, oxyimino-β-
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lactam substrates, cephamycins and clavulanates are often used to test for the presence of resistance 
mechanisms. Identification of ESBLs can be difficult because their activity and resistance mechanisms are 
so heterogeneous. For instance, AmpC-type β-lactamases can provide oxyimino-β-lactam resistance, but 
are resistant to inhibition by clavulanate 52. 
The CLSI and EUCAST recommendations have changed substantially over the years to contend with 
better understanding of ESBL resistance mechanisms 53. The new MIC breakpoints for ESBL disk diffusion 
tests re-categorize organisms that were once defined as susceptible to intermediate or resistant20,21. A 
large number of studies have focused on the risk of transmission of ESBLs in and outside of hospital 
settings. In a 2009 multi-national survey of risk factors for community-acquired ESBL infections by Ben-
Ami et al 2009, 35% of specimens from 938 patients were found to produce ESBL, 30% of which had no 
recent exposure to clinical settings or treatment54. A large number of studies have gone on to document 
the presence of ESBL-producing Enterobacteriaceae in food55, surface water 45, and sewage 56.  
More recently discovered ESBLs have been shown to confer multi-drug resistance by exhibiting 
hydrolytic activity against most classes of β-lactams. Treatment with carbapenem produces the most 
effective morbidity and mortality related outcomes from these multi-drug resistant infections 43. 
Carbapenems are considered to be a last resort treatment for Gram-negative infections, as they retain 
activity against chromosomal cephalosporinases and ESBLs. The first carbapenem was introduced in the 
1980s and has since grown to include imimpenem, meropenem, doripenem, and ertapenem. Less than 
thirty years later, carbapenem-resistant Enterobacteriaceae (CRE) is now a growing global threat, with 
estimated risks from infection at 48-71% mortality rate 57. Carbapenemases are emerging resistance 
determinants for Gram-negative pathogens, mediating resistance to most carbapenems and other β-
lactam antibiotics. Carbapenemase production is distinct from other mechanisms of carbapenem 
resistance like impaired permeability due to porin mutations. In the past decade, several different kinds 
of acquired carbapenemases have been identified 58.  
Class A β-lactamases with carbapenemase activity encode resistance on both chromosomes and 
plasmids. The most clinically important Class A is the K. pneumoniae carbapenemase (KPC) group, as the 
enzymes reside on a transmissible plasmid, making it resistant to all β-lactam antibiotics. KPC-producing 
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Enterobacteriaceae were first reported in 2001 in North Carolina 59. Klebsiella can transmit KPC to other 
genera of bacteria, including Pseudomonas, Citrobacter, Salmonella, Serratia, and Enterbater spp 58. The 
susceptibility profile of KPC-producing bacteria is variable, as there are several variants of KPC, some that 
hydrolyze β-lactams at different rates60.  
Class D β-lactamases have a preferential ability to hydrolyze oxacillin, and are often referred to as 
OXA-type enzymes. OXA carbapenemases have been found in Enterobacteriaceae as well as in 
Acinetobacter baumannii. OXA carbapenemases in A. baumannii are completely resistant while those in 
Enterobacteriaceae have variable susceptibility 58. Class B β-lactamases (metallo-β-lactamases, MBLs) 
were discovered in Japan in 199161 and have since spread globally. The spread of this gene has been 
associated with nosocomial transmission and international travel58. Naturally occurring MBLs can be found 
in Aeromonas hydrophila, Chryseobacterium spp, and Stenotrophomonas maltophilia 13. Acquired MBLs 
can be transferable between both species and genera as the genes that reside on the large plasmids and 
encode on integrons58. More recently, the New Delhi MBL (NDM-1) was discovered and may be 
potentially worse and more unpredictable than KPC, raising more alarm in the evolution of resistance 
determinants12. The blaNDM-1 gene can occur in many unrelated species and is spread around the 
environment. It also has been shown to be frequently acquired by K. pneumoniae and E. coli, specifically 
in strains known to cause community-acquired infections60. In a 2011 study by Walsh et al, NDM-1 
producing bacteria were found in tap and environmental water in New Delhi62.  
Accurately identifying CRE in clinical laboratories has proven difficult, as some KPC-producing isolates 
have carbapenem MICs that stay in the susceptible range 63. In 2010, CLSI revaluated the carbapenem 
breakpoints for Enterobacteriaceae and recommended lowering them 20. There has been debate 
regarding the suitability of CLSI standards and breakpoints for use in environmental analysis, as they are 
formulated around optimal chemotherapeutical levels, not transmission in environmental matrices 22. The 
modified Hodge test has been used to phenotypically detect KPC activity by evaluating the reduced 
susceptibility of a lawn of a specific E. coli bacteria strain from ATCC that is mediated by the 
carbapenemase production of the test isolate (for more information, see Chapter 2, Methods and 
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Materials). A 2007 study comparing four different methods for the identification of KPC in 
Enterobacteriaceae by Anderson et al reported 100% sensitivity and specificity for the performance of the 
modified Hodge test, which was compared to PCR for the blaKPC gene
64 as the “gold standard” or 
benchmark. However, other studies focused on the analysis of non-clinical specimens found higher rates 
of false positives and false negatives65.  
AMR Hotspots 
Human and animal excrement contains a diverse array of pathogens that if introduced into the 
environment could led to fecal-oral transmission of infectious diseases. In a best-case scenario, a 
governance-based system of accountability exists that manages, enforces, and monitors the safe 
conveyance, treatment, release, and disposal of treated sewage and manure back into the 
environment66,67. Again, best case scenario, the microbial load of the waste is reduced to a pre-
standardized level of safety by a fully functioning array of treatment methods prior to its introduction 
back into the environment, thereby reducing the potential risk of infectious disease. This is a best case 
scenario, as an estimated 90% of the world’s waste water is discharged untreated into rivers, lakes, and 
oceans68. The global burden of diarrheal disease is exemplary of the consequent impact of poor access to 
adequate water, sanitation, and hygiene69. Human and animal excrement can contain a broad assortment 
of antibiotic residues, antibiotic resistance genes, and antibiotic resistance bacterial70. There are no 
international guidelines or standards regarding their management, treatment, and disposal into the 
environment, exacerbating the emergence, spread and transmission of ARB and ARG globally. 
Antibiotics are used excessively and indiscriminately for medical, veterinary, and agricultural 
purposes and result in the continual release of waste water and excrement containing ARG, ARB, and 
antibiotic residue into the environment. Occurrence of ARG and ARB in human and animal gut flora are 
not always indicative of antibiotic consumption or illness71,72. Consideration of the fecal-oral route of 
infectious disease transmission and associated critical control points for remediation of AMR hotpots are 
critical to addressing global AMR18. Critical AMR hotspots include hospitals, waste water treatment plants, 
waterways impacted by treated and untreated waste water release, concentrated animal food-production 
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operations (both land and aquaculture), and agricultural fields irrigated and fertilized with waste 
water2,22,73,74. Before considering the established hotspots, it’s important to consider surface water 
environments in which treated and untreated wastes are discharged, as they may ultimately be the 
primary source of exposure, sustainment, and spread of AMR75–77.  
 Bacterial aquatic environments are very diverse and dynamic and constantly evolving. Pollution 
from antibiotics, bactericides, and heavy metals creates selection pressure that exacerbates and sustains 
resistance11. The water, as well as the indigenous, non-pathogenic bacteria, can act as reservoirs and 
dissemination pathways for ARG and other genetic mobile elements. There is also a pH dependent soil / 
water interaction where, broadly, antibiotics can be removed from solution into a complex with the humic 
material sediment. Antibiotics can then be re-released into the environment if conditions change, “re-
shocking” the present micro-ecology13. Untreated and treated wastewater is often discharged into surface 
water, impacting important environmental and biochemical parameters in relation to ARBs and ARGs. A 
2013 study by Harnisz analyzed the changes in total and intrinsic resistance of autochthonous bacteria 
before and after a treated wastewater release point in Poland by performing phenotypic susceptibility 
tests with eight strategically selected antibiotics78. Her team found, like Reinthaller, that there was no 
clear correlation between the presence of ARB in waterways and discharge of treated wastewater. The 
presence of ARB in waterways is more associated with the relative quality of the waste water pre-
treatment than discharge post-treatment.   
The use of antimicrobial agents in medical settings influences emergence and prevalence of 
resistant clinical bacterial pathogens of concern. An under-evaluated aspect of these settings is the 
relative ARB load in hospital sewage. Assessing hospital waste water is essential, as hospital sewage is a 
major contributor of antibiotic resistant bacteria and antibiotic resistant genes into wastewater networks 
and, subsequently, to the environment15,70,79. Waste water treatment plants are another well-established 
AMR hotspot. The relative loading of antibiotics in waste-water is dependent upon the sludge-wastewater 
partition coefficient. Different wastewater treatment methodologies can have different microbial 
treatment and antibiotic removal efficiencies. Antibiotics in the right pH conditions can bind to humic 
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material. In a waste treatment scenario, antibiotics can bind to effluent particles, then go into dissolution 
into the biosolid during secondary treatment11,16. Land application of biosolids (including animal manure) 
can become a significant source of resistance transmission. The quality of both the effluent and biosolids 
are important in the control, release, and spread of AMR. More must be done to inform and support 
efforts to control and prevent the presence and release of antimicrobial agents, ARB, and ARG in human 
and animal wastes and environmental media and reduce animal and human exposure18. 
Proposed Indicator System 
Presently there is a global paucity of antibiotic stewardship, timely AMR surveillance data, 
harmonized AMR detection methods, and coordinated action and governance around this growing threat 
to public, social, and economic health12. Complacency and cognitive dissonance manifests easily in the 
face of an enormous and potentially likely or inevitable disaster. The speed at which AMR has emerged 
and spread is frightening, and all actions towards its prevention and control should be done with urgency. 
Surveillance of ARB and ARG in the environment is daunting, but with global coordination and effort, 
strategic action is within our control1. 
It has been well established that raw and treated municipal and hospital sewage and aquaponics 
and animal production sites are AMR hotpots 15,16,70. Evaluations of these and other impacted 
environmental compartments are key to determining the magnitude of AMR as well as identifying critical 
control points to slow its emergence and spread18. Methods used for routine clinical AST may not be as 
efficient as other methods, but they are accessible, highly standardized, and implemented globally19–21. A 
new method and indicator system should be developed based on the suggestion of the WHO and others 
that incorporates present strategies and targets AMR evaluation and enumeration of representative 
samples from important environmental hotspots. Myriad pathogens and chemotherapies to treat those 
pathogens exist. It is not pragmatic nor realistic to evaluate all in the surveillance of AMR in the 
environment. Thus, the development and evaluation of an indicator system for detection of human and 
animal relevant AMR pathogens is essential.  
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A culture-based method for the direct detection and enumeration of ESBL producers and 
carbapenem resistant fecal indicator organisms in environmental water, wastewater, and other exposure-
relevant matrices is pertinent and needed. The use of already established fecal indicator organisms is 
pragmatic, as they are already institutionalized and routine in many places. ESBL production can confer 
resistance to most β-lactam antibiotics, including penicillins, cephalosporins, and monobactam aztreonam. 
Oftentimes, treatment with carbapenem produces the most effective morbidity and mortality related 
outcomes from these multi-drug resistant infections 43. Carbapenemase production can confer resistance 
to virtually all β-lactams and infections with carbapenemase-producing Enterobacteriaceae are associated 
with high mortality rates58. 
 
 
 
  
25 
 
 
 
 
CHAPTER 2: MATERIALS AND METHODS 
Introduction: 
This methodological study focused on the development, use, and evaluation of a simple, culture-
based monitoring method for the direct detection and enumeration of the target gram-negative fecal 
indicator bacteria having extended-β-lactam resistance as well as reduced susceptibility to carbapenems 
in hotspot environmental samples of wastewater and water impacted by wastewater. A summary of 
project elements can be found in Table 2.1, including overviews of the bacteriologic culture media that 
are the foci of the study, target organisms, sampling sites, and analysis strategies for the quantification 
and characterization of resulting assay data and bacterial isolates. 
The project occurred over five phases. Figure 2.6 shows a summary timeline of each phase and 
the objective-relevant activities that occurred during that phase. During phase 1, repeated, parallel 
assays involved direct, one-step membrane filtration of environmental samples onto chromogenic 
bacteriologic culture described in Table 2.1. After incubation, samples were characterized via visual 
identification and counting of presumptive target organism colonies on agar media used during 
membrane filtration. Colonies of presumptive ESBL and KPC positive target organisms were selected, 
streaked to purification, and isolated for future confirmation of isolate identities and resistance profiles.  
During phase 2, the resulting assay data was analyzed and a dataset was created that included 
site-, event-, and organism-specific calculations and statistical analysis concerning the presence, 
concentration, and relative proportion of presumptive target organisms. The third phase focused on the 
revival and purification of all KPC isolates, followed by confirmation of carbapenem-specific antimicrobial 
susceptibility and re-isolation for future characterization. Identity confirmation of presumptive of bacterial 
isolates detected on CHROMagar ESBL and KPC occurred in the fourth phase. Confirmation of resistance 
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profiles of ESBL isolates occurred in phase 5. CHROMagar ESBL and KPC media performance analysis was 
also finalized during the fifth phase. Project Objective summaries can be found in Tables 1.1 – 1.4.  
Table 2.1 Summary of Project Elements: Culture Media, Target Organisms, Environmental 
Samples and Analytical Methods 
Bacteriologic Culture Media 
Bio-Rad Rapid’E. coli 
2 agar 
Chromogenic environmental medium validated for the detection and enumeration 
of E. coli and other coliforms bacteria in food and waste waters. This medium 
was used as the “gold standard” comparator to evaluate the performance of the 
clinical medium.  
CHROMagar™ 
Orientation 
Chromogenic clinical diagnostic medium used for the isolation and differentiation 
of urinary tract pathogens, both Gram positive and negative. This medium 
represents the baseline clinical comparator as well as the agar base for the ESBL 
and KPC media.  
CHROMagar™ ESBL 
Chromogenic medium for the detection of Gram-negative bacteria producing 
ESBL in stools and urine. Agar medium is made by supplementing the above 
Orientation media with a proprietary antibiotic supplement. 
CHROMagar™ KPC 
Chromogenic medium for the detection of Gram-negative bacteria with reduced 
susceptibility to most carbapenem agents in stools and urine. Agar medium is 
made by supplementing the above Orientation media with a proprietary antibiotic 
supplement. 
Target Organisms 
E. coli 
Other Non-E. coli coliforms 
(Klebsiella, Enterobacter, 
Citrobacter, and Serratia) 
Combined Coliforms 
(E. coli+ Non-E. coli coliforms) 
Environmental Sampling Sites 
Hospital Sewage Community Sewage 
Treated Sewage 
Effluent 
Surface Water 
Impacted by Effluent 
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Analysis 
Quantitative Analysis 
(Phase 1 and 2) 
Comparisons were made between Bio-Rad Rapid’ E. coli 2 agar and CHROMagar 
Orientation to detect and quantify E. coli and coliforms in the different sample 
environmental matrices (Objective 1). Concentrations and proportions of 
presumptive ESBL and carbapenem resistant E. coli and coliforms in the 
environmental samples were made from counts taken on their respective media, 
CHROMagar ESBL and CHROMagar KPC (Objective 2). 
Confirmation of 
Antimicrobial 
Resistance Profile 
(Phase 3 and 5)  
For isolate originally detected on CHROMagar ESBL, reduced susceptibility to 
Extended-β-lactams (Cefpodoxime) and carbapenems (Imipenem) and ESBL 
production was evaluated via Vitek2 (Objective 3).  
 
For isolates originally detected on CHROMagar KPC, reduced susceptibility to 
carbapenems and KPC production was confirmed via non-automated antimicrobial 
susceptibility testing using the Modified Hodge test (Meropenem) for all 
successfully revived isolates. A select group of KPC isolates were also analyzed 
via the same Vitek analysis (Objective 4).  
Confirmation of 
Isolate Identity 
(Phase 4) 
 Matrix-assisted laser desorption / ionization time of flight mass spectrometry, or 
MALDI-TOF MS was used for definitive species confirmation analysis of all 
successfully revived bacterial isolates (Objective 3 and 4).  
 
Site Descriptions: 
 There were four different environmental matrices analyzed in this study: hospital sewage, 
municipal sewage (influent), secondary treated effluent, and surface water. Each site was located in 
Chapel Hill, NC and had relative hydrologic connectivity. The hospital collection sites were connected to 
the municipal waste water treatment plant (WWTP) where the influent and effluent samples were 
collected. The surface water samples were collected from a creek into which the WWTP discharges its 
secondary treated effluent. The creek sites were located up and downstream of the discharge point. 
Another surface water site is a recreational lake for which the aforementioned creek is an upstream 
tributary.  
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Hospital Sewage:  
The hospital collection sites are located at the main site of UNC Hospitals on Manning Drive in 
Chapel Hill. This is a highly performing and ranked teaching hospital with several specialty wards. It has a 
multi-winged, 830-bed general medical and surgical facility. In 2015, it received around one million 
clinical visits, including ~38,000 admissions, 12,000 inpatients and ~17,000 outpatient surgeries, and 
70,000 emergency room visits. Samples from the four collection sites were taken with the assistance of 
the hospital facilities staff from manholes serving four wings, each with distinct sewerage networks. The 
sewerage system at the first site served the medical intensive care unit (MICU) and the gastrointestinal 
(GI) clinic and surgical ward. The sewerage system at the second site served an intensive care unit (ICU), 
the burn unit, and a suite of medical laboratories. The sewerage system at the third site served another 
ICU, laundry facilities, and the cardiovascular clinic and surgical ward. The sewerage system at the fourth 
site served the emergency room, the psychiatric ward and an associated neuroscience ICU 80.  
Figure 2.1 - View of Hospital Site 1 
 
Figure 2.2 - View of Hospital Site 2 
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Figure 2.3 - View of Hospital Site 3 Figure 2.4 - View of Hospital Site 4 
 
Domestic Sewage and Treated Effluent:  
Samples of domestic, raw sewage and treated sewage effluent were taken at the Orange Water 
Sewage Authority (OWASA) at Mason Farm Wastewater Treatment Plant in Chapel Hill, NC. OWASA 
serves over 100,000 people in Orange County via 324 miles of wastewater collection piping. Much of this 
piping utilizes gravity flow, assisted by 21 pumping stations with 14 miles of pressured sewer. The peak 
capacity of the plant is 14.5 million gallons of wastewater per day (MGD), with the average around 8 
MGD.  
The treated wastewater, or secondary effluent, goes through a step-wise treatment process 
before release. First, during primary treatment, large grit and debris are removed from the sewage and 
then it is conveyed to settling tanks for primary clarification. Next, during secondary treatment, the 
primary effluent is pumped into a large aeration basin for aerobic biological degradation with production 
of settled biomass as activated sludge flocs. For secondary clarification and removal of biosolids the 
activated sludge is conveyed to clarifiers. The clarified effluent then undergoes rapid granular medium 
filtration, followed by ultraviolet light disinfection prior to release into Morgan Creek as a tributary of 
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Jordan Lake. Both samples were collected by OWASA staff. The raw sewage was collected after removal 
of large grit and debris and the disinfected secondary effluent was collected in a holding tank, prior to 
release.  
Figure 2.5 - View of Raw Sewage, Treated Effluent, and Surface Water Site 
 
 
Morgan Creek and Jordan Lake:  
Morgan Creek is 17 miles long and a primary tributary of Jordan Lake, a major drinking water 
source for the town of Cary, North Carolina. Jordan Lake was constructed as a reservoir in 1974, covers 
~14000 acres, and has a history of eutrophication due to excessive nutrient levels. Collection sites for 
Morgan Creek were located upstream and downstream of OWASA’s treated effluent release point. There 
were no shoreline public access points approximate to the confluence of Jordan Lake at Morgan Creek. 
The Jordan Lake collection site was located at a shore-line beach and boat ramp in the Jordan Lake State 
Recreational Area close to the intersection of Farrington Road and Martha’s Chapel Road, located less 
than 0.5 miles southwest of the confluence.   
In the flow chart below, the number of ESBL isolates on phase 5 should be specified 
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Project Timeline 
Figure 2.6 – Timeline with Project Phases with Associated Objectives 
 
Phase 5
(05 - 07/2016)
Objective 3 - Antimicrobial suceptibility 
analysis of (#) ESBL isolates via VITEK 
2 analysis
Objective 4 - Antimicrobial suceptiblity 
analysis of 25 selected KPC isolates via 
VITEK 2 anlaysis
Objective 3 and 4 - Performance 
evaluation of CHROMagar ESBL and 
KPC media
Phase 4
(04 - 05/2016)
Revival, purification and re-isolation of 
232 ESBL isolates 
Objective 3 - Identity confirmation and 
speciation of 232 ESBL isolates via 
MALDI-TOF MS 
Objective 4 - Identity confirmation and 
speciation of 233 KPC isolates via 
MALDI-TOF MS 
Phase 3
(10/2015 - 03/2016)
Revival, purification and re-isolation of 299 KPC isolates 
Objective 4 - Antimicrobial suceptibility analysis of 299 KPC 
isolates via Modified Hodge Test
Phase 2
(07 - 09/2015)
Laboratory training and preliminary 
analysis of duplicate isolates at UNAN 
Nicaragua
Development of antimicrobial 
susceptibility protocol for isolate 
analysis
Objective 2 - Determine presence, 
concentration and proportion of ESBL 
and KPC target organisms at sites 
Phase 1 
(02 - 07/2015)
Sampling events and assays (1 - 13) Collection of #ESBL and #KPC isolates
Objective 1 - CHROMagar Orientation 
Performance Evaluation
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Phase 1: 
Thirteen sampling events were performed from February - July 2015 (Table 2.2). The first seven 
sampling events focused on the collection and analysis of samples of raw sewage and secondary treated 
sewage effluent taken from OWASA and from Morgan Creek, up and downstream of the effluent 
discharge point. Sampling events eight through ten focused on collection and analysis of samples of 
hospital sewage from the four, distinct sewerage networks at the UNC hospital main facility on Manning 
Drive. Jordan Lake sampling started in week eleven. Events eleven through thirteen focused on the 
concurrent collection and analysis of samples from all nine sites.  
Table 2.2 – Schedule of Sampling by Site 
A blue box and plus sign indicates that sampling and subsequent analysis using the original 
protocol. A grey box with a dash indicates that sampling and analysis did not occur.  
2015 Sample Collection Dates 
Sample Site 
9-
Feb 
16-
Feb 
2-
Mar 
17-
Mar 
23-
Mar 
31-
Mar 
9-
Apr 
6-
May 
11-
May 
18-
May 
26-
May 
1 
Jun 
1 –
Jul 
W1 W2 W3 W4 W5 W6 W7 W8 W9 W10 W11 
W1
2 
W1
3 
UNC Hospital 
Sewage Site 1 
– – – – – – – + + + + + + 
UNC Hospital 
Sewage Site 2 
– – – – – – – + + + + + + 
UNC Hospital 
Sewage Site 3 
– – – – – – – + + + + + + 
UNC Hospital 
Sewage Site 4 
– – – – – – – + + + + + + 
OWASA Raw 
Sewage 
+ + + + + + + – – – + + + 
OWASA Secondary 
Effluent 
+ + + + + + + – – – + + + 
Morgan Creek, 
Upstream 
+ + + + + + + – – – + + + 
Morgan Creek, 
Downstream 
+ + + + + + + – – – + + + 
Jordan Lake – – – – – – – – – – + + + 
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Bacterial isolates of presumptive ESBL E. coli and other coliforms as well as presumptive KPC E. 
coli and other coliforms were collected during each sampling period, when available. An overview of 
bacterial isolates collected and specific methodological information on their selection, isolation, revival 
and analysis can be found in Table 2.7 and 2.8. Objective 1 (Table 1.1) was also completed during this 
phase, allowing for more informed analysis during Phase 2, Objective 2 (Table 1.2).  
Phase 2: 
The second phase of the project occurred in Fall 2015, post-laboratory training with project 
collaborators in the Department of Microbiology at the National Autonomous University of Nicaragua in 
León. Lessons learned during this training were incorporated into attempts to revive and further purify 
bacteria isolates collected during the first phase of work, as well as into iterative improvement in culture-
based analytical methods and further evaluation of the original culture isolation and enumeration 
protocol.  
Following the conclusion of sampling events, the resulting assay data were analyzed and datasets 
were created for site- event-, and organism-specific calculations and statistical analysis concerning the 
presence, concentration, and relative proportion of presumptive Extended Spectrum β-lactam resistant 
E. coli and other coliforms as well as presumptive carbapenem E. coli and other coliforms. With its 
completion, Objective 2 was achieved.  
Phase 3: 
The third phase of work focused on antimicrobial susceptibility testing of 298 successfully revived 
and purified KPC bacteria colony isolates via the Modified Hodge Test in order to validate the 
performance of CHROMagar KPC primary isolation medium to confirm and further evaluate the 
carbapenem resistance profiles of isolates. This analysis represents only a portion of Objective 4 and, due 
to funding limitations, was considered to be the last stage in the analysis associated with this project. 
However, new funding was obtained in March 2016 via a collaboration with Colorado State University that 
allowed for the implementation of Phase 4.  
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Phase 4: 
With this new funding and with a collaboration with UNC hospitals, confirmatory identification of 
bacterial isolates was initiated using Matrix Assisted Laser Desorption Ionization – Time of Flight (MALDI-
TOF) mass spectrometry in April 2016. This required the re-revival of KPC isolates and revival and 
purification of previously unanalyzed ESBL isolates. Due to limited time, funding, and capacity, isolates 
were prioritized for analysis as representative KPC and ESBL isolates. In one month, and aided by 
undergraduates, a total of 233 KPC isolates were revived and 232 ESBL isolates were purified and revived 
and submitted for MALDI-TOF MS. Phase 4 was completed in late May 2016 and was considered to be 
the last phase in the analysis until more funding was identified in April via a col laboration with North 
Carolina State University that allowed for antimicrobial susceptibility testing of the ESBL isolates, allowing 
for Phase 5 and the completion of Objective 3.  
Phase 5: 
In late April 2016, a portion of ESBL isolates being analyzed via MALDI-TOF MS were prioritized 
for VITEK 2 analysis. A total of 211 isolates were submitted for analysis at NCSU. Results were returned 
at the end of June, allowing for merging of the data for Modified Hodge Test (MHT), VITEK 2 and MALDI-
TOF MS. Data were compiled and analyzed for each culture medium to determine the rate of 
confirmation of presumptive identities and resistance profiles.  
With this final analysis, time was taken to identify performance deficiencies and incorporate 
iterative improvements into a new methodology to improve performance and provide a basis for future 
recommendations on candidate methods for direct, culture-based environmental monitoring using a 
harmonized and continuous surveillance system for specified AMR traits of E. coli and other coliforms in 
the environmental samples that are the same as or consistent with the methods used in clinical and 
agricultural/veterinary settings and samples. 
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Original Protocol and Analysis Schedule:  
Table 2.3 shows the original protocol and analysis schedule used to pilot the development of a 
culture-based indicator system for the detection and enumeration of ESBL and KPC (CRE) antimicrobial 
resistant enteric bacteria of health concern in fecal wastes and wastewaters. The original protocol was 
developed and utilized throughout the thirteen sampling periods and a description of each phase is 
provided throughout this chapter. The protocol has since been iteratively improved; thus it is not advised 
to use this exact schedule and set of procedures in practice. The key updates in the protocol will be 
discussed in the Recommendations section in Chapter 5.  
Table 2.3 Original Method Protocol by Day 
Day Objective 
Day 1 
Media, Diluent and Cryopreservative Preparation:  
- Bio Rad Rapid’ E. coli 2 agar medium, CHROMagar™ Orientation Medium, 
CHROMagar™ ESBL, CHROMagar™ KPC, Tryptic Soy Agar (Difco™), Phosphate-
buffered Saline, 1X Trypticase Soy Broth, and 40% Glycerol aqueous Solution 
Day 2 
- Sample Collection, Transport, and Storage 
- Direct, One-Step Membrane Filter Method for analysis of samples on Bio Rad Rapid’ 
E. coli 2, CHROMagar™ Orientation Medium, CHROMagar™ ESBL, and 
CHROMagar™ KPC 
Day 3 
- Bacteria Colony Identification and Enumeration on the Agar Media Used for Membrane 
Filtration Analysis 
- Presumptive Positive Bacteria Colony Selection and Initial Streak Plate Isolation and 
Purification on KPC and ESBL Agar Media 
Day 4 
- Second Step Colony Streak Plate Purification of Presumptive Positive Bacteria Isolates 
on KPC and ESBL Agar Media 
Day 5 
- Third Step Colony Streak Plate Purification of Presumptive Positive Bacteria on Tryptic 
Soy Agar (TSA) 
Day 6 
- Broth Culture Propagation of Selected Colony Isolates of Target Organisms from TSA 
Plates for All Sample Sites in Tryptic Soy Broth Medium 
Day 7 
- TSB Culture Isolate Supplementation with Glycerol for Frozen Storage and Later 
Confirmatory Identification and Antimicrobial Resistance Analysis 
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Media Preparation:  
All culture media and stock solutions were prepared and sterilized according to manufacturer’s 
instructions as well as by procedures in Standard Methods for The Examination of Water and Wastewater 
81. Sterilized, molten agar media were tempered to 55˚ C in a water bath prior to pouring plates. Agar 
medium plates were prepared in a laminar flow hood disinfected with 70% ethanol solution. Using a 
mechanical pipet gun and a sterile, polystyrene pipette, molten agar was dispensed into the plates at 
15mL per 100mm x 15mm plate and 6 – 5mL per 60mm x 15mm plate and then allowed to solidify and 
dry for approximately 30 minutes. After solidifying and drying, plates were stacked upside down in 
sterilized baskets, and stored at 4°C for greater than 18 hours and up to 1 month before use. For more 
specific information on preparation of Bio-Rad Rapid’E. coli 2, CHROMagar™ Orientation, CHROMagar™ 
ESBL, CHROMagar™ KPC, Tryptic Soy Agar (Difco™) media as well as the tryptic soy broth medium and 
other stock solutions (phosphate buffer and aqueous glycerol solution) used in this method, see Appendix 
1. 
Sample Collection, Transport, and Storage 
All environmental samples of wastewater and water were collected as grab samples in sterile 
polypropylene bottles and transported on ice in coolers to the laboratory. Grab samples from OWASA for 
both influent raw sewage and secondary effluent were collected by OWASA staff. Samples from Morgan 
Creek, both up and downstream, and Jordan Lake were collected in the field by UNC project staff. 
Hospital samples were obtained with the assistance of UNC hospital facilities staff. Manholes were 
uncovered and a weighted chain with a polypropylene sampling bottle held by a pipe clamp was lowered 
into the wastewater. No composite sampling was performed during the project. After collection, samples 
were stored at 4o C and analyzed within 48 hours. All used reusable nitrile gloves, bottles, clamps, chain 
and coolers were sterilized, post-collection, transport, and storage of samples for future use. 
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Direct, One-Step Membrane Filter Method: 
Membrane filtration techniques were adapted from the procedures of EPA Method 1604 82 and 
from Standard Methods 81. The laboratory bench was disinfected with 70% ethanol solution prior to the 
beginning the experiment and aseptic technique was used throughout each stage of analysis.  
Serial Dilutions  
Samples were removed from 4°C storage and placed on ice. Samples were then diluted serially 
10-fold using phosphate-buffered saline (PBS) to obtain countable colonies. See Table 2.4 for a list of 
typical dilutions used for each sample site and medium. Sterile bottles and pipettes were used for each 
dilution. Three dilutions were prepared for each sample in an effort to account for the great variability in 
bacteria concentrations observed at each sampling period.  
The priority was to avoid confluent colony growth for purpose of obtaining isolated colonies as 
well as preventing the occurrence of colonies that were crowded and too numerous to count. The 
dilutions made were sample- and medium- specific, with more dilutions made for more highly 
contaminated samples as well as for plating on the agar media lacking antibiotics (e.g. for raw sewage 
plated on CHROMagar Orientation medium) and fewer dilutions made for samples that were expected to 
be less contaminated and were to be plated on media containing antibiotics (e.g. surface water samples 
and plating on KPC and ESBL media).  
  
38 
 
Table 2.4 - Typical Sample Dilutions Used for Membrane Filtration Analysis by Sample Site 
and Culture Medium 
Sample Site 
Bio-Rad 
Rapid’E. coli 2 
CHROMagar™ 
Orientation 
CHROMagar™ 
ESBL 
CHROMagar™ 
KPC 
OWASA Raw 
Sewage 
10-4 
10-5 
10-6 
10-4 
10-5 
10-6 
10-2 
10-3 
10-4 
10-1 
10-2 
10-3 
OWASA Secondary 
Effluent 
10-2 
10-3 
10-4 
10-2 
10-3 
10-4 
100 
10-1 
10-2 
100 
10-1 
10-2 
Morgan Creek, 
Upstream 
100 
10-1 
10-2 
100 
10-1 
10-2 
100 
10-1 
10-2 
100 
10-1 
10-2 
Morgan Creek, 
Downstream 
100 
10-1 
10-2 
100 
10-1 
10-2 
100 
10-1 
10-2 
100 
10-1 
10-2 
UNC Hospital 
Sewage Site 1 
10-3 
10-4 
10-5 
10-3 
10-4 
10-5 
10-2 
10-3 
10-4 
10-1 
10-2 
10-3 
UNC Hospital 
Sewage Site 2 
10-3 
10-4 
10-5 
10-3 
10-4 
10-5 
10-2 
10-3 
10-4 
10-1 
10-2 
10-3 
UNC Hospital 
Sewage Site 3 
10-3 
10-4 
10-5 
10-3 
10-4 
10-5 
10-2 
10-3 
10-4 
10-1 
10-2 
10-3 
UNC Hospital 
Sewage Site 4 
10-3 
10-4 
10-5 
10-3 
10-4 
10-5 
10-2 
10-3 
10-4 
10-1 
10-2 
10-3 
 
Membrane Filtration 
The filter apparatus used for each experiment consisted of a sterile filter flask and filter funnel 
assembly (filter support base and filter funnel) fitted with a vacuum connection. A 0.45μm pore size, 47 
mm diameter, gridded membrane filter (Millipore HA filter) was placed on the filter support base of the 
filter funnel assembly using sterilized forceps that were dipped in ethanol and flamed in a Bunsen burner. 
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After attaching the filter funnel to the filter support base containing the membrane filter, 20 milliliters of 
the sample was pipetted onto the filter and then vacuumed through the apparatus. The interior of the 
filter assembly was then rinsed with sterile phosphate buffer to wash onto the filter any bacteria that 
might have attached to the inner wall of the filter assembly. The membrane was aseptically removed 
from the filter funnel support base and transferred gridded face up to a 60 x 15 mm plate of agar 
medium.  
Each sample was filtered in triplicate for membrane filter plating on all four agar culture media 
(Bio-Rad Rapid’E. coli 2, CHROMagar Orientation, CHROMagar ESBL, and CHROMagar KPC) at 
appropriate dilutions. A new, sterile filter funnel assembly was used for each water sample and a diluent 
negative control was run at the beginning of each membrane filtration session. Once complete, agar 
plates with membrane filters were then inverted and incubated at 37°C for 18 to 24 hours. 
Counting and Analysis of Bacterial Colonies:  
Colony Visualization and Enumeration: 
After incubation, colonies on the membranes of plates were observed and counted for those 
having the desired color and appearance. Numbers of colonies as colony forming units (CFUs) for 
presumptive E. coli and other coliforms were totaled for each plate and recorded as discrete counts 
according to colony color guides provided by the manufacturer. Colony plate counts for each target 
organism, sample type, medium and dilution were then used to calculate target bacteria concentrations in 
samples as CFU/100 mL. Tables 2.5 and 2.6 were derived from manufacturers’ descriptions of bacteria 
colony appearance.  
Colony color interpretation was the primary measure of evaluation, however, other colonial 
characteristics such as sheen, transparency, and shape were included when needed to evaluate colonies 
that were similar in appearance, but did not conform exactly to manufacturers’ descriptions. Other 
morphological characteristics were often used to differentiate between presumptive coliform and 
Enterococcus colonies on CHROMagar media.  
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Table 2.5 - Colony Appearance: Bio-Rad Rapid’E. coli 2 and CHROMagar Orientation 
Manufacturer’s description of colony appearance assumes incubation at 37°C for 18-24 hours. 
Agar Type Microorganism Appearance 
Bio-Rad Rapid’E. 
coli 2 agar 
Coliforms Blue to green  
E. coli Violet to pink 
CHROMagar™ 
Orientation 
Coliforms (Klebsiella, Enterobacter, Citrobacter, 
Serratia) 
Metallic blue (+/- reddish 
halo) 
E. coli Dark pink to reddish 
Proteus, Morganella, Providencia Brown halo 
Proteus vulgaris Blue with brown halo 
Pseudomonas  
Translucent (+/- natural 
pigmentation cream to green) 
Acinetobacter Cream 
Stenotrophomonas Colourless 
Enterococcus Turquoise blue 
Staphylococcu. aureus Golden, opaque, small 
Staphylococcus epidermidis Cream, pinpoint colonies 
Staphylococcus saprophyticus Pink, opaque, small 
Streptococcus Group B Light blue 
Candida albicans Cream, pinpoint colonies  
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Table 2.6 - Colony Appearance: CHROMagar ESBL and CHROMagar KPC  
Manufacturer’s description of colony appearance assumes incubation at 37°C for 18-24 hours 
Agar Type Microorganism Appearance 
CHROMagar™ 
ESBL 
ESBL KEC (Klebsiella, Enterobacter, Citrobacter) Metallic blue 
ESBL E.coli Dark pink to reddish 
ESBL Proteus Brown halo 
ESBL Acinetobacter Cream 
ESBL Pseudomonas 
Translucent (+/- natural 
pigmentation cream to green) 
Stenotrophomonas Colorless 
CHROMagar™ 
KPC 
CarbapenemR KEC (Klebsiella, Enterobacter, 
Citrobacter) 
Metallic blue 
CarbapenemR E. coli  Dark pink to reddish 
CarbapenemR Pseudomonas 
Translucent (+/- natural 
pigmentation cream to green) 
CarbapenemR Acinetobacter Cream 
Stenotrophomonas Colorless 
 
Bacteria Concentration (CFU / 100 mL)  
Bacteria concentrations for each culture medium, sample and presumptive organism identity 
were calculated from counts of colonies having the expected color and appearance on membranes of 
60mm diameter agar medium plates. Each sample and agar medium was plated on average at 3-sample 
specific dilutions, each with replicates per dilution. Too numerous to count was set at 250 colonies per 
plate. No lower limit was established for colony counts used to determine bacteria concentration. 
Calculation of colony forming unit (CFU) concentration involved adding up counts of total colonies 
of the expected color and appearance for all countable plates and dividing this total number of colonies 
by the total undiluted sample volumes they represented per counted plate (including plates with zero 
colonies at a sample dilution that also had some plates with visible colonies at the same sample dilution) 
to calculate CFU/mL, then multiplying by 100 to express the concentration as CFU/100 mL. The estimated 
upper and lower 95% confidence limits of these bacteria concentrations were calculated according to the 
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Poisson distribution from the sum of the actual colony counts for all replicates and dilutions used, taking 
the square root of this number and then multiplying by 2 and then adding and subtracting from the total 
colony count, respectively.  
Calculations for Proportions of Presumptive Antimicrobial Resistant Bacteria  
The proportions of presumptive ESBL and KPC positive target organisms were calculated by 
dividing the presumptive ESBL and KPC positive bacteria concentration of the sample obtained by plating 
on the ESBL and KPC media by the total concentration obtained by plating on the base medium (Bio-Rad 
Rapid’E. coli 2 medium). This calculation was only performed on parallel assays, e.g. same sample, same 
time period, same target organisms. Bacterial concentrations from CHROMagar Orientation medium were 
only used if the Bio-Rad concentrations were compromised or if the medium was not available. Each 
occurrence is noted in Appendix 2. All hospital proportions were calculated using CHROMagar Orientation 
concentrations for like-organisms, as the Bio-Rad medium was not available consistently throughout 
weeks 8 – 10 of the project period.  
Average, Standard Error, and Confidence Interval Calculations:  
 Averages were calculated to measure the central tendencies of presumptive concentrations and 
proportions of target organism. As microorganisms are assumed to be randomly distributed, Poisson 
standard errors were calculated for concentrations by taking the square root of (x-bar/n). Standard errors 
bacteria concentrations and proportions of presumptive ESBL and KPC positive organisms were calculated 
by dividing the associated standard deviation of the sample set by the square root of the sample number. 
Ninety-five-percent confidence intervals were calculated for all of the above by multiplying the standard 
error by 1.96 and expressed as plus or minus the average.  
Normality Determination: 
Prior to deeper analysis, the data was subjected to a Shapiro-Wilk test to evaluate its normality. 
This was performed in R and confirmed that non-parametric testing was required.  
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Paired Wilcoxon Signed Rank Tests and Mann-Whitney U-Tests: 
Wilcoxon Signed Rank tests and Mann-Whitney U-tests are non-parametric tests that utilize 
summation of ranks and are similar to t-tests performed in normally distributed data. Wilcoxon Signed 
Rank tests are applied dependent or matched samples. Mann-Whitney U-tests are applied to independent 
samples.  
Bacteria concentration and proportion data were organized by date collected, target organism, 
sample site, and bacteriological agar medium and maintained in Excel and then exported as a CSV file 
into R for analysis. Paired Wilcoxon Signed Rank tests were done to evaluate the performance of the 
clinical medium (Orientation) against the detection performance of the gold standard, environmental 
medium (Bio-Rad) in each type of representative water and wastewater sample based on concentrations 
as CFU / 100 mL. Site- and organism-specific paired Wilcoxon Signed Rank tests were also performed for 
concentrations and proportions to compare presumptive ESBL and KPC positive target organisms.  
Figure 2.7 – Visual Example of Wilcoxon Signed Rank Pairing 
 
 
 
 
 
 
The data for the Bio-Rad Rapid’E. coli 2 and CHROMagar Orientation comparison paired by site 
and between parallel assays and target organism concentration results are shown as examples in Fig 
2.7). At α = 0.05) the null hypothesis is that the median difference between the two pairs of 
observations is equal to zero. Results were expressed as two-tailed P values, with values of p < 0.05 
taken as statistically significant, for each sample site and target organism. See Objective 1 and 2 for 
more detail on its application.  
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Mann-Whitney U-Tests were performed to compare two independent sites by the same variable 
(e.g. compare the concentrations of presumptive KPC positive E. coli in Raw Sewage and Secondary 
Effluent). This was performed to compare proportions of presumptive ESBL and KPC positive target 
organisms in raw sewage and secondary effluent. Mann-Whitney U-Tests were also performed to 
compare target organism concentrations and presumptive ESBL and KPC positive organisms between 
secondary effluent and Morgan Creek upstream of the WWTP, between secondary effluent and Morgan 
Creek downstream of the WWTP, and between Morgan Creek up- and downstream of the WWTP. At α = 
0.05, the null hypothesis is that the median difference between the two pairs of observations is equal 
to zero. Results were expressed as two-tailed P values, with values of p < 0.05 taken as statistically 
significant, for each sample site and target organism. 
Kruskal Wallis One-way analysis of Variance:  
Bacteria concentration and proportion data were organized by date collected, target organism, 
sample site, and bacteriological agar medium and maintained in Excel and then exported as  a CSV file 
into R for analysis. Kruskal Wallis was used to compare three or more independent groups. At α = 0.05, 
the null hypothesis is that the mean ranks of the groups are the same. A P>0.05 indicates that there is 
not a significant difference between the group means. A P<0.05, indicates that there is a significant 
difference and necessitates a post-test, for which a Dunn’s test was used to evaluate which of the 
observations created the difference in the pooled rankings. The post-test was performed in R.  
Selection, Purification and Isolation of Colonies 
Three successive purification steps by streaking onto agar media were used to isolate and purify 
selected bacteria colonies from membrane filters, each step with incubation at 37°C for 18 – 24 hour 
periods. First, well-isolated, single colonies exhibiting expected appearance of presumptive KPC and ESBL 
E. coli and other coliforms were selected from the membrane filter with a sterile wooden stick and 
aseptically streaked onto 100 mm x 15mm plates of KPC or  ESBL medium, respectively. A maximum of 5 
colonies were selected per resistance type and target organism for each sample, with one colony 
streaked for isolation per plate.  
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After incubation of the first streaked plate of each type, another purification streak was 
performed by selecting a single, representative colony per plate and re-streaking it for isolation on a 
100mm x15 mm plate of the same medium. Next, a well isolated colony having the correct appearance 
from this second plate was streaked a third time, this time onto a 100 mm x15 mm tryptic soy agar plate 
for both ESBL and KPC isolates. After incubation on TSA, well isolated colonies were selected and 
inoculated into 5 mL of 1 X Tryptic Soy Broth. After overnight incubation, 1 mL aliquots of the TSB culture 
in 20% glycerol were prepared as alphanumerically labeled, 1.5 mL freezer tubes, organized into boxes 
and frozen at - 80°C for future characterization.  
Overview of CHROMagar ESBL and KPC Media Performance Evaluation: 
Funding for the first three phases of the project was very limited. Consequently, no confirmatory 
analyses were performed to assess the validity of visual colony characterizations of presumptive isolates 
or to further evaluate the antimicrobial susceptibility profiles of colonies prior to isolation of bacteria. 
Fortunately, a student research scholarship was awarded that funded travel to Nicaragua to train with 
project collaborators at UNAN, thereby supporting a subsequent performance evaluation of CHROMagar 
ESBL and KPC agar media via confirmatory analysis of duplicate isolates. During this training and 
analysis, problems arose that revealed methodological issues with the original protocol and assay 
execution. These included markedly poor rates of KPC isolate revival and discovery that several of the 
isolates contained mixed cultures of target organisms or were contaminated with non-target organisms.  
Isolation and contamination issues, combined with the availability of funding, ultimately structured 
the remaining phases of the project and underlie the stepwise, and sometimes piecemeal, approach of 
confirmatory analysis of isolates and media performance evaluations. Though more ESBL isolates were 
collected in phase 1, analysis of KPC isolates was initially prioritized. Phase 3 focused heavily on the re-
revival, re-purification, and antimicrobial susceptibility testing of KPC isolates due concerns that arose 
during phase 2. When more funding became available in March, the purified KPC isolates and a selected 
portion of the ESBL isolates were subjected to MALDI-TOF MS for identity confirmation in phase 4. All 
ESBL raw sewage and secondary effluent isolates as well as a portion of hospital sewage isolates (sites 
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H3 and H4) were prioritized for analysis. When other funding became available in April, phase 5 was 
initiated and a portion of the MALDI-TOF analyzed ESBL isolates and KPC isolates were subjected to 
analysis with VITEK 2. 
Tables 2.7 and 2.8 provide site- and presumptive organisms-specific summaries including: the 
number of archived isolates originally detected on CHROMagar ESBL and KPC, the number of isolates 
prioritized for analysis and successfully revived, the number of isolates subjected to MALDI-TOF analysis, 
and the number of isolates subjected to antimicrobial resistance analysis. Resistance profiles of all ESBL 
isolates were confirmed via VITEK 2 automated analysis of susceptibility to Cefpodoxime, an Extended-β-
lactam, and Imipenem, a carbapenem. VITEK 2 was also used to evaluate ESBL production in several of 
the isolates. Resistance profiles for KPC isolates were confirmed via the culture-based, non-automated  
Modified Hodge disk diffusion test with meropenem. A few KPC isolates were selected for further analysis 
via VITEK 2 and are summarized in Table 2.9. All isolate-specific results for ESBL and KPC can be found 
in Appendix 3 and 4, respectively. Results for VITEK 2 analysis of KPC isolates can be found in Appendix 
5.  
  
47 
 
Table 2.7 – Summary of Isolates of Presumptive ESBL Positive Target Organisms and their 
Sources 
Code Description 
Total 
Isolates 
Total 
Revived 
Total 
MALDI-
TOF 
Total VITEK 
2 
FT HOSPITAL 1_GI+MICU_ESBL_KLEB 41 39 39 0 
FE HOSPITAL 1_GI+MICU_ESBL_ECOLI 13 8 8 0 
GT HOSPITAL 2_BURN+LAB+ICU_ESBL_KLEB 34 0 0 0 
GE HOSPITAL 2_BURN+LAB+ICU_ESBL_ECOLI 10 5 5 0 
HT HOSPITAL 3_HEART+ICU_ESBL_KLEB 26 3 3 3 
HE HOSPITAL 3_HEART+ICU_ESBL_ECOLI 14 7 7 0 
IT HOSPITAL 4_ER+NEURO_ESBL_KLEB 31 27 27 26 
IE HOSPITAL 4_ER+NEURO_ESBL_ECOLI 23 15 15 15 
AT RS DOMESTIC_ESBL_KLEB 41 41 41 41 
AE RS DOMESTIC_ESBL_ECOLI 29 20 20 17 
BT SEC EFFLUENT_ESBL_KLEB 38 35 35 33 
BE SEC EFFLUENT_ESBL_ECOLI 29 29 29 28 
CT UPSTREAM_ESBL_KLEB 28 0 0 0 
CE UPSTREAM_ESBL_ECOLI 3 3 3 0 
DT DOWNSTREAM_ESBL_KLEB 30 0 0 0 
DE DOWNSTREAM_ESBL_ECOLI 3 0 0 0 
ET JORDAN LAKE_ESBL_KLEB 0 0 0 0 
EE JORDAN LAKE_ESBL_ECOLI 0 0 0 0 
All Total  393 232 232 163 
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Table 2.8 – Summary of Isolates of Presumptive KPC Positive Target Organisms and their 
Sources 
Code Description 
Total 
Isolates 
Total 
Revived 
Total 
MALDI-
TOF 
Total 
Modified 
Hodge Test 
OT HOSPITAL 1_GI+MICU_KPC_KLEB 45 45 45 45 
OE HOSPITAL 1_GI+MICU_KPC_ECOLI 11 9 0 9 
PT HOSPITAL 2_BURN+LAB+ICU_KPC_KLEB 27 27 27 27 
PE HOSPITAL 2_BURN+LAB+ICU_KPC_ECOLI 17 17 4 17 
QT HOSPITAL 3_HEART+ICU_KPC_KLEB 16 16 12 16 
QE HOSPITAL 3_HEART+ICU_KPC_ECOLI 18 11 0 11 
RT HOSPITAL 4_ER+NEURO_KPC_KLEB 26 24 12 24 
RE HOSPITAL 4_ER+NEURO_KPC_ECOLI 18 15 12 15 
JT RS DOMESTIC_KPC_KLEB 52 42 42 42 
JE RS DOMESTIC_KPC_ECOLI 35 16 12 16 
KT SEC EFFLUENT_KPC_KLEB 40 32 22 32 
KE SEC EFFLUENT_KPC_ECOLI 19 17 16 17 
LT UPSTREAM_KPC_KLEB 11 10 10 8 
LE UPSTREAM_KPC_ECOLI 0 0 0 0 
MT DOWNSTREAM_KPC_KLEB 11 11 10 11 
ME DOWNSTREAM_KPC_ECOLI 0 0 0 0 
NT LAKE_KPC_KLEB 8 8 8 8 
NE LAKE_KPC_ECOLI 0 0 0 0 
All  Total  354 300 232 298 
 
Table 2.9 Summary of KPC Isolates and their Sources 
Selected for VITEK 2 Analysis 
Code Description Total Isolates 
RT HOSPITAL 4_ER+NEURO_KPC_KLEB 4 
KT SEC EFFLUENT_KPC_KLEB 4 
LT UPSTREAM_KPC_KLEB 4 
MT DOWNSTREAM_KPC_KLEB 9 
NT LAKE_KPC_KLEB 8 
All  Total  25 
 
The codes are based on the initial, presumptive colony color interpretation during counting, 
purification, and isolation (Phase 1) and not on the colony color during the secondary purification step 
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that occurred months later (Phases 2 – 5). Manufacturers’ color guides, found in Tables 2.5 and 2.6, are 
the criteria used for these interpretations. The codes were maintained for consistency as well as for 
association with assay week during following revival, re-purification, analysis, and re-isolation. In 
Objective 3 and 4 Results sections in Chapter 3, VITEK identities are presented as “Number of Correctly 
Confirmed based on original presumptive ID prior to isolation.” These results are associated with the 
initially assigned code and not with the colony phenotype during Phases 2 – 5.  
Bacteria Isolate Revival and Re-purification  
Pure cultures are necessary for the further validation of this primary colony detection and 
enumeration methodology via biochemical tests and other characterization. It was found necessary to re-
purify all frozen isolates prior to additional characterization and validation steps in order to address mixed 
culture and non-target bacteria problems that occurred during the original colony isolation process. These 
bacteria culture purity and identity problems were due to confluent colony growth and high levels of 
contamination with non-target organisms. Frozen isolate aliquots were removed from the - 80°C freezer 
and warmed slowly in a -20 °C freezer for 2 hours.  
Each isolate was then aseptically inoculated into 5 mL of 1X TSB with 10 μL plastic loops and 
incubated overnight at 37°C. If the broth was visibly turbid, a loopful was streaked for isolation onto 
100mm x 15mm CHROMagar Orientation plates using 10 μL plastic loops. Colony morphological 
characteristics were documented and well isolated colonies were then re-streaked for isolation on a 
100mm x 15mm KPC or ESBL plate, depending on the medium from which the isolate was originally 
selected. If the sample was still mixed or too concentrated to give well isolated colonies, an additional 
streak was performed on 100mm x 15mm MacConkey agar plates. Representative colonies considered 
coliforms were then streaked onto TSA, incubated, re-inoculated into 1X TSB, incubated again and re-
frozen in 1 mL aliquots with 20% glycerol as in the first isolation. These re-purified isolated were saved at 
-80 oC for further characterization. 
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Identity Confirmation via MALDI-TOF MS:  
Matrix-assisted laser desorption -Time of Flight Mass Spectrometry (MALDI-TOF MS) is a soft 
ionization process used to analyze biomolecules and large organic molecules. Successfully revived and 
purified bacteria isolates were subjected to MALDI-TOF MS in partnership with the clinical molecular 
microbiology laboratory of UNC hospital. This was done to investigate and confirm the presumptive 
identities of bacterial colonies originally isolated from membrane filters that were cultured on 
CHROMagar™ KPC and CHROMagar ESBL media.  
Selected isolates were revived and purified using the aforementioned methods; isolates were 
streaked on TSA and incubated overnight for 18 - 24 hours at 36°C. Isolates were then re-streaked onto 
TSA to remove any traces of glycerol and incubated. These plates were then transported to the staff of 
the Clinical Molecular Microbiology Laboratory at UNC hospitals in Chapel Hill. There, they performed 
MALDI-TOF MS on the fresh colonies using the FDA-cleared VITEK MS per manufacture’s 
recommendations for direct colony spotting 83. A colony was picked from the TSA plates using a sterile 
toothpick and smeared on a MALDI-TOF MS plate. The inoculated plate was irradiated with a laser pulse 
to ionize and desorb biomolecules, such as DNA and proteins. The resulting sample ions were exposed to 
an electric field, accelerated into a flight tube, then separated based on relative mass and abundance of 
ions. The mass to charge ratio present in each sample was analyzed against a digital library of 
biomolecules known to be associated with different organisms.  
Antimicrobial Susceptibility Testing: 
Antimicrobial susceptibility testing of the selectively revived presumptive ESBL positive isolates 
was performed via VITEK 2 (Table 2.7). All of the antimicrobial susceptibility testing for presumptive KPC 
positive organisms was performed via the Modified Hodge Test, with a smaller portion selected for further 
VITEK 2 analysis (Tables 2.8 and 2.9). 
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VITEK 2 Analysis 
The VITEK 2 (bioMerieux) test system was used evaluate the antimicrobial resistance profile of a 
selected portion of ESBL isolates and KPC isolates. This automated system evaluates susceptibility to  
Cefpodoxime, an Extended-β-lactam, and Imipenem, a carbapenem against associated CLSI MIC 20. 
VITEK 2 was also used to evaluate ESBL production in several of the isolates.  
This analysis was performed by collaborators at North Carolina State University, College of 
Veterinary Medicine. Isolates were transferred to their laboratory, revived by two successive streaks on to 
TSA. Using the FDA-cleared VITEK MS per manufacture’s recommendations for direct colony spotting 83, a 
colony was picked from the TSA plates using a sterile toothpick and smeared on a VITEK 2 AST card. The 
card has a series of wells that contain substrates designed to catalyze multiple biochemical reactions, in 
this case the wells contained MIC of Cefpodoxime and Imipenem. When a colony is spotted on the card, 
the system inoculates the wells, causing a series of reactions that are then subjected to automated 
analysis with an optical scanner that then compares the reaction against a database of containing API 
reference ranges and CLSI and EUCAST appropriate MIC. The results are then reported as having 
resistance, intermediate resistance, and susceptibility to the antibiotics used.  
ESBL production was analyzed using a test panel (card NO45) with wells containing cefepime, 
cefotaxime, and ceftazidime, alone and in combination with clavulanate. The wells and growth in each 
well is quantitatively assessed by means of an optical scanner. The ESBL production was reported as 
being positive or negative and assessed via analysis of the proportional reduction in growth in wells 
containing cephalosporin plus clavulanate compared to those containing the cephalosporin alone84. 
 
Modified Hodge Test for Detection of Carbapenemase Production 
The Modified Hodge Test (MHT), a culture-based, antimicrobial susceptibly testing method to 
detect carbapenemase production of Enterobacteriaceae, was adapted from methodologies from the 
Centers for Disease Control and Clinical and Laboratory Standards Institute 20,85 Test isolates and an E. 
coli ATCC 25922 strain were revived from in 1 mL aliquots of 1 X TSB and 20% glycerol and individually 
inoculated on 100mm x 15mm TSA agar plates via streaking with a sterilized loop and then incubated at 
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37°C for 18-24 hours. Mueller Hinton 100 x 15mm agar plates and buffered peptone water were 
prepared as described in Appendix 1. The next day, Mueller Hinton plates and 10 μg meropenem disks 
(Oxoid™) - one for each plate - were removed from the at 4°C refrigerator and allowed to equilibrate to 
room temperature for one hour prior to the experiment. If the agar plates had condensation, they were 
placed in a laminar flow hood at room temperature with lids ajar until excess surface moisture was 
removed. Plates were then labeled with a maximum of three test isolates per plate, spaced 120 degrees 
apart.  
Next, a 0.5 McFarland dilution of E. coli ATCC 25922 was prepared by pipetting 5 mL of peptone 
water into a sterile 16 x 125mm glass test tube and then inoculating it with a colony from the TSA ATCC 
25922 E. coli plate using sterile wooden stick. The tube was capped, vortexed and the turbidity was 
compared to a pre-prepared McFarland Standard (Remel™). Once confirmed for turbidity, the tube was 
briefly flamed in a Bunsen burner; a sterile cotton-tipped swab was submerged into the dilution and then 
swirled along the sides of the glass tube in order to remove excess liquid.  
To create a lawn of the diluted E. coli, the cotton swab was then streaked uniformly onto the 
entire surface of the Mueller Hinton agar plate and then allowed to sit for 3-5 minutes. Using a sterilized 
needle, a 10 μg meropenem disk, was placed in the center of the prepared plate. A single, well -isolated 
colony was selected from the appropriate test isolate TSA plate of each sample using a 10 μL plastic loop. 
The picked colony was then dragged from the outer rim of the plate towards, and eventually touching, 
the 10 μg meropenem disk in the center of the plate. This procedure was repeated for each sample 
colony. A maximum of three plates were done simultaneously to ensure appropriate drying intervals. In 
addition, a new 0.5 McFarland dilution was prepared every 20 minutes to avoid overgrowth. The plates 
were inverted and incubated for 18 - 24 hours at 37°C.  
After incubation, plates were analyzed for enhanced growth around the intersection of the test 
organism streak and the zone of inhibition in the lawn. If enhanced growth had a clover -leaf like 
appearance, it was indicative of positive carbapenemase production. If there was not enhanced growth, it 
was negative for carbapenemase production 
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Figure 2.8 Non-Standard Interpretation of Modified Hodge Test 
 
The above figure shows plates that are representative of the evaluation criteria used for 
interpretation of carbapenemase production and carbapenem intermediate resistance and susceptibility, 
or KPC(+), KPC(-)R, and KPC(-), respectively. Interpretation of intermediate resistance results do not 
align with clinical standards and breakpoints as outlined in the CLSI 20. These results are, however, 
inclusive of growing concern regarding the current limitations of said breakpoints, as their relevancy may 
ultimately be associated with therapeutic success and not with the evaluation of carbapenem resistance 
in the environmental context 1,13. These are alternative interpretations of Modified Hodge Test to be 
inclusive of intermediate resistance results, as suggested in the aforementioned literature. VITEK 2 was 
performed on a small selection of intermediate isolates to evaluate if Imipenem resistance was also 
present in isolates that showed “intermediate” production of KPC on the Modified Hodge Test.  
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CHAPTER 3: RESULTS 
Objective 1 Results: 
The first objective of this study was to evaluate the performance of a chromogenic substrate 
standard clinical agar medium for use in the direct detection and enumeration of E. coli and coliforms 
as fecal indicator bacteria in representative waste waters and surface waters by comparing it to the 
performance of a “gold standard” chromogenic substrate agar medium for the direct detection and 
enumeration of E. coli and coliforms in environmental water, wastewater and other matrices. 
Concentrations of E. coli, non-E. coli coliforms, and combined coliforms were measured using 
repeated, parallel assays of environmental and wastewater samples. Each sample (Figure 3.1) was 
measured using CHROMagar Orientation agar, chosen as a standard clinical agar medium, and Bio-Rad 
Rapid’E. coli 2 agar medium chosen as a gold standard medium. There were four sample types including 
hospital sewage (n=4), domestic sewage (n=1), treated sewage (n=1) and surface water (n=3) with a 
total of nine samples analyzed (Table 3.1).  
In Figure 3.1 is shown paired E. coli concentration data from the clinical medium (Orientation) 
and the “gold standard” enviornmental medium (Bio-Rad). There is great variability in the central 
tendencies and ranges of E. coli concentration data between sample types, and expected differences in 
the concentrations of these bacteria according to sample type. Raw sewage samples have the highest 
overall median E. coli concentrations. The sample median concentration detected by Orientation is higher 
in seven out of nine sample sites when compared to the sample median concentration detected by Bio-
Rad. When viewed as a subset of sample types, each of the hospital sewage sites has an outlier 
concentration on Orientation, but there is greater overall dispersion of concentations on Bio-Rad as 
indicated by the larger sizes of the interquartile ranges on this medium compared to the Orientation in 
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some of the samples analyzed. In the Morgan Creek surface water sites, there is a noticable difference in 
concentrations between the two media, with higher concentrations on Orientation. The Bio-Rad 
concentrations for Jordan Lake lack an actual box due to the low sample number (N=3) and 
concentrations were higher on Orientation.  
Figure 3.1 - Box plot comparison of E. coli concentrations from parallel assays on 
CHROMagar Orientation and Bio-Rad Rapid'E. coli 2 agar media 
 
In Table 3.1 is shown Wilcoxon Signed Rank tests data to evaluate the performance of the 
clinical medium (Orientation) against the detection performance of the gold standard environmental 
medium (Bio-Rad) in each type of representative water and wastewater sample based on presumptive E. 
coli concentrations as CFU/100 mL. Data were paired by site and by sampling time from parallel assays. 
The performance of the clinical medium was comparable to the gold standard environmental medium and 
capable of effective use in the direct detection and enumeration of E. coli as fecal indicator bacteria in 
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hospital sewage, treated sewage effluent and one of the three surface water matrices  at the 95% 
confidence level. However, the performance of the clinical medium was not comparable to the gold 
standard environmental medium by giving higher E. coli concentrations in some samples.  
Table 3.1 Bio-Rad Rapid'E. coli 2 v. CHROMagar Orientation Performance Comparison for 
the Enumeration of E. coli by Wilcoxon Signed Rank Test (α = 0.05) 
Sample Type Sample Site N P value 
Hospital Sewage 
H1 GI + MICU 4 0.181 
H2 Burn + Lab + ICU 4 0.125 
H3 Heart + ICU 4 0.181 
H4 ER + Neuro 5 0.313 
Domestic Sewage Raw Sewage 8   0.031 * 
Treated Sewage Secondary Effluent 10 0.160 
Surface Water 
Morgan Creek Upstream 10   0.015 * 
Morgan Creek Downstream 10   0.006 * 
Jordan Lake 3 0.250 
 
In Figure 3.2 are shown paired non-E. coli coliform (such as Klebsiella, Enterobacter, Citrobacter, 
Serratia) concentration data from the clinical medium (Orientation) and the gold standard environmental 
medium (Bio-Rad). There is less variability in the dispersion of the coliform concentration data between 
sample types, when compared to the E. coli data of Figure 3.2. Raw sewage still has the highest overall 
median concentration, but Hospital Site 1 has very right, upper skew and more variable concentration 
data, with high outliers that exceed raw sewage concentrations in other samples analyzed. However, the 
sample median coliform concentrations detected by Orientation are numerically and visually similar to 
those on Bio-Rad agar, with the exception of Hospital Site 2 in which the median concentration on 
Orientation is higher than on Bio-Rad. In the Morgan Creek surface water sites, there are high outliers in 
each site that overlap or exceed concentrations in secondary effluent. Coliform concentrations in Jordan 
Lake also show agreement, despite the low sample number (N=3). 
57 
 
Figure 3.2 Box plot comparison of other coliform concentrations from parallel assays on 
CHROMagar Orientation and Bio-Rad Rapid'E. coli 2 agar media 
 
 
In Table 3.2 are the Wilcoxon Signed Rank tests data that evaluate the performance of the 
clinical medium (Orientation) against the detection performance of the gold standard, environmental 
medium (Bio-Rad) in each type of representative water and wastewater sample based on presumptive 
non-E. coli coliform concentrations as CFU/100 mL. Data were paired by site and by sample date for 
parallel assays. The performance of the clinical medium was comparable to the gold standard 
environmental medium. Based on these results of non-significant differences in other coliform 
concentrations compared to Bio-Rad agar, Orientation agar is capable of use in the direct detection and 
quantification of other coliforms as fecal indicator bacteria in hospital sewage, raw sewage, secondary 
effluent, and surface water at the 95% confidence level.  
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Table 3.2 Bio-Rad Rapid'E. coli 2 v. CHROMagar Orientation Performance Comparison for 
the detection of other coliforms by Wilcoxon Signed Rank Test (α = 0.05) 
Sample Type Sample Site N P value 
Hospital Sewage 
H1 GI + MICU 5 1.000 
H2 Burn + Lab + ICU 5 0.625 
H3 Heart + ICU 5 1.000 
H4 ER + Neuro 5 1.000 
Domestic Sewage Raw Sewage 10 0.625 
Treated Sewage Secondary Effluent 10 0.846 
Surface Water 
Morgan Creek Upstream 10 0.770 
Morgan Creek Downstream 10 0.432 
Jordan Lake 3 0.500 
 
In Figure 3.3 are shown paired Combined coliform concentrations (non-E. coli coliform 
concentrations added to E. coli concentrations from the clinical medium (Orientation) and the gold 
standard environmental medium (Bio-Rad). Raw sewage still has the highest overall median 
Combined coliform concentration, with the exception of one Hospital Site 1 sample as an outlier value. 
The sample median concentrations of Combined coliforms detected by Orientation and Bio-Rad are 
similar, with the exception of the Hospital Site 3 where it is higher on Bio-Rad. In the Morgan Creek 
surface water sites Combined coliform concentrations are similar on Orientation and Bio-Rad, and for 
both media there are outliers at each site that overlap or exceed concentrations in secondary effluent. 
The Jordan Lake Combined concentrations are in agreement for both media, despite the low sample 
number (N=3).  
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Figure 3.3 Box plot comparison of Combined coliform concentrations from parallel assays 
on CHROMagar Orientation and Bio-Rad Rapid'E. coli 2 agar media 
 
 
In Table 3.3 are shown Wilcoxon Signed Rank test results from comparing the performance of 
the clinical medium (Orientation) against the performance of the gold standard, environmental medium 
(Bio-Rad) based on Combined coliform concentrations as CFU/100 mL in each type of representative 
water and wastewater sample. Data were paired by site and by sample date in parallel assays. The 
performance of the clinical medium was comparable to the gold standard environmental medium and 
capable of effective use in the direct detection and quantification of Combined coliforms as  fecal indicator 
bacteria in hospital sewage, raw sewage, secondary effluent, and surface water at 95% confidence level 
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Table 3.3 Bio-Rad Rapid'E. coli 2 v. CHROMagar Orientation Performance Comparison for 
the detection of Combined coliforms by Wilcoxon Signed Rank Test (α = 0.05) 
Sample Type Sample Site N P value 
Hospital Sewage 
H1 GI + MICU 4 1.000 
H2 Burn + Lab + ICU 4 0.313 
H3 Heart + ICU 4 0.625 
H4 ER + Neuro 5 0.438 
Domestic Sewage Raw Sewage 8 0.578 
Treated Sewage Secondary Effluent 10 1.000 
Surface Water 
Morgan Creek Upstream 10 0.846 
Morgan Creek Downstream 10 0.846 
Jordan Lake 3 0.750 
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Objective 2 Results 
Objective 2 was completed during Phase 2 and focused on determining the presence, 
concentration, and relative proportion of presumptive Extended Spectrum β-lactam resistant E. coli and 
coliforms as well as presumptive carbapenem resistant E. coli and coliforms in representative samples of 
hospital sewage, municipal sewage influent and secondary treated effluent as well as surface waters up 
and downstream from the effluent discharge point.  
The following analysis was done to evaluate resistance profiles within each site and amongst 
other sites. Wilcoxon-signed rank tests were performed to compare pared observations within the same 
site. Mann-Whitney U tests were used to compare observations between sites. When three or more 
sites were compared, a Kruskal-Wallis one-way analysis of variance was performed.  
 
Hospital Sewage 
As shown in Table 3.4, the average concentrations of presumptive ESBL and KPC positive E. coli 
in H1 were 1.26 x 106 and 4.73 x 105 CFU / 100 mL, respectively. The average proportions of ESBL and 
KPC E. coli were 7.00% and 2.50%, respectively. The average concentrations of presumptive ESBL and 
KPC positive E. coli in H2 were 2.93 x 104 and 8.30 x 103 CFU / 100 mL, respectively. The average 
proportions of ESBL and KPC E. coli were 3.22% and 1.48%, respectively. The average concentrations of 
presumptive ESBL and KPC positive E. coli in H3 were 3.57 x 104 and 1.56 x 105 CFU / 100 mL, 
respectively. The average proportions of ESBL and KPC E. coli were 24.19% and 13.82%, respectively. 
The average concentrations of presumptive ESBL and KPC positive E. coli in H4 were 5.65 x 105 and 6.81 
x 104 CFU / 100 mL, respectively. The average proportions of ESBL and KPC E. coli were 61.61% and 
2.15%, respectively. The average concentrations of presumptive ESBL and KPC positive E. coli in all 
hospital sewage samples combined were 5.00 x 105 and 1.80 x 105 CFU / 100 mL, respectively. The 
average proportions of ESBL and KPC E. coli were 27.0% and 4.8%, respectively. 
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Table 3.4 - Average Concentrations and Proportions of Presumptive ESBL and KPC Positive 
E. coli in Hospital Sewage Samples 
Hospital 1 (GI and MICU) 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
E. coli 
N = 5 
  
Average 2.27E+06 1.26E+06 4.73E+05 7.00% 2.50% 
Standard Error 7.54E+02 5.02E+02 3.08E+02 3.10% 1.10% 
95% Confidence ± 1.48E+03 9.83E+02 6.03E+02 6.00% 2.20% 
Hospital 2 (Burn, Lab, ICU) 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
E. coli 
N = 5 
  
Average 3.79E+05 2.93E+04 8.30E+03 3.22% 1.48% 
Standard Error 3.08E+02 7.65E+01 4.07E+01 1.69% 0.72% 
95% Confidence ± 6.04E+02 1.50E+02 7.99E+01 3.32% 1.41% 
Hospital 3 (ICU, cardiac, laundry) 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
E. coli 
N = 5 
  
Average 7.73E+06 3.57E+04 1.56E+05 24.19% 13.82% 
Standard Error 1.61E+03 8.45E+01 1.76E+02 13.52% 6.75% 
95% Confidence ± 3.15E+03 1.66E+02 3.46E+02 26.51% 13.24% 
Hospital 4 (ER, Neuro) 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
E. coli 
N = 6 
  
Average 6.98E+06 5.65E+05 6.81E+04 61.61% 2.15% 
Standard Error 1.18E+03 3.07E+02 1.07E+02 34.57% 0.75% 
95% Confidence ± 2.32E+03 6.02E+02 2.09E+02 67.76% 1.47% 
All Hospitals Combined  
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
E. coli 
N = 20 
  
Average 
4.30E+06 5.00E+05 1.80E+05 27.0% 4.8% 
Standard Error 
5.18E+02 1.58E+02 9.48E+01 11.6% 2.0% 
95% Confidence ± 
1.02E+03 3.10E+02 1.86E+02 22.7% 3.9% 
 
** The proportions of ESBL and KPC E. coli were calculated using CHROMagar Orientation in the denominator, as 
there was one week without a parallel assay on Bio-Rad Rapid’E. coli 2 agar. Consequently, the average 
concentration, standard error, and confidence intervals for Bio-Rad combined analysis were calculated with an N = 
16.  
 
In H1 (N=5), H2 (N=5), and H3 (N=5) the Wilcoxon Signed Rank comparison of concentrations 
of presumptive ESBL and KPC positive E. coli showed that the distribution of the two groups did not differ 
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significantly at a 95% CL (Table 3.5). The same concentration analysis for H4 showed that the E. coli 
concentrations did differ significantly (N = 6, P = 0.031), at 95% CL.  
In Table 3.5 is also shown the Wilcoxon Signed Rank tests comparing the proportions of 
presumptive ESBL and KPC positive E. coli in the hospital sites. Tests for H1 (N=5), H2 (N=5), and H3 
(N=5) showed that the proportions of the E. coli did not differ significantly at 95% CL. In H4, the 
proportions of the E. coli did differ significantly (N = 6, P = 0.031), at the 95% CL.  
Table 3.5 - Comparison of Presumptive ESBL and KPC Positive E. coli in Hospital Sewage: 
Site-Specific Wilcoxon Signed Rank Tests of Concentrations and Proportions (α = 0.05) 
 E. coli Concentration % E. coli  
Sample N V P-value N V P-value 
H1 5 12 0.313 5 12 0.313 
H2 5 10 0.1 5 10 0.100 
H3 5 9 0.813 5 7 0.584 
H4 6 21 0.031 6 21 0.031 
 
As shown in Table 3.6, the average concentrations of presumptive ESBL and KPC positive Non-E. 
coli coliforms in H1 were 5.38 x 106 and 3.00 x 106 CFU / 100 mL, respectively. The average proportions 
of ESBL and KPC non-E. coli coliforms were 36.2% and 26.30%, respectively. The average concentrations 
of presumptive ESBL and KPC positive non-E. coli coliforms in H2 were 1.62 x 105 and 3.95 x 104 CFU / 
100 mL, respectively. The average proportions of ESBL and KPC non-E. coli coliforms were 21.74% and 
27.59%, respectively. The average concentrations of presumptive ESBL and KPC positive non-E. coli 
coliforms in H3 were 1.36 x 105 and 3.18 x 105 CFU / 100 mL, respectively. The average proportions of 
ESBL and KPC non-E. coli coliforms were 49.35% and 46.55%, respectively. The average concentrations 
of presumptive ESBL and KPC positive non-E. coli coliforms in H4 were 8.07 x 105 and 2.02 x 105 CFU / 
100 mL, respectively. The average proportions of ESBL and KPC non-E. coli coliforms were 70.12% and 
13.11%, respectively. The average concentrations of presumptive ESBL and KPC positive non-E. coli 
coliforms in all hospital sewage samples combined were 1.62 x 106 and 8.89 x 105 CFU / 100 mL, 
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respectively. The average proportions of ESBL and KPC non-E. coli coliforms were 44.4% and 28.4%, 
respectively. 
Table 3.6 - Average Concentrations and Proportions of Presumptive ESBL and KPC Positive 
Non-E. coli coliforms in Hospital Sewage Samples 
Hospital 1 (GI and MICU) 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
Other 
Coliforms 
N = 6 
  
Average 3.04E+08 5.38E+06 3.00E+06 36.20% 26.30% 
Standard Error 7.80E+03 9.47E+02 7.07E+02 13.40% 15.50% 
95% Confidence ± 1.53E+04 1.86E+03 1.38E+03 26.20% 30.40% 
Hospital 2 (Burn, Lab, ICU) 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
Other 
Coliforms 
N = 6 
  
Average 5.70E+05 1.62E+05 3.95E+04 21.74% 27.59% 
Standard Error 3.38E+02 1.64E+02 8.11E+01 10.46% 16.75% 
95% Confidence ± 6.62E+02 3.22E+02 1.59E+02 20.50% 32.83% 
Hospital 3 (ICU, cardiac, 
laundry) 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
Other 
Coliforms 
N = 6 
  
Average 3.16E+06 1.36E+05 3.18E+05 49.35% 46.55% 
Standard Error 7.95E+02 1.51E+02 2.30E+02 26.00% 29.25% 
95% Confidence ± 1.56E+03 2.95E+02 4.52E+02 50.96% 57.33% 
Hospital 4 (ER, Neuro) 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
Other 
Coliforms 
N = 6 
  
Average 1.73E+06 8.07E+05 2.02E+05 70.12% 13.11% 
Standard Error 5.88E+02 3.67E+02 1.84E+02 22.65% 5.02% 
95% Confidence ± 1.15E+03 7.19E+02 3.60E+02 44.39% 9.84% 
All Hospitals Combined  
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
Other 
coliforms 
Average 
7.74E+07 1.62E+06 8.89E+05 44.4% 28.4% 
N = 24 Standard Error 
1.97E+03 2.60E+02 1.92E+02 9.7% 9.1% 
  95% Confidence ± 
3.86E+03 5.09E+02 3.77E+02 19.0% 17.8% 
** The proportions of ESBL and KPC Non-E. coli coliform were calculated using CHROMagar Orientation in the 
denominator, as there was one week without a parallel assay on Bio-Rad Rapid’E. coli 2 agar. Consequently, the 
average concentration, standard error, and confidence intervals for Bio-Rad combined analysis were calculated with 
an N = 20.  
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In H1 (N=6), H2 (N=6), and H3 (N=6), the Wilcoxon Signed Rank comparison of concentrations 
of presumptive ESBL and KPC positive non-E. coli coliforms showed that the distribution of the two 
groups did not differ significantly at a 95% CL (Table 3.7). The same concentration analysis for H4 
showed that the non-E. coli coliform concentrations did differ significantly (N = 6, P = 0.031), at the 95% 
CL.  
Table 3.7 also shows Wilcoxon Signed Rank tests comparing the proportions of presumptive ESBL 
and KPC positive non-E. coli coliforms in the hospital sites. Tests for H1 (N=6), H2 (N=6), and H3 (N=6) 
showed that the proportions of the non-E. coli coliforms did not differ significantly at a 95% CL. In H4, 
the proportions of the non-E. coli coliforms did differ significantly (N = 6, P = 0.031), at the 95% CL.  
Table 3.7 - Comparison of Presumptive ESBL and KPC Positive Non-E. coli Coliforms in 
Hospital Sewage: Site-Specific Wilcoxon Signed Rank Tests of Concentrations and 
Proportions (α = 0.05) 
 
Non-E. coli coliforms Concentration % Non-E. coli coliforms 
Sample N V P-value N V P-value 
H1 6 18 0.156 6 16 0.313 
H2 6 15 0.438 6 13 0.688 
H3 6 5 0.59 6 7 1 
H4 6 21 0.031 6 21 0.031 
 
As shown in Table 3.8, the average concentrations of presumptive ESBL and KPC positive 
combined coliforms in H1 were 4.40 x 106 and 1.87 x 106 CFU / 100 mL, respectively. The average 
proportions of ESBL and KPC combined coliforms were 26.9% and 18.50%, respectively. The average 
concentrations of presumptive ESBL and KPC positive combined coliforms in H2 were 1.57 x 105 and 5.57 
x 104 CFU / 100 mL, respectively. The average proportions of ESBL and KPC combined coliforms were 
9.25% and 22.06%, respectively. The average concentrations of presumptive ESBL and KPC positive 
combined coliforms in H3 were 1.32 x 105 and 4.71 x 105 CFU / 100 mL, respectively. The average 
proportions of ESBL and KPC combined coliforms were 39.82% and 31.89%, respectively. The average 
concentrations of presumptive ESBL and KPC positive combined coliforms in H4 were 1.37 x 106 and 2.71 
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x 105 CFU / 100 mL, respectively. The average proportions of ESBL and KPC combined coliforms were 
52.28% and 5.93%, respectively. The average concentrations of presumptive ESBL and KPC positive 
combined coliforms in all hospital sewage samples combined were 1.51 x 106 and 6.47 x 105 CFU / 100 
mL, respectively. The average proportions of ESBL and KPC combined coliforms were 33.0% and 18.9%, 
respectively. 
Table 3.8 - Average Concentrations and Proportions of Presumptive ESBL and KPC Positive 
Combined Coliforms in Hospital Sewage  
Hospital 1 (GI and MICU) 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
Combined 
coliforms 
N = 5 
Average 2.11E+07 4.40E+06 1.87E+06 26.90% 18.50% 
Standard Error 2.30E+03 9.38E+02 6.11E+02 6.50% 10.20% 
95% Confidence ± 4.50E+03 1.84E+03 1.20E+03 12.80% 20.00% 
Hospital 2 (Burn, Lab, ICU) 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
Combined 
coliforms 
N = 5 
Average 1.01E+06 1.57E+05 5.57E+04 9.25% 22.06% 
Standard Error 5.02E+02 1.77E+02 1.06E+02 5.12% 15.68% 
95% Confidence ± 9.84E+02 3.48E+02 2.07E+02 10.03% 30.74% 
Hospital 3 (ICU, cardiac, laundry) 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
Combined 
coliforms 
N = 5 
Average 9.67E+06 1.32E+05 4.71E+05 39.82% 31.89% 
Standard Error 1.55E+03 1.63E+02 3.07E+02 23.52% 23.02% 
95% Confidence ± 3.05E+03 3.19E+02 6.02E+02 46.10% 45.12% 
Hospital 4 (ER, Neuro) 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
Combined 
coliforms 
N = 6 
Average 8.71E+06 1.37E+06 2.71E+05 52.28% 5.93% 
Standard Error 1.32E+03 4.78E+02 2.12E+02 17.36% 2.34% 
95% Confidence ± 2.59E+03 9.37E+02 4.16E+02 34.02% 4.59% 
All Hospitals Combined 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
Combined 
coliforms 
N = 21 
Average 
1.00E+07 1.51E+06 6.47E+05 33.0% 18.9% 
Standard Error 
7.69E+02 2.68E+02 1.76E+02 8.0% 6.8% 
95% Confidence ± 
1.51E+03 5.25E+02 3.44E+02 15.7% 13.4% 
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** The proportions of ESBL and KPC Non-E. coli coliform were calculated using CHROMagar Orientation in the 
denominator, as there was one week without a parallel assay on Bio-Rad Rapid’E. coli 2 agar. Consequently, the 
average concentration, standard error, and confidence intervals for Bio-Rad combined analysis were calculated with 
an N = 17.  
In H1 (N=5), H2 (N=5), and H3 (N=5) the Wilcoxon Signed Rank comparison of concentrations 
of presumptive ESBL and KPC positive combined coliforms showed that the distribution of the two groups 
did not differ significantly at a 95% CL (Table 3.9). The same concentration analysis for H4 showed that 
the combined coliform concentrations did differ significantly (N = 6, P = 0.031), at a 95% CL.  
Table 3.5 also shows Wilcoxon Signed Rank tests comparing the proportions of presumptive ESBL 
and KPC positive combined coliforms in the hospital sites. Tests for H1 (N=5), H2 (N=5), and H3 (N=5) 
showed that the proportions of the combined coliforms did not differ significantly at a 95% CL. In H4, the 
proportions of the combined coliforms did differ significantly (N = 6, P = 0.031), at a 95% CL.  
Table 3.9 - Comparison of Presumptive ESBL and KPC Positive Combined Coliforms in 
Hospital Sewage: Site-Specific Wilcoxon Signed Rank Tests of Concentrations and 
Proportions (α = 0.05) 
 Combined Coliforms Concentration % Combined Coliforms 
Sample N V P-value N V P-value 
H1 5 12 0.313 5 11 0.438 
H2 5 10 0.625 5 8 1 
H3 5 7 1 5 8 1 
H4 6 21 0.031 6 21 0.031 
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Raw Sewage 
As shown in Table 3.10, the average concentrations of presumptive ESBL and KPC positive E. coli 
in municipal sewage were 2.70 x 105 and 6.43 x 104 CFU / 100 mL, respectively. The average proportions 
of ESBL and KPC E. coli were 12.19% and 2.76%, respectively. The average concentrations of ESBL and 
KPC positive other coliforms were 1.17 x 106 and 2.37 x 105 CFU / 100 mL, respectively. The average 
proportions of ESBL and KPC positive other coliforms were 4.40% and 1.02%, respectively. The average 
concentrations of ESBL and KPC positive combined coliforms were 1.44 x 106 and 3.01 x 105 CFU / 100 
mL, respectively. The average proportions of ESBL and KPC positive combined coliforms were 3.09% and 
0.74%, respectively.  
Table 3.10 - Average Concentrations and Proportions of Presumptive ESBL and KPC 
Positive Target Organisms in Municipal Sewage  
Raw Sewage 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
E. coli 
N = 10 
Average 2.58E+06 2.70E+05 6.43E+04 12.19% 2.76% 
Standard Error 5.68E+02 1.64E+02 8.02E+01 7.10% 1.30% 
95% Confidence ± 1.11E+03 3.22E+02 1.57E+02 13.90% 2.50% 
Other 
Coliforms 
N = 10 
Average 3.34E+07 1.17E+06 2.37E+05 4.40% 1.02% 
Standard Error 1.83E+03 3.42E+02 1.54E+02 1.3% 0.3% 
95% Confidence ± 3.58E+03 6.71E+02 3.02E+02 2.6% 0.6% 
Combined 
coliforms 
N = 10 
Average 4.22E+07 1.44E+06 3.01E+05 3.09% 0.74% 
Standard Error 2.30E+03 3.80E+02 1.73E+02 0.7% 0.1% 
95% Confidence ± 4.50E+03 7.44E+02 3.40E+02 1.3% 0.3% 
 
In Table 3.11, the Wilcoxon Signed Rank comparison of concentrations of presumptive ESBL and 
KPC positive E. coli in municipal sewage showed that the distribution of the two groups did differ 
significantly (N = 10, P = 0.010), at a 95% CL (Table 3.11). The same concentration analysis for the 
other coliforms and combined coliforms in municipal sewage showed that the non-E. coli coliforms did 
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differ significantly (N = 10, P = 0.002) and the combined coliform concentrations did differ significantly 
(N = 10, P = 0.002), at a 95% CL. 
The Wilcoxon Signed Rank tests comparing the proportions of presumptive ESBL and KPC 
positive target organisms in municipal sewage showed that the proportions of the E. coli did differ 
significantly (N = 10, P = 0.006), the proportions of non-E. coli coliforms did differ significantly (N = 10, 
P = 0.006), and the proportions of combined coliforms did differ significantly (N = 10, P = 0.002), at a 
95% CL (Table 3.11).  
Table 3.11 - Comparison of Presumptive ESBL and KPC Positive Target Organisms in 
Municipal Sewage: Organism-Specific Wilcoxon Signed Rank Tests of Concentrations and 
Proportions (α = 0.05) 
E. coli Concentration 
Non-E. coli coliforms 
Concentration 
Combined Coliforms 
Concentration 
N V P-value N V P-value N V P-value 
10 52 0.010 10 55 0.002 10 55 0.002 
         
% E. coli  % Non-E. coli coliforms % Combined Coliforms 
N V P-value N V P-value N V P-value 
10 53 0.006 10 55 0.006 10 55 0.002 
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Secondary Effluent 
As shown in Table 3.12, the average concentrations of presumptive ESBL and KPC positive E. coli 
in secondary effluent were 2.89 x 102 and 1.53 x 102 CFU / 100 mL, respectively. The average 
proportions of ESBL and KPC E. coli were 3.50% and 1.78%, respectively. The average concentrations of 
ESBL and KPC positive other coliforms were 1.11 x 103 and 1.10 x 103 CFU / 100 mL, respectively. The 
average proportions of ESBL and KPC positive other coliforms were 1.60% and 1.55%, respectively. The 
average concentrations of ESBL and KPC positive combined coliforms were 1.39 x 103 and 1.26 x 103 CFU 
/ 100 mL, respectively. The average proportions of ESBL and KPC positive combined coliforms were 
1.31% and 1.23%, respectively.  
Table 3.12 - Average Concentrations and Proportions of Presumptive ESBL and KPC 
Positive Target Organisms in Secondary Effluent   
Secondary Effluent 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
E. coli 
N = 10 
Average 3.93E+04 2.89E+02 1.53E+02 3.50% 1.78% 
Standard Error 6.27E+01 5.38E+00 3.92E+00 1.3% 0.9% 
95% Confidence ± 1.23E+02 1.05E+01 7.68E+00 2.6% 1.7% 
Other 
Coliforms 
N = 10 
Average 9.58E+04 1.11E+03 1.10E+03 1.60% 1.55% 
Standard Error 9.79E+01 1.05E+01 1.05E+01 0.4% 0.4% 
95% Confidence ± 1.92E+02 2.06E+01 2.06E+01 0.7% 0.7% 
Combined 
coliforms 
N = 10 
Average 1.35E+05 1.39E+03 1.26E+03 1.31% 1.23% 
Standard Error 1.16E+02 1.18E+01 1.12E+01 0.3% 0.3% 
95% Confidence ± 2.28E+02 2.31E+01 2.20E+01 0.6% 0.5% 
 
In Table 3.13, the Wilcoxon Signed Rank comparison of concentrations of presumptive ESBL and 
KPC positive E. coli in secondary effluent showed that the distribution of the two groups did differ 
significantly (N = 10, P = 0.049), at a 95% CL (Table 3.13). The same concentration analysis for the 
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other coliforms and combined coliforms in municipal sewage showed that the non-E. coli coliforms did not 
differ significantly (N = 10, P = 0.846) and the combined coliform concentrations did not differ 
significantly (N = 10, P = 0.625), all at a 95% CL. 
The Wilcoxon Signed Rank tests comparing the proportions of presumptive ESBL and KPC 
positive target organisms in secondary effluent showed that the proportions of the E. coli did not differ 
significantly (N = 10, P = 0.064), the proportions of non-E. coli coliforms did not differ significantly (N = 
10, P = 0.846), and the proportions of combined coliforms did not differ significantly (N = 10, P = 
0.770), all at a 95% CL (Table 3.13).  
Table 3.13 - Comparison of Presumptive ESBL and KPC Positive Target Organisms in 
Secondary Effluent: Organism-Specific Wilcoxon Signed Rank Tests of Concentrations and 
Proportions (α = 0.05) 
E. coli Concentration 
Non-E. coli coliforms 
Concentration 
Combined Coliforms 
Concentration 
N V P-value N V P-value N V P-value 
10 47 0.049 10 30 0.846 10 33 0.625 
         
% E. coli  % Non-E. coli coliforms % Combined Coliforms 
N V P-value N V P-value N V P-value 
10 46 0.064 10 30 0.846 10 31 0.770 
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Morgan Creek, Upstream of WWTP 
As shown in Table 3.14, the average concentrations of presumptive ESBL and KPC positive E. coli 
in Morgan Creek, upstream of WWTP were 2.48 x 101 and 9.13 x 101 CFU / 100 mL, respectively. The 
average proportions of ESBL and KPC E. coli were 3.18% and 3.19%, respectively. The average 
concentrations of ESBL and KPC positive other coliforms were 1.77 x 102 and 3.89 x 102 CFU / 100 mL, 
respectively. The average proportions of ESBL and KPC positive other coliforms were 2.11% and 1.43%, 
respectively. The average concentrations of ESBL and KPC positive combined coliforms were 2.02x 102 
and 4.81 x 102 CFU / 100 mL, respectively. The average proportions of ESBL and KPC positive combined 
coliforms were 2.01% and 1.56%, respectively.  
Table 3.14 - Average Concentrations and Proportions of Presumptive ESBL and KPC 
Positive Target Organisms in Morgan Creek, Upstream of WWTP 
Morgan Creek Upstream 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
E. coli 
N = 10 
Average 4.02E+02 2.48E+01 9.13E+01 3.18% 3.19% 
Standard Error 6.34E+00 1.58E+00 3.02E+00 1.60% 3.00% 
95% Confidence ± 1.24E+01 3.09E+00 5.92E+00 3.20% 5.80% 
Other 
Coliforms 
N = 10 
  
Average 1.52E+04 1.77E+02 3.89E+02 2.11% 1.43% 
Standard Error 3.89E+01 4.21E+00 6.24E+00 1.10% 0.60% 
95% Confidence ± 7.63E+01 8.24E+00 1.22E+01 2.20% 1.20% 
Combined 
coliforms 
N = 10 
  
Average 1.56E+04 2.02E+02 4.81E+02 2.01% 1.56% 
Standard Error 3.95E+01 4.49E+00 6.93E+00 1.00% 0.70% 
95% Confidence ± 7.73E+01 8.80E+00 1.36E+01 2.00% 1.30% 
 
In Table 3.15, the Wilcoxon Signed Rank comparison of concentrations of presumptive ESBL and 
KPC positive E. coli in Morgan Creek, upstream of WWTP showed that the distribution of the two groups 
did not differ significantly (N = 10, P = 1.000), at a 95% CL (Table 3.15). The same concentration 
analysis for the other coliforms and combined coliforms in municipal sewage showed that the non-E. coli 
coliforms did not differ significantly (N = 10, P = 0.813) and the combined coliform concentrations did 
not differ significantly (N = 10, P = 0.813), all at a 95% CL. 
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The Wilcoxon Signed Rank tests comparing the proportions of presumptive ESBL and KPC 
positive target organisms in secondary effluent showed that the proportions of the E. coli did not differ 
significantly (N = 10, P = 1.000), the proportions of non-E. coli coliforms did not differ significantly (N = 
10, P = 0.636), and the proportions of combined coliforms did not differ significantly (N = 10, P = 
0.722), all at a 95% CL (Table 3.15). 
Table 3.15 - Comparison of Presumptive ESBL and KPC Positive Target Organisms in 
Morgan Creek, Upstream: Organism-Specific Wilcoxon Signed Rank Tests of 
Concentrations and Proportions (α = 0.05) 
E. coli Concentration 
Non-E. coli coliforms 
Concentration 
Combined Coliforms 
Concentration 
N V P-value N V P-value N V P-value 
10 7.5 1.000 10 20 0.813 10 20 0.813 
         
% E. coli  % Non-E. coli coliforms % Combined Coliforms 
N V P-value N V P-value N V P-value 
10 8 1.000 10 27 0.636 10 26 0.722 
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Morgan Creek, Downstream of WWTP 
As shown in Table 3.16, the average concentrations of presumptive ESBL and KPC positive E. coli 
in Morgan Creek, downstream of WWTP were 6.03 x 101 and 3.17 CFU / 100 mL, respectively. The 
average proportions of ESBL and KPC E. coli were 11.55% and 1.89%, respectively. The average 
concentrations of ESBL and KPC positive other coliforms were 3.70 x 102 and 1.42 x 102 CFU / 100 mL, 
respectively. The average proportions of ESBL and KPC positive other coliforms were 1.92% and 0.87%, 
respectively. The average concentrations of ESBL and KPC positive combined coliforms were 4.30x 102 
and 1.45 x 102 CFU / 100 mL, respectively. The average proportions of ESBL and KPC positive combined 
coliforms were 2.18% and 0.87%, respectively.  
Table 3.16 - Average Concentrations and Proportions of Presumptive ESBL and KPC 
Positive Target Organisms in Morgan Creek, Downstream of WWTP 
Morgan Creek Downstream 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
E. coli 
N = 10 
  
Average 1.29E+03 6.03E+01 3.17E+00 11.55% 1.89% 
Standard Error 1.14E+01 2.46E+00 5.63E-01 6.40% 1.60% 
95% Confidence ± 2.23E+01 4.81E+00 1.10E+00 12.50% 3.20% 
Other 
Coliforms 
N = 10 
  
Average 3.12E+04 3.70E+02 1.42E+02 1.92% 0.87% 
Standard Error 5.59E+01 6.08E+00 3.77E+00 0.63% 0.41% 
95% Confidence ± 1.10E+02 1.19E+01 7.38E+00 1.23% 0.81% 
Combined 
coliforms 
N = 10 
  
Average 3.25E+04 4.30E+02 1.45E+02 2.18% 0.87% 
Standard Error 5.70E+01 6.56E+00 3.81E+00 0.71% 0.43% 
95% Confidence ± 1.12E+02 1.29E+01 7.46E+00 1.38% 0.85% 
 
In Table 3.17, the Wilcoxon Signed Rank comparison of concentrations of presumptive ESBL and 
KPC positive E. coli in Morgan Creek, downstream of WWTP showed that the distribution of the two 
groups did not differ significantly (N = 10, P = 0.107), at a 95% CL (Table 3.17). The same concentration 
analysis for the other coliforms and combined coliforms in municipal sewage showed that the non-E. coli 
coliforms did not differ significantly (N = 10, P = 0.477) and the combined coliform concentrations did 
not differ significantly (N = 10, P = 0.407), at a 95% CL. 
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The Wilcoxon Signed Rank tests comparing the proportions of presumptive ESBL and KPC 
positive target organisms in secondary effluent showed that the proportions of the E. coli did not differ 
significantly (N = 10, P = 0.107), the proportions of non-E. coli coliforms did not differ significantly (N = 
10, P = 0.343), and the proportions of combined coliforms did not differ significantly (N = 10, P = 
0.236), all at a 95% CL (Table 3.17).  
Table 3.17 - Comparison of Presumptive ESBL and KPC Positive Target Organisms in 
Morgan Creek, Downstream: Organism-Specific Wilcoxon Signed Rank Tests of 
Concentrations and Proportions (α = 0.05) 
E. coli Concentration 
Non-E. coli coliforms 
Concentration 
Combined Coliforms 
Concentration 
N V P-value N V P-value N V P-value 
10 30 0.107 10 29 0.477 10 30 0.407 
         
% E. coli  % Non-E. coli coliforms % Combined Coliforms 
N V P-value N V P-value N V P-value 
10 30 0.107 10 31 0.343 10 33 0.236 
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Jordan Lake 
As shown in Table 3.17, the average concentrations of presumptive ESBL and KPC positive E. coli 
in Jordan Lake, downstream of WWTP were 3.50 x 101 and 8.33 x 10-1 CFU / 100 mL, respectively. The 
average proportions of ESBL and KPC E. coli were 0.48% and 0.67%, respectively. The average 
concentrations of ESBL and KPC positive other coliforms were 4.02 x 102 and 5.52 x 102 CFU / 100 mL, 
respectively. The average proportions of ESBL and KPC positive other coliforms were 0.84% and 
127.15%, respectively. The average concentrations of ESBL and KPC positive combined coliforms were 
4.37x 102 and 5.53 x 102 CFU / 100 mL, respectively. The average proportions of ESBL and KPC positive 
combined coliforms were 1.40% and 153.30%, respectively. 
 
Table 3.18 - Average Concentrations and Proportions of Presumptive ESBL and KPC 
Positive Target Organisms in Jordan Lake, Downstream of WWTP 
Jordan Lake 
Bio-Rad 
Rapid Agar 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
E. coli 
N = 3 
  
Average 1.42E+02 3.50E+01 8.33E-01 0.48% 0.67% 
Standard Error 6.87E+00 3.42E+00 6.45E-01 0.20% 0.70% 
95% Confidence ± 1.35E+01 6.69E+00 1.27E+00 0.50% 1.30% 
Other 
Coliforms 
N = 3 
  
Average 2.48E+04 4.02E+02 5.52E+02 0.84% 127.15% 
Standard Error 9.10E+01 1.16E+01 1.66E+01 0.80% 126.50% 
95% Confidence ± 1.78E+02 2.27E+01 3.26E+01 1.60% 248.00% 
Combined 
Coliforms 
N = 3 
  
Average 2.50E+04 4.37E+02 5.53E+02 0.72% 78.69% 
Standard Error 9.13E+01 1.21E+01 1.66E+01 0.70% 78.20% 
95% Confidence ± 1.79E+02 2.36E+01 3.26E+01 1.40% 153.30% 
 
In Table 3.19, the Wilcoxon Signed Rank comparison of concentrations of presumptive ESBL and 
KPC positive E. coli in Jordan Lake, downstream of WWTP showed that the distribution of the two groups 
did not differ significantly (N = 3, P = 0.500), at a 95% CL (Table 3.19). The same concentration analysis 
for the other coliforms and combined coliforms in municipal sewage showed that the non-E. coli coliforms 
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did not differ significantly (N = 3, P = 0.750) and the combined coliform concentrations did not differ 
significantly (N = 3, P = 0.750), at a 95% CL. 
The Wilcoxon Signed Rank tests comparing the proportions of presumptive ESBL and KPC 
positive target organisms in secondary effluent showed that the proportions of the E. coli did not differ 
significantly (N = 3, P = 1.000), the proportions of non-E. coli coliforms did not differ significantly (N = 3, 
P = 1.000), and the proportions of combined coliforms did not differ significantly (N = 3, P = 0.236), at a 
95% CL (Table 3.19). 
 
Table 3.19 - Comparison of Presumptive ESBL and KPC Positive Target Organisms in Jordan 
Lake: Organism-Specific Wilcoxon Signed Rank Tests of Concentrations and Proportions (α 
= 0.05) 
E. coli Concentration 
Non-E. coli coliforms 
Concentration 
Combined Coliforms 
Concentration 
N V P-value N V P-value N V P-value 
3 5 0.500 3 4 0.750 3 4 0.750 
         
% E. coli  % Non-E. coli coliforms % Combined Coliforms 
N V P-value N V P-value N V P-value 
3 3 1.000 3 3 1.000 10 33 0.236 
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Intra-Site Comparison and Analysis of All Hospital Sites 
Kruskal Wallis tests were performed to compare target organism concentration from all the 
hospital sewage sampling sites (Table 3.20). All tests had a N equal to or greater than 4. No significant 
differences were found in the concentrations of presumptive E. coli, other coliforms, and combined 
coliforms detected on Bio-Rad and detected on CHROMagar KPC (P > 0.05) for all hospital samples, at 
95% CI. There were significant differences in the concentrations of presumptive other and combined 
coliforms directly detected on CHROMagar ESBL (P = 0.006 and 0.013, respectively). There was not a 
significant difference in the ESBL concentration of presumptive E. coli (P = 0.072). 
Table 3.20 - Comparison of Concentrations of Presumptive E. coli, Non-E. coli coliforms, 
and Combined coliforms in Hospital Sewage Sites (H1 – H4): Medium- and Organism-
Specific Kruskal Wallis Tests (α = 0.05) 
Medium Target Organism N CHI SQUARED DF P VALUE 
Bio-Rad 
E. coli 
 
Other coliforms 
 
Combined coliforms 
4 1.97 3 0.579 
5 5.18 3 0.159 
4 3.19 3 0.364 
CHROMagar ESBL 
E. coli 
 
Other coliforms 
 
Combined coliforms 
5 6.99 3 0.072 
6 12.56 3 0.006 
5 10.85 3 0.013 
CHROMagar KPC 
E. coli 
 
Other coliforms 
 
Combined coliforms 
5 3.70 3 0.296 
6 6.02 3 0.111 
5 3.76 3 0.289 
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Comparison of Raw Sewage and Secondary Effluent 
Mann-Whitney U-tests comparing the proportions of presumptive ESBL and KPC positive target 
organisms in Secondary Effluent and Raw Sewage are shown in Table 3.22. The proportions of the ESBL 
E. coli did not differ significantly (N = 10, P = 0.123), the proportions other coliforms as well as combined 
coliforms did differ significantly, (N = 10, P = 0.015 and 0.029), at a 95% CL. The proportions of all 
presumptive KPC positive target organisms did not differ significantly between secondary effluent and 
raw sewage (N = 10, P > 0.05), at a 95% CL.  
3. 21 - Comparison of the Proportions of Presumptive ESBL and KPC Positive Target 
Organisms in Municipal WWTP Influent and Effluent: Medium-Specific Mann-Whitney U-
Tests (α = 0.05) 
Resistance Profile Target Organism  N W P VALUE 
% ESBL Positive 
E. coli 
 
Other coliforms 
 
Combined coliforms 
10 71 0.123 
10 82 0.015 
10 79 0.028 
% KPC Positive 
E. coli 
 
Other coliforms 
 
Combined coliforms 
10 62 0.393 
10 28 0.104 
10 31 0.162 
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Comparison of Secondary Effluent and Morgan Creek  
Concentrations of presumptive target organisms were compared between Secondary Effluent and 
Morgan Creek Upstream of the WWTP using Mann-Whitney U-tests (Table 3.23). Test results showed 
that the concentration distributions between the two sites were significantly different for all target 
organisms (P < 0.05), at a 95% CL.  
Table 3.22 – Comparison of Target Organism Concentrations in Secondary Effluent and 
Morgan Creek Upstream of WWTP: Medium- and Organism-Specific Mann-Whitney U-Tests 
(α = 0.05) 
Medium Target Organism N W P VALUE 
Bio-Rad 
E. coli 
 
Other coliforms 
 
Combined coliforms 
10 97 0.000 
10 88 0.003 
10 95 0.000 
CHROMagar ESBL 
E. coli 
 
Other coliforms 
 
Combined coliforms 
10 93 0.001 
10 84 0.011 
10 92 0.002 
CHROMagar KPC 
E. coli 
 
Other coliforms 
 
Combined coliforms 
10 85 0.007 
10 86.5 0.006 
10 86.5 0.006 
 
Mann-Whitney U-tests comparing the proportions of presumptive ESBL and KPC positive target 
organisms in Secondary Effluent and Morgan Creek upstream from the WWTP are shown in Table 3.23. 
The proportions of all ESBL target organisms in Secondary Effluent did not differ significantly from 
proportions of all ESBL target organisms in Morgan Creek Upstream of the WWTP (N = 10, P > 0.05), at 
a 95% CL. The proportions of the KPC E. coli did not differ significantly between Secondary Effluent and 
Morgan Creek, upstream from its discharge but was borderline (N = 10, P = 0.051), at the 95% CL. The 
proportions of the presumptive other KPC positive target organisms in Secondary Effluent did not differ 
significantly from Morgan Creek, upstream (N= 10, P = >0.05) at the 95% CL.  
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Table 3.23 – Comparison of the Proportions of Presumptive ESBL and KPC Positive Target 
Organisms in Secondary Effluent and Morgan Creek Upstream of WWTP: Medium-Specific 
Mann-Whitney U-Tests (α = 0.05) 
Resistance Profile Target Organism  N W P VALUE 
% ESBL Positive 
E. coli 
 
Other coliforms 
 
Combined coliforms 
10 34.5 0.255 
10 41.5 0.545 
10 49 0.971 
% KPC Positive 
E. coli 
 
Other coliforms 
 
Combined coliforms 
10 24.5 0.051 
10 39.5 0.449 
10 43 0.623 
 
Concentrations of presumptive target organisms were compared between Secondary Effluent and 
Morgan Creek Downstream of the WWTP using Mann-Whitney U-tests (Table 3.24). Test results showed 
that the concentration distributions between the two sites were significantly different for all target 
organisms (P < 0.05), at a 95% CL.  
Table 3.24 – Comparison of Target Organism Concentrations in Secondary Effluent and 
Morgan Creek Downstream of WWTP: Medium- and Organism-Specific Mann-Whitney U-
Tests (α = 0.05) 
Medium Target Organism  N W P VALUE 
Bio-Rad 
E. coli 
 
Other coliforms 
 
Combined coliforms 
10 92 0.002 
10 81 0.019 
10 88 0.003 
CHROMagar ESBL 
E. coli 
 
Other coliforms 
 
Combined coliforms 
10 90 0.003 
10 80.5 0.023 
10 88 0.005 
CHROMagar KPC 
E. coli 
 
Other coliforms 
 
Combined coliforms 
10 90 0.002 
10 89 0.004 
10 90 0.003 
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Mann-Whitney U-tests comparing the proportions of presumptive ESBL and KPC positive target 
organisms in Secondary Effluent and Morgan Creek downstream of the WWTP are shown in Table 3.25. 
The proportions of all ESBL target organisms in Secondary Effluent did not differ significantly from 
proportions of all ESBL target organisms in Morgan Creek Upstream of the WWTP (N = 10, P > 0.05), at 
a 95% CL. However, the proportions of presumptive KPC positive E. coli were significantly different (N = 
10, P = 0.029), at a 95% CL. The proportions of the presumptive other KPC positive target organisms in 
Secondary Effluent did not differ significantly from Morgan Creek, upstream (N= 10, P = >0.05) at a 
95% CL.  
Table 3. 25– Comparison of the Proportions of Presumptive ESBL and KPC Positive Target 
Organisms in Secondary Effluent and Morgan Creek Downstream of WWTP: Medium-
Specific Mann-Whitney U-Tests (α = 0.05) 
Resistance Profile Target Organism  N W P VALUE 
% ESBL Positive 
E. coli 
 
Other coliforms 
 
Combined coliforms 
10 59.5 0.496 
10 49.5 1.000 
10 54 0.791 
% KPC Positive 
E. coli 
 
Other coliforms 
 
Combined coliforms 
10 22 0.029 
10 24.5 0.059 
10 29 0.121 
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Comparison of Morgan Creek Up and Downstream of WWTP 
Concentrations of presumptive target organisms were compared between Morgan Creek up and 
downstream of the WWTP using Mann-Whitney U-tests (Table 3.26). Test results showed that the -
concentration distributions between the two sites were not significantly different for all target organisms 
(P > 0.05), at a 95% CL.  
Table 3.26 – Comparison of Target Organism Concentrations in Morgan Creek Upstream 
and Downstream of WWTP Discharge: Medium- and Organism-Specific Mann-Whitney U-
Tests (α = 0.05) 
Medium Target Organism  N W P VALUE 
Bio-Rad 
E. coli 
 
Other coliforms 
 
Combined coliforms 
10 49 0.970 
10 44 0.684 
10 44 0.684 
CHROMagar ESBL 
E. coli 
 
Other coliforms 
 
Combined coliforms 
10 35 0.265 
10 40 0.472 
10 39 0.427 
CHROMagar KPC 
E. coli 
 
Other coliforms 
 
Combined coliforms 
10 56 0.585 
10 45 0.732 
10 45 0.732 
 
Proportions of presumptive ESBL and KPC positive target organisms were compared between 
Morgan Creek up and downstream of the WWTP using Mann-Whitney U-tests (Table 3.27). Test results 
showed no significant differences in the proportions all target organisms in the two sites (P > 0.05), at a 
95% CL.  
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Table 3.27 – Comparison of the Proportions of Presumptive ESBL and KPC Positive Target 
Organisms in Morgan Creek Upstream and Downstream of WWTP Discharge: Medium-
Specific Mann-Whitney U-Tests (α = 0.05) 
Resistance Profile Target Organism  N W P VALUE 
% ESBL Positive 
E. coli 
 
Other coliforms 
 
Combined coliforms 
10 33 0.206 
10 44.5 0.705 
10 44.5 0.705 
% KPC Positive 
E. coli 
 
Other coliforms 
 
Combined coliforms 
10 54 0.728 
10 55 0.732 
10 52.5 0.879 
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Objective 3 Results for Presumptive ESBL E. coli and Non-E. coli Coliforms 
Objective three focused on the performance evaluation of CHROMagar ESBL agar medium for the 
direct detection and quantification of Extended β-lactam resistant E. coli and coliforms in the 
aforementioned nine sampling sites to determine its utility as a part of the proposed indicator system for 
the surveillance of antimicrobial resistance in the water, wastewater, and other environmental matrices. 
Presumptive ESBL positive E. coli and other coliform isolates were collected during the first phase of the 
project. These isolates were saved for future analysis outside of this technical report, however, when 
more funding was awarded in March, 2016, isolate identity confirmation via MALDI-TOF MS was included 
in the fourth phase of the project. In April, more funding became available that supported VITEK 2 
analysis of susceptibility to Cefpodoxime, an Extended-β-lactam, and Imipenem, a carbapenem against 
associated CLSI MIC criteria. VITEK 2 was also used to evaluate ESBL production in several of the 
isolates.  
Hospital Sewage Presumptive ESBL E. coli and Non-E. coli Isolates 
In Table 3.28 are shown number of ESBL isolates from Hospital Sewage chosen for analysis by 
presumptive identity and then summarizes the number of isolates subjected to confirmatory analysis. A 
breakdown of the number of isolates in each type of analysis by site and presumptive organism can be 
found in Tables 2.7.  
Table 3.28 - Summary of ESBL Hospital Sewage Isolates and Confirmatory Analyses  
 Hospital Sewage ESBL Isolates Number of Isolates % of Total 
Total Isolates 104   
Presumptive E. coli Isolates 35 33.7% 
Presumptive other coliform Isolates 69 66.3% 
Summary of Analyses Number of Isolates % of Total 
Performed MALDI-TOF MS 104 100%  
Performed VITEK AST - Cefpodoxime Resistance 42 40.4% 
Performed VITEK AST - Imipenem Resistance 44 42.3% 
Combined MALDI-TOF and VITEK 44 42.3% 
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In Table 3.29 are shown the results for the 104 ESBL isolates that were subjected to MALDI-TOF 
MS for confirmation of presumptive identities that were based on the original visual interpretation of 
colony color, prior to isolation in the original assay. Of the 35 E. coli isolates, 5 (14.3%) were positively 
confirmed as E. coli . Twenty-three (65.7%) of presumptive E. coli isolates were identified as other 
coliforms, 7 (20%) were other Gram-Negative bacteria, and 0 were Gram-positive. Sixty-six (95.7%) of 
the 69 presumptive other coliform isolates were positively confirmed as coliforms. The remaining 3 
isolates were other Gram-negative bacteria. Of the 104 total isolates, 4.8% (N = 5) were E. coli, 85.6% 
(N = 89) were Non-E. coli coliforms, 9.6% (N = 10) were other Gram-negative bacteria, and 0 were 
Gram-positive bacteria. See Appendix 3 for a complete results section of MALDI-TOF speciation for all 104 
ESBL isolates.  
 
Table 3.29 - MALDI-TOF MS Confirmatory Analysis of Presumptive ESBL E. coli and Other 
Coliform Isolates from Hospital Sewage 
Hospital Sewage Isolates 
Presumptive  
E. coli 
Presumptive 
coliform 
Total Isolates 
Original Number of Isolates 35 69 104 
Number of Correctly Confirmed based on 
original presumptive ID prior to isolation  
5 66 71 
% Correctly Confirmed 
14.3% 95.7% 68.3% 
MALDI-TOF Identity  
Presumptive 
E. coli 
Presumptive 
coliform 
# 
Isolates 
% 
Total 
E. coli 5 0 5 4.8% 
Other Coliforms 23 66 89 85.6% 
Other Gram-Negative 7 3 10 9.6% 
Gram-Positive / Other 0 0 0 0.0% 
 
In Table 3.30 are shown paired MALDI-TOF and VITEK 2 results for susceptibility to Cefpodoxime 
and Imipenem in 44 ESBL isolates. Of the 4 confirmed E. coli isolates analyzed for resistance to 
Cefpodoxime, 100% were found to be resistant, 0 had intermediate susceptibility, and 0 were 
susceptible. Of the 4 confirmed E. coli isolates analyzed for resistance to Imipenem, 100% were found to 
be resistant, 0 had intermediate susceptibility, and 0 were susceptible. Of the 36 confirmed Non-E. coli 
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coliform isolates analyzed for resistance to Cefpodoxime, 100% were found to be resistant, 0 had 
intermediate susceptibility, and 0 were susceptible. Of the 38 confirmed Non-E.coli coliform isolates 
analyzed for resistance to Imipenem, 39.5% were found to be resistant, 7.9% had intermediate 
susceptibility, and 52.6% were susceptible. Of the 2 confirmed other Gram-negative bacteria isolates 
analyzed for resistance to Imipenem, 100% were found to be resistant, 0 had intermediate susceptibility, 
and 0 were susceptible. See Appendix 3 for a complete results section of MALDI-TOF and VITEK 2 results 
for all ESBL isolates.  
Table 3.30 - VITEK 2 Cefpodoxime and Imipenem Susceptibility Analysis Based on MALDI-
TOF MS Identities of Presumptive ESBL E. coli and non-E coli Isolates from Hospital 
Sewage 
MALDI-TOF MS 
+ VITEK 2 
(N) 
Number 
Cefpodoxime 
Resistant 
Number 
Cefpodoxime 
Intermediate 
Number 
Cefpodoxime 
Susceptible 
% Res 
% 
Inter 
% 
Suscep 
E. coli 4 4 0 0 100% 0% 0% 
Other coliforms 36 36 0 0 
100.0
% 
0.0% 0.0% 
Other Gram-
Negative bacteria 
2 2 0 0 
100.0
% 
0.0% 0.0% 
Gram-Positive 
Bacteria 
0 0 0 0 0% 0.0% 0.0% 
Total (N) 42 42 0 0 
100.0
% 
0.0% 0.0% 
MALDI-TOF MS 
+ VITEK 2 
(N) 
Number 
Imipenem 
Resistant 
Number 
Imipenem 
Intermediate 
Number 
Imipenem 
Susceptible 
% Res 
% 
Inter 
% 
Suscep 
E. coli 4 4 0 0 100% 0% 0% 
Other coliforms 38 15 3 20 39.5% 7.9% 52.6% 
Other Gram-
Negative bacteria 
2 1 1 1 50.0% 50.0% 50.0% 
Gram-Positive 
Bacteria 
0 0 0 0 0% 0% 0% 
Total (N) 44 20 4 21 45.5% 9.1% 47.7% 
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Raw Sewage 
In Table 3.31 are show the number of ESBL isolates from Raw Sewage chosen for analysis by 
presumptive identity and then summarizes the number of isolates subjected to confirmatory analysis. A 
breakdown of the number of isolates in each type of analysis by site and presumptive organism can be 
found in Tables 2.7.  
Table 3.31 - MALDI-TOF MS Confirmatory Analysis of Presumptive ESBL E. coli and Other 
Coliform Isolates from Raw Sewage  
 Raw Sewage ESBL Isolates Number of Isolates % of Total 
Total Isolates 61   
Presumptive E. coli Isolates 20 32.8% 
Presumptive other coliform Isolates 41 67.2% 
Summary of Analyses Number of Isolates % of Total 
Performed MALDI-TOF MS 61 100.0% 
Performed VITEK AST - Cefpodoxime Resistance 56 91.8% 
Performed VITEK AST - Imipenem Resistance 57 93.4% 
Combined MALDI-TOF and VITEK 57 93.4% 
 
In Table 3.32 are shown the results for the 61 presumptive ESBL E. coli and Non-E. coli isolates 
that were subjected to MALDI-TOF MS for confirmation of presumptive identities that were based on the 
original visual interpretation of colony color, prior to isolation in the original assay. Of the 20 E. coli 
isolates, 14 (70%) were positively confirmed as E. coli. Three (15%) of the presumptive E. coli isolates 
were identified as other coliforms, 1 (5%) was another Gram-Negative bacteria and 2 were Gram-
positive. Thirty (73.2%) of the 41 presumptive ESBL other coliform isolates were positively confirmed as 
coliforms. One isolate was E. coli and the remaining 10 isolates were other Gram-negative bacteria. Of 
the 61 total isolates, 24.6% (N = 15) were E. coli, 54.1% (N = 33) were Non-E. coli coliforms, 18% (N = 
11) were other Gram-negative bacteria, and 3.3% (N = 2) were Gram-positive bacteria. See Appendix 3 
for a complete results section of MALDI-TOF speciation for all 61 ESBL isolates.  
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Table 3.32 - MALDI-TOF MS Confirmatory Analysis of Presumptive ESBL E. coli and Other 
Coliform Isolates from Raw Sewage 
Raw Sewage Isolates 
Presumptive  
E. coli 
Presumptive 
coliform 
Total Isolates 
Original Number of Isolates 20 41 61 
Number of Correctly Confirmed based on 
original presumptive ID prior to isolation  
14 30 44 
% Correctly Confirmed 70.0% 73.2% 72.1% 
MALDI-TOF Identity  
Presumptive  
E. coli 
Presumptive 
coliform 
# 
Isolates 
% 
Total 
E. coli 14 1 15 24.6% 
Other Coliforms 3 30 33 54.1% 
Other Gram-Negative 1 10 11 18.0% 
Gram-Positive / Other 2 0 2 3.3% 
 
In Table 3.33 are shown paired MALDI-TOF and VITEK 2 results for susceptibility to Cefpodoxime 
and Imipenem in 57 ESBL isolates. Of the 14 confirmed E. coli isolates analyzed for resistance to 
Cefpodoxime, 100% were found to be resistant, 0 had intermediate susceptibility, and 0 were 
susceptible. Of the 14 confirmed E. coli isolates analyzed for resistance to Imipenem, 93% were found to 
be resistant, 0 had intermediate susceptibility, and 7% were susceptible. Of the 32 confirmed Non-E. coli 
coliform isolates analyzed for resistance to Cefpodoxime, 96.9% were found to be resistant, 3.1% had 
intermediate susceptibility, and 0 were susceptible. Of the 33 confirmed Non-E. coli coliform isolates 
analyzed for resistance to Imipenem, 72.7% were found to be resistant, 15.2% had intermediate 
susceptibility, and 12.1% were susceptible. Of the 10 confirmed other Gram-negative bacteria isolates 
analyzed for resistance to Imipenem, 80% were found to be resistant, 0 had intermediate susceptibility, 
and 20% were susceptible. See Appendix 3 for a complete results section of MALDI-TOF and VITEK 2 
results for all 57 ESBL isolates.  
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Table 3.33 - Table 3.30 - VITEK 2 Cefpodoxime and Imipenem Susceptibility Analysis Based 
on MALDI-TOF MS Identities of Presumptive ESBL E. coli and non-E. coli Isolates from Raw 
Sewage 
MALDI-TOF MS 
+ VITEK 2 
(N) 
Number 
Cefpodoxime 
Resistant 
Number 
Cefpodoxime 
Intermediate 
Number 
Cefpodoxime 
Susceptible 
% Res 
% 
Inter 
% 
Suscep 
E. coli 14 14 0 0 100% 0% 0% 
Other coliforms 32 31 1 0 96.9% 3.1% 0.0% 
Other Gram-
Negative bacteria 
10 8 0 2 80.0% 0.0% 20.0% 
Gram-Positive 
Bacteria 
0 0 0 0 0% 0% 0% 
Total (N) 56 53 1 0 94.6% 1.8% 0.0% 
MALDI-TOF MS 
+ VITEK 2 
(N) 
Number 
Imipenem 
Resistant 
Number 
Imipenem 
Intermediate 
Number 
Imipenem 
Susceptible 
% Res 
% 
Inter 
% 
Suscep 
E. coli 14 13 0 1 93% 0% 7% 
Other coliforms 33 24 5 4 72.7% 15.2% 12.1% 
Other Gram-
Negative bacteria 
10 1 3 6 10.0% 30.0% 60.0% 
Gram-Positive 
Bacteria 
0 0 0 0 0% 0% 0% 
Total (N) 57 38 8 11 66.7% 14.0% 19.3% 
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Secondary Effluent 
In Table 3.34 are show the number of presumptive ESBL E. coli and non-E. coli isolates from 
Secondary Effluent chosen for analysis by presumptive identity and then summarizes the number of 
isolates subjected to confirmatory analysis. A breakdown of the number of isolates in each type of 
analysis by site and presumptive organism can be found in Tables 2.7.  
Table 3.34 - Summary of ESBL Secondary Effluent Isolates and Confirmatory Analyses  
 Secondary Effluent ESBL Isolates Number of Isolates % of Total 
Total Isolates 64   
Presumptive E. coli Isolates 29 45.3% 
Presumptive other coliform Isolates 35 54.7% 
Summary of Analyses Number of Isolates % of Total 
Performed MALDI-TOF MS 64 100.0% 
Performed VITEK AST - Cefpodoxime Resistance 57 91.8% 
Performed VITEK AST - Imipenem Resistance 60 93.4% 
Combined MALDI-TOF and VITEK 57 93.4% 
 
In Table 3.35 are shown the results for the 60 ESBL isolates that were subjected to MALDI-TOF 
MS for confirmation of presumptive identities that were based on the original visual interpretation of 
colony color, prior to isolation in the original assay. Of the 27 E. coli isolates, 23 (85.2%) were positively 
confirmed as E. coli. Three (11.1%) of the presumptive E. coli isolates were identified as other coliforms, 
1 (3.7%) was another Gram-Negative bacteria, and none were Gram-positive. Twenty-six (78.8%) of the 
33 presumptive other coliform isolates were positively confirmed as coliforms. One isolate was E. coli, and 
the remaining 6 isolates were other Gram-negative bacteria. Of the 60 total isolates, 40% (N = 24) were 
E. coli, 48.3% (N = 29) were Non-E. coli coliforms, 11.7% (N = 7) were other Gram-negative bacteria, 
and 0 were Gram-positive bacteria. See Appendix 3 for a complete results section of MALDI-TOF 
speciation for all 60 ESBL isolates.  
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Table 3.35 - MALDI-TOF MS Confirmatory Analysis of Presumptive ESBL E. coli and Other 
Coliform Isolates from Secondary Effluent 
Secondary Effluent Isolates 
Presumptive  
E. coli 
Presumptive 
coliform 
Total Isolates 
Original Number of Isolates 27 33 60 
Number of Correctly Confirmed based on 
original presumptive ID prior to isolation  
23 26 49 
% Correctly Confirmed 85.2% 78.8% 81.7% 
MALDI-TOF Identity  
Presumptive  
E. coli 
Presumptive 
coliform 
# 
Isolates 
% 
Total 
E. coli 23 1 24 40.0% 
Other Coliforms 3 26 29 48.3% 
Other Gram-Negative 1 6 7 11.7% 
Gram-Positive / Other 0 0 0 0.0% 
 
Table 3.36 shows paired MALDI-TOF and VITEK 2 results for susceptibility to Cefpodoxime and 
Imipenem in 60 ESBL isolates. Of the 24 confirmed E. coli isolates analyzed for resistance to 
Cefpodoxime, 100% were found to be resistant, 0 had intermediate susceptibility, and 0 were 
susceptible. Of the 24 confirmed E. coli isolates analyzed for resistance to Imipenem, 100% were found 
to be resistant, 0 had intermediate susceptibility, and 0 were susceptible. Of the 26 confirmed Non-E. coli 
coliform isolates analyzed for resistance to Cefpodoxime, 96.2% were found to be resistant, 3.8% had 
intermediate susceptibility, and 0 were susceptible. Of the 29 confirmed Non-E. coli coliform isolates 
analyzed for resistance to Imipenem, 75.9% were found to be resistant, 6.9% had intermediate 
susceptibility, and 17.2% were susceptible. Of the 7 confirmed other Gram-negative bacteria isolates 
analyzed for resistance to Imipenem, 14.3% were found to be resistant, 42.9% had intermediate 
susceptibility, and 42.9% were susceptible. See Appendix 3 for a complete results section of MALDI-TOF 
and VITEK 2 results for all 60 ESBL isolates.  
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Table 3.36 - VITEK 2 Cefpodoxime and Imipenem Susceptibility Analysis Based on MALDI-
TOF MS Identities of Presumptive ESBL E. coli and non-E coli Coliform Isolates from 
Secondary Effluent 
MALDI-TOF MS 
+ VITEK 2 
(N) 
Number 
Cefpodoxime 
Resistant 
Number 
Cefpodoxime 
Intermediate 
Number 
Cefpodoxime 
Susceptible 
% Res 
% 
Inter 
% 
Suscep 
E. coli 24 24 0 0 100% 0% 0% 
Other coliforms 26 25 1 0 96.2% 3.8% 0.0% 
Other Gram-
Negative bacteria 
7 7 0 0 
100.0
% 
0.0% 0.0% 
Gram-Positive 
Bacteria 
0 0 0 0 0% 0% 0% 
Total (N) 57 56 1 0 98.2% 1.8% 0.0% 
MALDI-TOF MS 
+ VITEK 2 
(N) 
Number 
Imipenem 
Resistant 
Number 
Imipenem 
Intermediate 
Number 
Imipenem 
Susceptible 
% Res 
% 
Inter 
% 
Suscep 
E. coli 24 24 0 0 100% 0% 0% 
Other coliforms 29 22 2 5 75.9% 6.9% 17.2% 
Other Gram-
Negative bacteria 
7 1 3 3 14.3% 42.9% 42.9% 
Gram-Positive 
Bacteria 
0 0 0 0 0% 0% 0% 
Total (N) 60 47 5 8 78.3% 8.3% 13.3% 
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Objective 4 Results for Presumptive Carbapenem (KPC) Resistant E. coli and 
Non-E. coli Coliforms 
Objective four focused on the performance evaluation of CHROMagar KPC agar medium for the 
direct detection and quantification of carbapenemase producing (KPC) E. coli and non-E. coli coliforms in 
the aforementioned nine sampling sites to determine its utility as a part of the proposed indicator system 
for the surveillance of antimicrobial resistance in the water, wastewater, and other environmental 
matrices. Presumptive carbapenemase-positive E. coli and other non-E. coli coliform isolates were 
collected during the first phase of the project. Phase 3 focused on the revival, purification, and non-
automated, antimicrobial susceptibility analysis of carbapenemase production using meropenem disks in 
the Modified Hodge Test. Phase 4 focused on isolate identity confirmation of selected isolates via MALDI-
TOF MS (Table 2.8). Several of the surface water isolates and a few of hospital sewage and secondary 
effluent isolates were also subjected to VITEK 2 analysis for susceptibility to Cefpodoxime, an Extended-
β-lactam, and Imipenem, a carbapenem, against associated CLSI MIC criteria (Table 2.9).  
Of the 354 presumptive KPC positive isolates collected, 300 were successfully revived (84.7%). 
Analysis of KPC production via the Modified Hodge Test (N=298) occurred before a portion of the isolates 
were subjected to identity confirmation via MALDI-TOF MS (N = 233). After both Modified Hodge and 
MALDI-TOF analysis, 23 isolates were selected for analysis via VITEK-2 for further confirmation and 
analysis 
CHROMagar KPC Performance Analysis for Presumptive KPC E. coli and Non-E. coli 
Isolates from Hospital Sewage 
In Table 3.37 are shown the number of successfully revived KPC isolates from Hospital Sewage 
by presumptive identity as E. coli or non-E. coli coliforms and then a summary of the number of isolates 
subjected to confirmatory analysis. A breakdown of the number of presumptive isolates in each type of 
analysis by site and presumptive organism can be found in Tables 2.8 and 2.9.  
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Table 3.37 - Summary of KPC Hospital Sewage Isolates and Confirmatory Analyses  
 Hospital Sewage KPC Isolates Number of Isolates % of Total 
Total Isolates 166  
Presumptive E. coli Isolates 52 31.3% 
Presumptive other coliform Isolates 114 68.7% 
Summary of Analyses Number of Isolates % of Total 
Performed Modified Hodge Test 164 98.8% 
Performed MALDI-TOF MS 112 67.5% 
Combined MALDI-TOF and Modified Hodge 110 66.3% 
Combined MALDI-TOF, Modified Hodge, and VITEK 2 4 2.4% 
 
Of the 52 hospital sewage isolates of presumptive KPC positive E. coli subjected to analysis via 
the Modified Hodge Test, 12 (23.1%) were positive for KPC production, 31 (59.6%) showed signs of 
“intermediate” KPC production, and 8 (17.3%) were negative (Table 3.38). Site H1 had the highest 
proportion of positive results (66.7%, N = 9). Analysis of the 112 hospital sewage other coliform isolates 
showed more KPC production overall, with 68 (60.75%) positive results, 28 (25%) intermediate, and 15 
(13.4%) negative results. Site H1 also had the highest proportion of positive results overall (93.3%, N = 
45).  
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Table 3.38 - Modified Hodge Test Results for Presumptive KPC Hospital Sewage Isolates 
KPC Hospital Sewage  
Modified 
Hodge 
Test (N) 
KPC(+) % KPC(-R) % KPC(-) % 
E. coli        
OE H1 GI + MICU 9 6 66.7% 2 22.2% 1 11.1% 
PE H2 Burn + Lab + ICU 17 1 5.9% 13 76.5% 3 17.6% 
QE H3 Heart + ICU 11 0 0.0% 8 72.7% 3 27.3% 
RE H4 ER + Neuro 15 5 33.3% 8 53.3% 2 13.3% 
   Total  52 12 23.1% 31 59.6% 8 17.3% 
KPC Hospital Sewage 
Isolates  
Modified 
Hodge 
Test (N) 
KPC(+) % KPC(-R) % KPC(-) % 
Non-E. coli coliforms        
OT H1 GI + MICU 45 42 93.3% 2 4.4% 1 2.2% 
PT H2 Burn + Lab + ICU 27 9 33.3% 10 37.0% 7 25.9% 
QT H3 Heart + ICU 16 5 31.3% 10 62.5% 1 6.3% 
RT H4 ER + Neuro 24 12 50.0% 6 25.0% 6 25.0% 
   Total  112 68 60.7% 28 25.0% 15 13.4% 
 
In Table 3.39 are shown the results for the 112 presumptive KPC isolates that were subjected to 
MALDI-TOF MS for confirmation of presumptive identities that were based on the original visual 
interpretation of colony color, prior to isolation in the original assay. One of the 16 E. coli isolates was 
positively confirmed as E. coli . Ten (6.3%) of the presumptive E. coli isolates were identified as other 
coliforms, 8 (50%) were other Gram-Negative bacteria such as Aeromonas, Cronobacter, Raoutella, and 
Stenotrophomonas, and none were Gram-positive. Eighty-nine (92.7%) of the 96 presumptive other 
coliform isolates were positively confirmed as coliforms. The remaining isolates were identified as 6 other 
Gram-negative bacteria Ochrobactrum, Stenotrophomonas and Cronobacter) and 1 Gram-positive 
bacterium. Of the 112 total isolates, 0.8% (N = 1) were E. coli, 86.6% (N = 97) were Non-E. coli 
coliforms, 11.6% (N = 13) were other Gram-negative bacteria, and 0.9% (N = 1) were Gram-positive 
bacteria. See Appendix 4 for a complete results section of MALDI-TOF speciation for all 112 KPC hospital 
sewage isolates.  
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Table 3.39 - MALDI-TOF MS Confirmatory Analysis of Presumptive KPC E. coli and Other 
Coliform Isolates from Hospital Sewage 
Raw Sewage Isolates 
Presumptive  
E. coli 
Presumptive 
coliform 
Total Isolates 
Original Number of Isolates 16 96 112 
Number of Correctly Confirmed based on 
original presumptive ID prior to isolation  
1 89 90 
% Correctly Confirmed 6.3% 92.7% 80.4% 
MALDI-TOF Identity  
Presumptive  
E. coli 
Presumptive 
coliform 
# 
Isolates 
% 
Total 
E. coli 1 0 1 0.9% 
Other Coliforms 8 89 97 86.6% 
Other Gram-Negative 7 6 13 11.6% 
Gram-Positive / Other 0 1 1 0.9% 
 
In Table 3.40 are shown paired MALDI-TOF and Modified Hodge Test results for 110 hospital 
sewage isolates. Of the 1 confirmed E. coli isolate, it was negative for KPC production and had 
intermediate production. Of the 95 confirmed as Non-E. coli coliform isolates, 95 (61.5%) were positive 
for KPC production, 63 (21.1%) had intermediate production, and 11 (11.6%) were negative. Of the 13 
isolates confirmed as other Gram-Negative bacteria, 2 (15.4%) were positive for KPC production, 8 
(61.5%) had intermediate production, and 3 (23.1%) were negative. See Appendix 4 for a complete 
results section of MALDI-TOF and Modified Hodge results for all 112 KPC hospital sewage isolates.  
Table 3.40 - Modified Hodge Test Results of KPC Production Based on MALDI-TOF MS 
Identities of Isolates from Hospital Sewage 
 Total (N) KPC(+) KPC(-R) KPC(-) % KPC(+) % KPC(-R) % KPC (-) 
E. coli 1 0 1 0 0% 100% 0% 
Other coliforms 95 63 20 11 66.3% 21.1% 11.6% 
Other Gram-Negative 
bacteria 
13 2 8 3 15.4% 61.5% 23.1% 
Gram-Positive Bacteria 1 0 1 0 0.0% 100.0% 0.0% 
Total 110 65 30 14 59.1% 27.3% 12.7% 
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Four KPC hospital sewage isolates were submitted for VITEK 2 analysis because the isolates grew 
on the CHROMagar KPC medium but had negative Modified Hodge Test results. Table 3.41 shows the 
combined results. Complete isolate analysis can be found Appendix 5.  
Table 3.41 - KPC Hospital Sewage Isolates with Combined VITEK 2, MALDI-TOF MS, and 
Modified Hodge Test Results 
Cod
e 
MALDI-TOF Result 
Cefpodoxi
me 
Imipene
m Hodge 
Results 
Confirmation 
S/I/R S/I/R 
RT0
4 
Enterobacter cloacae/asburiae I S KPC(-) Confirms KPC (-) 
RT0
7 
Raoultella 
planticola/ornithinolytica 
R I KPC(-) 
Does not confirm 
interpretation 
RT1
0 
Raoultella 
planticola/ornithinolytica 
R S KPC(-) Confirms KPC (-) 
RT1
8 
Citrobacter amalonaticus R S KPC(-) Confirms KPC (-) 
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CHROMagar KPC Performance Analysis for Presumptive KPC E. coli and Non-E. coli 
Isolates from Raw Sewage 
In Table 3.42 are shown the number of successfully revived KPC isolates from raw sewage by 
presumptive identity and then a summary of the number of isolates subjected to confirmatory analysis. A 
breakdown of the number of isolates in each type of analysis by presumptive organism can be found in 
Tables 2.8.  
Table 3.42- Summary of KPC Raw Sewage Isolates and Confirmatory Analyses  
Raw Sewage KPC Isolates Number of Isolates % of Total 
Total Isolates 58  
Presumptive E. coli Isolates 16 27.6% 
Presumptive other coliform Isolates 42 72.4% 
Summary of Analyses Number of Isolates % of Total 
Performed Modified Hodge Test 58 100.0% 
Performed MALDI-TOF MS 54 93.1% 
Combined MALDI-TOF and Modified Hodge 54 93.1% 
 
Modified Hodge test results for 16 raw sewage isolates of presumptive KPC positive E. coli 
indicated that 10 (62.5%) were positive for KPC production, 5 (31.1%) had “intermediate” production, 
and 1 (6.3%) were negative (Table 3.43) The same analysis of 42 presumptive other coliform isolates 
showed that 34 (81.1%) were positive for KPC production, 4 (9.5%) showed signs of “intermediate” KPC 
production, and 4 (9.5%) were negative.  
Table 3.43 - Modified Hodge Analysis of Presumptive KPC positive E. coli and Other 
Coliform Isolates from Raw Sewage 
KPC Municipal Sewage Isolates 
Modified 
Hodge 
Test (N) 
KPC(+) % KPC(-R) % KPC(-) % 
JT Non-E. coli coliforms 42 34 81.0% 4 9.5% 4 9.5% 
JE E. coli 16 10 62.5% 5 31.3% 1 6.3% 
 
In Table 3.44 are shown the results for the 54 raw sewage KPC isolates that were subjected to 
MALDI-TOF MS for confirmation of presumptive identities that were based on the original visual 
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interpretation of colony color, prior to isolation in the original assay. None of the 12 presumptive E. coli 
isolates were positively confirmed by MALDI-TOF MS. Eight of the presumptive E. coli isolates were 
identified as other coliforms, 3 were other Gram-Negative bacteria such as Pseudomonas and 
Stentrophomonas, and the 1 Gram-positive was Enterococcus. Thirty-six (85.7%) of the 42 presumptive 
other coliform isolates were positively confirmed as coliforms. The remaining 6 isolates were other Gram-
negative bacteria including Cronobacter and Aeromonas. Of the 54 total isolates, 81.5% (N = 44) were 
Non-E. coli coliforms, 16.7% (N = 9) were other Gram-negative bacteria, and 1.9% (N = 1) was a Gram-
positive bacterium. See Appendix 4 for a complete results section of MALDI-TOF speciation for all 54 raw 
sewage isolates.  
Table 3.44 - MALDI-TOF MS Confirmatory Analysis of Presumptive KPC E. coli and Other 
Coliform Isolates from Raw Sewage 
Raw Sewage Isolates 
Presumptive  
E. coli 
Presumptive 
coliform 
Total Isolates 
Original Number of Isolates 12 42 54 
Number of Correctly Confirmed based on 
original presumptive ID prior to isolation  
0 36 36 
% Correctly Confirmed 0.0% 85.7% 66.7% 
MALDI-TOF Identity  
Presumptive  
E. coli 
Presumptive 
coliform 
# 
Isolates 
% 
Total 
E. coli 0 0 0 0.0% 
Other Coliforms 8 36 44 81.5% 
Other Gram-Negative 3 6 9 16.7% 
Gram-Positive / Other 1 0 1 1.9% 
 
In Table 3.45 are shown paired MALDI-TOF and Modified Hodge Test results for 54 KPC raw 
sewage isolates. Of the 44 confirmed coliform isolates, 81.8% were positive for KPC production, 11.4% 
had intermediate production, and 6.8% were negative. Of the 9 isolates confirmed as other Gram-
Negative bacteria, 5 were positive for KPC production, 3 had intermediate production, and 1 was 
negative. See Appendix 4 for a complete results section of MALDI-TOF and Modified Hodge results for all 
54 raw sewage KPC isolates.  
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Table 3.45 - Modified Hodge Test Results of KPC Production Based on MALDI-TOF MS 
Identities of Isolates from Raw Sewage 
 Total (N) KPC(+) KPC(-R) KPC(-) % KPC(+) % KPC(-R) % KPC (-) 
E. coli 0 0 1 0 0.0%  0.0% 0.0% 
Other coliforms 44 36 5 3 81.8% 11.4% 6.8% 
Other Gram-Negative 
bacteria 
9 5 3 1 55.6% 33.3% 11.1% 
Gram-Positive Bacteria 1 0 0 1 0.0% 0.0% 100.0% 
Total 54 41 9 5 75.9% 16.7% 9.3% 
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CHROMagar KPC Performance Analysis for Presumptive KPC E. coli and Non-E. coli 
Isolates from Secondary Effluent 
In Table 3.46 are shown numbers of successfully revived presumptive KPC isolates from 
secondary effluent by presumptive identity and then a summary of the number of isolates subjected to 
confirmatory analysis. A breakdown number of isolates in each type of analysis by presumptive organism 
can be found in Tables 2.8 and 2.9. 
Table 3.46 - Summary of Presumptive KPC Secondary Effluent Isolates and Confirmatory 
Analyses  
Surface Water Isolates Number of Isolates % of Total 
Total Isolates 49  
Presumptive E. coli Isolates 17 34.7% 
Presumptive other coliform Isolates 32 65.3% 
Summary of Analyses Number of Isolates % of Total 
Performed Modified Hodge Test 49 100.0% 
Performed MALDI-TOF MS 38 77.6% 
Combined MALDI-TOF and Modified Hodge 38 77.6% 
Combined MALDI-TOF, Modified Hodge, and VITEK 2 4 8.2% 
 
In Table 3.47 are shown Modified Hodge test results for 17 secondary effluent isolates of 
presumptive KPC positive E. coli with 23 (76.5%) positive for KPC production and 4 (23.5%) 
“intermediate” production. The same analysis of 32 other coliform isolates showed that 23 (71.9%) were 
positive for KPC production, 5 (15.6%) showed signs of “intermediate” KPC production, and 4 (12.5%) 
were negative.  
Table 3.47 - Modified Hodge Test Results for KPC Secondary Effluent Isolates 
KPC Treated Sewage Isolates 
Modified 
Hodge 
Test (N) 
KPC(+) % KPC(-R) % KPC(-) % 
KT Non-E. coli coliforms 32 23 71.9% 5 15.6% 4 12.5% 
KE E. coli 17 13 76.5% 4 23.5% 0 0.0% 
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In Table 3.48 are shown the results for 38 secondary effluent KPC isolates that were subjected to 
MALDI-TOF MS for confirmation of presumptive identities that were based on the original visual 
interpretation of colony color, prior to isolation in the original assay. None of the 16 E. coli isolates were 
positively confirmed as E. coli. Ten (62.5%) of the presumptive E. coli isolates were identified as other 
coliforms, 6 (37.5%) were other Gram-Negative bacteria such as Pseudomonas and Stenotrophomonas, 
and none were Gram-positive. Twenty (91%) of the 22 presumptive other coliform isolates were 
positively confirmed as coliforms. One remaining isolate was E. coli and 1 remaining isolate was another 
Gram-negative bacterium, Pantoea agglomerans. Of the 38 total presumptive other KPC isolates, 2.6% (N 
= 1) were E. coli, 78.9% (N = 30) were Non-E. coli coliforms, 18.4% (N = 7) were other Gram-negative 
bacteria, and 0% (N = 0) were Gram-positive bacteria. See Appendix 4 for a complete results section of 
MALDI-TOF speciation for all 38 secondary effluent KPC isolates.  
Table 3.48 - MALDI-TOF MS Confirmatory Analysis of Presumptive KPC E. coli and Other 
Coliform Isolates from Secondary Effluent 
Raw Sewage Isolates 
Presumptive  
E. coli 
Presumptive 
coliform 
Total Isolates 
Original Number of Isolates 16 22 38 
Number of Correctly Confirmed based on 
original presumptive ID prior to isolation  
0 20 20 
% Correctly Confirmed 
0.0% 90.9% 52.6% 
MALDI-TOF Identity  
Presumptive 
E. coli 
Presumptive 
coliform 
# 
Isolat
es 
% 
Total 
E. coli 
0 1 1 2.6% 
Other Coliforms 
10 20 30 78.9% 
Other Gram-Negative 6 1 7 18.4% 
Gram-Positive / Other 0 0 0 0.0% 
 
In Table 3.49 are shown paired MALDI-TOF and Modified Hodge Test results for 38 secondary 
effluent KPC isolates. Of the 1 confirmed E. coli isolate was found to be negative for KPC production. Of 
the 30 confirmed as Non-E. coli coliform isolates, 80% were positive for KPC production, 10% had 
intermediate production, and 10% were negative. Of the 7 isolates confirmed as other Gram-Negative 
bacteria, 57.1% were positive for KPC production, 42.9% had intermediate production, and 0 were 
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negative. See Appendix 4 for a complete results section of MALDI-TOF and Modified Hodge results for all 
38 secondary effluent KPC isolates.  
Table 3.49 - Modified Hodge Test Results of KPC Production Based on MALDI-TOF MS 
Identities of Presumptive KPC Isolates from Secondary Effluent 
 Total (N) KPC(+) KPC(-R) KPC(-) % KPC(+) % KPC(-R) % KPC (-) 
E. coli 
1 0 0 1 0.0% 0.0% 100% 
Other coliforms 30 24 3 3 80.0% 10.0% 10.0% 
Other Gram-Negative 
bacteria 
7 4 3 0 57.1% 42.9% 0.0% 
Gram-Positive Bacteria 0 0 0 0 0.0% 0.0% 0.0% 
Total 38 28 6 4 73.7% 15.8% 10.5% 
 
Four KPC secondary effluent isolates were submitted for VITEK 2 analysis because all isolates 
were identified as target organisms via MALDI-TOF (Table 3.50). One of them (KT16) was originally 
detected on CHROMagar KPC, but, after revival in TSB and on CHROMagar Orientation, it did not grow on 
the CHROMagar KPC medium and had negative Modified Hodge Test results. VITEK 2 confirmed 
susceptibility to both Cefpodoxime and Imipenem. The other three isolates were chosen to evaluate the 
“intermediate KPC production” designation created by this study. All three were resistant to Cefpodoxime. 
One isolate (KT24) was resistant to Imipenem and the other two (KT35A and B) had intermediate 
resistance when compared to CLSI MIC criteria. Complete isolate analysis can be found Appendix 5.  
Table 3.50 - Secondary Effluent Presumptive KPC Isolates with Combined VITEK 2, MALDI-
TOF MS, and Modified Hodge Test Results 
Code MALDI-TOF Result 
Cefpodoxime Imipenem 
Hodge Results Confirmation 
S/I/R S/I/R 
KT16 Escherichia coli S S KPC(-) Confirms KPC (-) 
KT24 Klebsiella pneumoniae R* R* KPC(-R) Confirms KPC (-R) 
KT35A Enterobacter cloacae/asburiae R I KPC(-R) Confirms KPC(-R) 
KT35B Enterobacter cloacae/asburiae R I KPC(-R) Confirms KPC(-R) 
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CHROMagar KPC Performance Analysis for Presumptive KPC E. coli and Non-E. coli 
Isolates from Surface Water 
In Table 3.51 are shown the number of successfully revived KPC isolates from Surface Water by 
presumptive identity and then a summary of the number of isolates subjected to confirmatory analysis. A 
breakdown of the number of isolates in each type of analysis by site and presumptive organism can be 
found in Tables 2.8 and 2.9.  
Table 3.51 - Summary of KPC Surface Water Isolates and Confirmatory Analyses  
Surface Water Isolates Number of Isolates % of Total 
Presumptive other coliform Isolates 29 100% 
Summary of Analyses Number of Isolates % of Total 
Performed Modified Hodge Test 28 96.5% 
Performed MALDI-TOF MS 29 100.0% 
Combined MALDI-TOF and Modified Hodge 28 96.5% 
Combined MALDI-TOF, Modified Hodge, and VITEK 2 22 75.9% 
 
Of the 27 surface water isolates of presumptive KPC positive other coliforms subjected to analysis 
via the Modified Hodge Test, zero were positive for KPC production, 19 (70.4%) showed signs of 
“intermediate” KPC production, and 8 (29.6%) were negative (Table 3.52). Morgan Creek, upstream had 
the highest proportion of intermediate production (75.0%, N = 8). There were no KPC positive E. coli 
isolates collected or analyzed during this project.  
Table 3.52 - Modified Hodge Test Results for KPC Surface Water Isolates 
KPC Surface Water Isolates 
Modified 
Hodge 
Test (N) 
KPC(+) % KPC(-R) % KPC(-) % 
Non-E. coli coliforms        
LT Morgan Creek Upstream 8 0 0.0% 6 75.0% 2 25.0% 
MT Morgan Creek Downstream 11 0 0.0% 8 72.7% 3 27.3% 
NT Jordan Lake 8 0 0.0% 5 62.5% 3 37.5% 
   Total  27 0 0.0% 19 70.4% 8 29.6% 
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In Table 3.53 are shown the results for the 28 presumptive KPC other coliform isolates that were 
subjected to MALDI-TOF MS for confirmation of presumptive identities that were based on the original 
visual interpretation of colony color, prior to isolation in the original assay. There were no presumptive E. 
coli isolates. 0 of the 28 presumptive other coliform isolates were positively confirmed as coliforms. 26 
isolates were other Gram-negative bacteria including Ochrobactrum, Sphingebacterium, and 
Stenotrophomonas, and 2 were Gram-Positive Staphlococcus and Bacillius. Of the 28 presumptive KPC 
total isolates, 0 were E. coli, 0 were Non-E. coli coliforms, 89.7% (N = 26) were other Gram-negative 
bacteria, and 6.9% (N = 2) were Gram-positive bacteria. See Appendix 4 for a complete results section of 
MALDI-TOF speciation for all 28 surface water KPC isolates.  
Table 3.53 - MALDI-TOF MS Confirmatory Analysis of Presumptive KPC E. coli and Other 
Coliform Isolates from Surface Water 
Raw Sewage Isolates 
Presumptive  
E. coli 
Presumptive 
coliform 
Total Isolates 
Original Number of Isolates 
0 28 28 
Number of Correctly Confirmed based on 
original presumptive ID prior to isolation  
0 0 0 
% Correctly Confirmed 0.0% 0.0% 0.0% 
MALDI-TOF Identity  
Presumptive  
E. coli 
Presumptive 
coliform 
# 
Isolates 
% 
Total 
E. coli 0 0 0 0.0% 
Other Coliforms 0 0 0 0.0% 
Other Gram-Negative 0 26 26 89.7% 
Gram-Positive / Other 0 2 2 6.9% 
 
In Table 3.54 are shown paired MALDI-TOF and Modified Hodge Test results for 25 surface water 
KPC isolates. There were no confirmed E. coli isolates. There were no confirmed Non-E. colicoliform 
isolates. Of the 25 isolates confirmed as other Gram-Negative bacteria, 0 were positive for KPC 
production, 56% had intermediate production, and 44% were negative. See Appendix 4 for a complete 
results section of MALDI-TOF and Modified Hodge results for all 25 surface KPC isolates.  
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Table 3.54 - Modified Hodge Test Results of KPC Production Based on MALDI-TOF MS 
Identities of Isolates From Surface Water 
 Total (N) KPC(+) KPC(-R) KPC(-) % KPC(+) % KPC(-R) % KPC (-) 
E. coli 
0 0 0 0 0.0% 0.0% 0.0% 
Other coliforms 
0 0 0 0 0.0% 0.0% 0.0% 
Other Gram-Negative 
bacteria 
25 0 14 11 0.0% 56.0% 44.0% 
Gram-Positive Bacteria 0 0 0 1 0.0% 0.0% 0.0% 
Total 25 0 14 12 0.0% 56.0% 48.0% 
 
Twenty-two KPC surface water isolates were submitted for VITEK 2 analysis, however, those 
identified as Stenotrophomonas maltophilia via MALDI-TOF MS were rejected by the VITEK 2 system due 
to lack of information in the API database. Table 3.55 is the results for the remaining 17 isolates. None of 
the isolates were identified as target organisms, but grew on CHROMagar KPC medium. Eleven isolates 
had the “intermediate KPC production” designation created by this study. Of these, six were found to be 
resistant to Imipenem and five were found to be susceptible. Nine of the eleven were resistant to 
Cefpodoxime and two had intermediate susceptibility. Six of the isolates had negative Modified Hodge 
test results. Of these 6, five were susceptible to Imipenem and one was resistant. Furthermore, five of 
these KPC(-) isolates were resistant to Cefpodoxime, one was susceptible, and one had intermediate 
resistance. Complete isolate analysis can be found Appendix 5.  
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Table 3.55 - Surface Water Isolates with Combined VITEK 2, MALDI-TOF MS, and Modified 
Hodge Test Results 
Co
de 
Site MALDI-TOF Result 
Cefpodox
ime 
Imipen
em 
Hodge 
Results 
Confirmati
on 
S/I/R S/I/R 
LT0
2 
Morgan Creek 
Upstream 
Ochrobactrum anthropic R S KPC(-R)  
LT0
4 
Morgan Creek 
Upstream 
Ochrobactrum anthropic R S KPC(-R)  
LT0
5 
Morgan Creek 
Upstream 
Ochrobactrum anthropic I S KPC(-R)  
LT0
7 
Morgan Creek 
Upstream 
Ochrobactrum anthropic R S KPC(-R)  
LT1
0 
Morgan Creek 
Upstream 
Sphingobacterium 
multivorum 
R R KPC(-)  
LT1
1 
Morgan Creek 
Upstream 
Sphingobacterium 
multivorum 
R R KPC(-R) 
Confirms 
KPC(-R) 
MT
04 
Morgan Creek 
Downstream 
Pseudomonas 
chororaphis/fluorescens 
R R KPC(-R) 
Confirms 
KPC(-R) 
MT
05 
Morgan Creek 
Downstream 
Ochrobactrum anthropic R S KPC(-) 
Confirms 
KPC (-) 
MT
06 
Morgan Creek 
Downstream 
Ochrobactrum anthropic R S KPC(-R)  
MT
07 
Morgan Creek 
Downstream 
Ochrobactrum anthropic R S KPC(-) 
Confirms 
KPC (-) 
MT
09 
Morgan Creek 
Downstream 
Ochrobactrum anthropic R S KPC(-) 
Confirms 
KPC (-) 
MT
11 
Morgan Creek 
Downstream 
Elizabethkingia 
meningoseptica 
R R KPC(-R) 
Confirms 
KPC(-R) 
MT
13 
Morgan Creek 
Downstream 
Sphingobacterium 
multivorum 
I R KPC(-R) 
Confirms 
KPC(-R) 
NT0
2 
Jordan Lake 
Sphingobacterium 
multivorum 
R R KPC(-R) 
Confirms 
KPC(-R) 
NT0
5 
Jordan Lake 
Sphingobacterium 
multivorum 
R R KPC(-R) 
Confirms 
KPC(-R) 
NT0
6 
Jordan Lake Ochrobactrum anthropic S S KPC(-) 
Confirms 
KPC (-) 
NT0
7 
Jordan Lake Ralstonia insidiosa I S KPC(-) 
Confirms 
KPC (-) 
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CHAPTER 4 DISCUSSION, RECOMMENDATIONS, AND 
CONCLUSIONS 
 
Discussion: 
Repeated and often parallel assays of representative wastewater and environmental surface 
water samples were performed using the procedures of EPA Method 1604 for membrane filtration 
followed by plating on CHROMagar ESBL and KPC agar media. These assays were done in parallel with 
plating the same samples on the aforementioned Bio-Rad Rapid’E. coli 2 agar/CHROMagar Orientation 
agar to determine percentages of all culturable E. coli and coliforms that are resistant to these classes 
of antimicrobials. Following incubation, presumptive colonies of E. coli and coliforms were enumerated 
using manufacturers’ guides for colony color and appearance (Table 2.5 and 2.6). During each assay, 
five or fewer representative colonies of presumptive E. coli and other coliforms were selected from the 
CHROMagar ESBL and KPC membranes. Each colony was presumed to express the resistance property 
of the culture medium on which they were detected. Presumptive positive colonies were streaked 
successively for isolation, purification and preservation for future analysis to determine the 
performance of the two culture media in hospital sewage, raw sewage, secondary effluent and surface 
waters.  
The first objective of this study was to evaluate the performance of a chromogenic substrate 
standard clinical agar medium for use in the direct detection and enumeration of E. coli and coliforms 
as fecal indicator bacteria in representative wastewaters and surface waters by comparing it to the 
performance of a “gold standard” chromogenic substrate agar medium for the direct detection and 
enumeration of E. coli and coliforms in the same samples.  
The results from the Wilcoxon signed-rank test comparing the clinical medium (CHROMagar 
Orientation) against the performance of the “gold standard” environmental medium (Bio-Rad Rapid’E. 
coli 2 agar) for the detection of presumptive E. coli was comparable in hospital sewage and treated 
sewage effluent matrices at a 95% CL (Table 3.1). The clinical medium performance was not comparable 
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in the detection of presumptive E. coli in raw sewage and surface water samples. In both matrices, the 
clinical medium detected on average 20% more E. coli than the environmental medium (Tables 5.A, 7.A, 
and 8.A in Appendix 2).  
The results from the Wilcoxon signed-rank test comparing the clinical medium (CHROMagar 
Orientation) against the performance of the “gold standard”, environmental medium (Bio-Rad Rapid’E. 
coli 2 agar) for the detection of presumptive other and combined coliforms were comparable and thus 
capable for use in the direct detection of these target organisms in hospital sewage, raw sewage, treated 
sewage effluent, and surface water matrices at a 95% CL (Tables 3.2 and 3.3).  
Results from this study suggest that the performance of CHROMagar Orientation in raw sewage 
and surface water matrices for the detection of E. coli do not fulfill the needed requirements for the 
proposed method associated with discrimination of target bacteria in mixed microbial communities of 
environmental matrices. CHROMagar Orientation was originally validated for urine and stool analysis, not 
analysis of environmental samples86. The medium is also inherently non-selective, and supports 
interfering growth and overgrowth of other Gram-negative and Gram-positive bacteria like Pseudomonas 
spp. and Enterococcus spp. Limitations in the performance of the clinical medium may also be due to 
colony visualization and characterization issues by the analyst. Merlino et al. found that the color of 
bacterial colonies grown on Orientation are stable in the dark, but change when exposed to light, 
becoming deeper in tone and more diffuse than the originally noted color. The same deepening of color 
was noted by investigators of this study during colony counting, potentially impacting characterization 
and enumeration of target organisms 86.   
In the second objective of the study, concentrations of E. coli and coliform presumed to be ESBL 
resistant and concentrations of E. coli and coliforms presumed to be KPC resistant, were calculated and 
expressed as CFU/100 mL. Proportions of presumptive ESBL and KPC resistant bacteria relative to total 
E. coli and coliform concentrations were also calculated for each resistance type, per sample, per target 
organism (E. coli and other coliforms) and per collection event relative to total E. coli and coliforms 
enumerated in the same samples.  
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High concentrations of presumptive E. coli and other coliforms were found in all hospital sewage 
samples (N = 24) and presumptive ESBL positive and KPC positive E. coli and other coliforms were 
consistently found. The average concentrations of presumptive ESBL and KPC positive E. coli for all 
hospital sewage samples combined were 5.00 x 105 and 1.80 x 105 CFU / 100 mL, respectively. The 
average concentration of E. coli cultured on Bio-Rad agar during the same assays was 2.27 x 106 CFU / 
100 mL. The average proportions of ESBL and KPC E. coli were 27.0% and 4.8%, respectively (Table 
3.4). When hospital site-specific Wilcoxon-signed rank tests comparing the concentrations of ESBL and 
KPC producing E. coli were performed, no significant differences were found in Hospital Sites 1 -3 at a 
95% CL, suggesting similar magnitudes of resistance in hospital sewage E. coli  three of the four sites  
(Table 3.5).  Kuskal Wallis tests comparing presumptive E. coli concentrations for all hospital sites on all 
three media also showed no significant differences between the hospital sites, indicating relative 
consistency (Table 3.20).  
The average concentrations of presumptive ESBL and KPC positive non-E. coli coliforms in all 
hospital sewage samples combined (N=24) were 1.62 x 106 and 8.89 x 105 CFU / 100 mL, respectively. 
The average concentration of non-E. coli coliforms cultured on Bio-Rad agar during the same assays was 
7.74 x 108 CFU / 100 mL. The average proportions of ESBL and KPC non-E. coli coliforms were 44.4% 
and 28.4%, respectively (Table 3.6). A Kruskal Wallis test comparing presumptive non-E. coli coliform 
concentrations for all hospital sites on all three media showed no significant differences between the 
hospital sites on Bio-Rad and KPC media, but not on CHROMagar ESBL (Table 3.20). This significant 
difference is derived from the variability of the mean concentrations of presumptive ESBL non-E. coli 
coliform in the four hospital samples. Each of these collection sites serve distinct wings of the hospital, 
thus conveying the waste and waste water of different types of patients, services, procedures, and 
employees. The observed variability in concentrations of target organisms may be due to several factors 
such as dissimilar antibiotics use and stewardship, severity and type of illnesses seen, length of stay at 
hospital, as well as the relative dilution of collected sewage87–89.  These dynamics are beyond the scope 
of this study, but their determination would address a knowledge gap within the literature.  
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Hospital samples were collected near the points of human excretion, directly adjacent to each ward 
without any holding time or treatment infrastructure. One would expect to find highly resistant organisms 
of clinical significance in the hospital sewage, as it was likely to be excreted from patients with severe 
infections 70. The high bacterial load and frequency of AMR in hospital wastewaters are comparable to 
several previous studies, including Prado et al. 2011 and Korzeniewksa and Harnisz 2013 who found 
bacterial loads of upwards of 7.1 X 1010 CFU / 100 mL in a Brazilian hospital sewage and 2.72 107 CFU / 
100 mL in Polish hospital sewage87,90. The UNC hospital sewage does not receive on-site treatment prior 
to introduction into municipal sewage systems and represents a large potential contribution to the 
possible further dissemination of AMR. This lack of treatment at hospitals is typical, exacerbating the 
dissemination potential and resulting health impact of AMR49.  
High concentrations of presumptive E. coli and other coliforms were found in all municipal sewage 
samples (N = 10) and presumptive ESBL positive and KPC positive E. coli and other coliforms were 
consistently found. Sewage samples were taken at the facility and represented a mix of several different 
sources with microbial interactions occurring both during transit and during initial removal of large solids 
and debris. The average concentrations of presumptive ESBL and KPC positive E. coli in municipal sewage 
were 2.70 x 105 and 6.43 x 104 CFU / 100 mL, respectively. The average concentration of presumptive E. 
coli cultured on Bio-Rad agar during the same assays was 2.58 x 106 CFU / 100 mL. The average 
proportions of ESBL and KPC E. coli were 12.19% and 2.76%, respectively. The average concentrations 
of ESBL and KPC positive non-E. coli coliforms were 1.17 x 106 and 2.37 x 105 CFU / 100 mL, 
respectively. The average concentration of non-E. coli coliforms cultured on Bio-Rad agar during the 
same assays was 3.34 x 107 CFU / 100 mL. The average proportions of ESBL and KPC positive other 
coliforms were 4.40% and 1.02%, respectively (Table 3.10). 
At OWASA WWTP, the influent was exposed to primary, secondary and tertiary treatment by 
physical, biological and chemical processes, including chlorine disinfection. Such treatment creates 
pressures that could modify the characteristics and resistance profiles of the organisms still present after 
treatment. The average concentrations of presumptive ESBL and KPC positive E. coli in the secondary 
113 
 
effluent were 2.89 x 102 and 1.53 x 102 CFU / 100 mL, respectively. The average concentration of 
presumptive E. coli cultured on Bio-Rad agar during the same assays was 3.93 x 104 CFU / 100 mL. The 
average proportions of ESBL and KPC E. coli were 3.50% and 1.78%, respectively. The average 
concentrations of ESBL and KPC positive other coliforms were 1.11 x 103 and 1.10 x 103 CFU / 100 mL, 
respectively. The average concentration of non-E. coli coliforms cultured on Bio-Rad agar during the 
same assays was 9.58 x 104 CFU / 100 mL. The average proportions of ESBL and KPC positive other 
coliforms were 1.31% and 1.23%, respectively (Table 3.12). 
A Mann-Whitney U test was performed to compare the proportions of presumptive ESBL and KPC 
positive target organisms in raw sewage and secondary effluent. Results indicated that there was not a 
significant difference in the proportions of ESBL and KPC positive E. coli and KPC other coliforms but a 
significant difference in the proportion of ESBL other coliforms between raw sewage and secondary 
treated effluent (Tables 3.10, 3.12 and 3.21). In this study, there was a higher proportion of presumptive 
ESBL other coliforms found in raw sewage, based on presumptive concentration and not on the 
proportion of confirmed bacterial isolates taken from samples. A 2006 Chilean study by Silva et al. 
derived the relative frequency of transferable multiple antibiotic resistance in confirmed coliform bacteria 
isolated from raw and treated sewage and found a higher overall frequency of resistance in the treated 
effluent and not the raw sewage88.  In a study by Reinthaler et al. 2010, sewage from five different 
Austrian sewage plants were analyzed for ESBL E. coli to investigate the degree of contamination as well 
as the efficacy of different treatment methods and found that ESBL E. coli can still persist even after 
treatment 16. In a 2013 study by Brechet et al., the raw sewage in a Parisian WWTP and sewage network 
was found to have higher concentrations of ESBL positive E. coli than were collected at the hospital. The 
authors suggest that this may be due to hospital water use, leading to overall higher dilutions in the 
samples and potential development and transferal of resistance during sustained containment at the 
WWTP 91.  
Higher magnitude of confirmed antimicrobial resistance may be associated with the ephemeral 
nature of the hospital sewage in comparison to the longer-term residence times of community raw 
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sewage and secondary effluent samples79. Hospitals release a high concentration of antibiotics into 
municipal WWTP via hospital effluent. This creates selection pressure in these systems that sustain and 
foster AMR92. Presumptive ESBL positive E. coli and other coliform were found in 9 out of 10 secondary 
effluent samples. Likewise, presumptive KPC positive E. coli and other coliforms were found in 9 out of 10 
secondary effluent samples. This is a concerning finding, as treated effluent is discharged into a water 
body that is hydrologically connected to an important drinking water source and recreational area.  
The average concentrations of presumptive ESBL and KPC positive E. coli in Morgan Creek, 
upstream of WWTP were 2.48 x 101 and 9.13 x 101 CFU / 100 mL, respectively. The average 
concentration of presumptive E. coli cultured on Bio-Rad agar during the same assays was 4.02 x 102 
CFU / 100 mL. The average proportions of ESBL and KPC E. coli were 3.18% and 3.19%, respectively 
(Table 3.14). The average concentrations of presumptive ESBL and KPC positive E. coli in Morgan Creek, 
downstream of WWTP were 6.03 x 101 and 3.17 CFU / 100 mL, respectively. The average concentration 
of presumptive E. coli cultured on Bio-Rad agar during the same assays was 1.29 x 103 CFU / 100 mL. 
The average proportions of ESBL and KPC E. coli were 11.55% and 1.89%, respectively (Table 3.16).  
The average concentrations of ESBL and KPC positive other coliforms in Morgan Creek upstream 
of the WWTP were 1.77 x 102 and 3.89 x 102 CFU / 100 mL, respectively. The average concentration of 
presumptive non-E. coli coliforms cultured on Bio-Rad agar during the same assays was 1.52 x 104 CFU / 
100 mL. The average proportions of ESBL and KPC positive other coliforms were 2.11% and 1.43%, 
respectively (Table 3.14). The average concentrations of ESBL and KPC positive other coliforms in Morgan 
Creek downstream of the WWTP were 3.70 x 102 and 1.42 x 102 CFU / 100 mL, respectively. The average 
concentration of presumptive non-E. coli coliforms cultured on Bio-Rad agar during the same assays was 
3.12 x 104 CFU / 100 mL. The average proportions of ESBL and KPC positive other coliforms were 1.92% 
and 0.87%, respectively (Table 3.16).  
When both the proportions and concentrations of KPC and ESBL positive E. coli and other 
coliforms were compared between the upstream and downstream site using a Mann-Whitney U test, no 
significant difference was found at a 95% CL (Tables 3.26 and 3.27). The relative consistency of AMR 
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loads and resistance characteristics of collected isolates from surface water samples impacted by WWTP 
effluent is also comparable to other studies that show there are other sources influencing the AMR load 
outside of effluent discharge. This was found by Blaak et al. in a 2014 Dutch study, Harnisz in a 2013 
Polish study, Goñi-Urriza et al. in a 2000 Brazilian study all focused on the comparison of upstream and 
downstream resistance characteristics 45,78,93.  
The third and fourth objectives of this study focused on the performance evaluation of CHROMagar 
ESBL and KPC agar medium for the detection and enumeration of ESBL and KPC positive E. coli and other 
coliforms in hospital sewage, raw sewage, treated sewage effluent and surface waters impacted by 
WWTPs. Overall, CHROMagar ESBL performed well in hospital sewage, raw sewage and secondary 
effluent samples. There was a high level of identity confirmation in these samples for presumptive 
coliforms, but not for E. coli via MALDI-TOF MS speciation. Many of the presumptive E. coli isolates were 
identified as “other coliforms” with exact identities found in Appendix 3. During VITEK 2 analysis,  there 
was high confirmation of resistance to Cefpodoxime, a cephalosporin antimicrobial, in all sample for 
identified coliforms. In addition, many of the same isolates were also confirmed to have resistance to 
Imipenem, a carbapenem antimicrobial, and harbor multi-resistance.  
Overall, CHROMagar KPC did not perform as well in environmental samples when compared to the 
confirmation rates from CHROMagar ESBL medium. There was a high level of identity confirmation in the 
evaluation of hospital sewage, raw sewage and secondary effluent samples for presumptive coliforms, 
but not for E. coli via MALDI-TOF MS speciation. Many of the presumptive E. coli isolates were identified 
as “other coliforms” with exact identities found in Appendix 4.  
None of the surface water isolates were confirmed as coliforms, but were instead identified as 
other Gram-negative bacteria, many of which harbor intrinsic carbapenem resistance traits (Tables 3.51 -  
3.55) 58. During Modified Hodge testing, there was high confirmation of KPC presence in raw sewage and 
secondary effluent (Tables 3.42 – 3.50). Of the forty-four raw sewage confirmed non-E. coli coliform 
isolates that received both MALDI-TOF and Modified Hodge Testing, 82% were positive for KPC, 11% had 
“intermediate” levels of KPC, and 7% were negative (Table 3.45). Of the thirty secondary effluent 
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confirmed non-E. coli coliform isolates, 80% were positive for KPC, 10% had “intermediate” levels, and 
10% were KPC negative (Table 3.49).  
 None of the twelve raw sewage or sixteen secondary effluent isolates of presumptive E. coli were 
confirmed via MALDI-TOF (Tables 3.44 and 3.48).  These isolates were identified as other coliforms such 
and other Gram-negative bacteria such as Serratia marcescens, Stenotrophomonas maltophilia, and 
Aeromonas caviae (Appendix 4). All of the aforementioned bacteria are known to harbor resistance to 
carbapenems, are of clinical concern, and demonstrate clear to pink growth on CHROMagar Orientation 
58,86,93–95. 
 Rapid identification of an infectious organism is invaluable for the administration of appropriate 
patient treatment, as well as useful for evaluating microbial source characteristics and transmission 
pathways. Before the introduction of chromogenic agar media in the 1990s, an array of phenotypic 
characteristics and simple biochemical tests were required to identify bacteria. Culture-based agar media 
have evolved considerably from nutrient, non-selective agar to the two substrate-specific chromogenic 
agars compared in this analysis, both designed to detect specific bacteria or groups of bacteria 3,96.  
Modern chromogenic agar media contain specific substrates that impart differential, genus-specific 
(and sometimes species-specific) indicator properties that facilitate expedited identification of certain 
bacteria based on the color of their colonies96. The color comes from the hydrolysis product of the 
carbohydrate substrate-chromogen complexes that were generated by the reactions of genus- or species-
specific enzymes. A requisite utility of all the culture agar media to be used in the proposed method is the 
capacity to discriminate common, clinically significant bacteria present in mixed cultures in environmental 
specimens after direct plating from representative waste waters and surface waters.  
E. coli and other coliform bacteria are fitting indicator organisms, as they are presently used in many 
parts of the world for surveillance of fecal contamination as well as to monitor the efficacy of treatment 
and relative quality of waste and drinking waters. In particular, pathogenic strains of E. coli are known to 
be major contributors to community-acquired infections and Klebsiella pneumonia has been identified as 
having an important role as a cause of infections and illnesses in hospital settings. β-lactam antibiotics 
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are among the most important clinical antibiotics. Bacteria with resistance to Extended-spectrum β-
lactams like cephalosporins and/or resistance to carbapenems can have significant medical 
consequences. Detection of ESBL and KPC production in bacteria indicates significant mechanisms of 
AMR, making detection of ESBL and KPC production in coliform bacteria an appropriate indicator system 
for evaluation of environmental AMR presence, concentrations and significance.  
Antibiotic resistant bacteria have a series of phenotypic traits that increase their persistence and 
resistance. The base medium of CHROMagar Orientation supported the growth of interfering organisms 
that harbor like-resistance profiles. During the 13 assays, complex colonial characteristics were observed 
that both aided and hindered identification of the bacteria in question. Though similar in color, colonies 
varied in size, opacity, elevation, shape and consistency within the same plate. Pure colonies from surface 
water did not always exhibit the same properties as pure colonies from the other samples, making it very 
important to learn, acknowledge and include the sample source in culture examination and judgement.   
A 1996 study of CHROMagar Orientation found that mucoid E. coli and K. pneumoniae strains often 
masked underlying growth of different organisms and that the medium may not be suitable for direct 
isolation86. Mucoid colonies were often seen in hospital sewage, raw sewage and secondary effluent and 
were initially very difficult to isolate and characterize, as confluent mixtures of non-mucoid colonies often 
had the same appearance. Colonies of presumptive target organisms cultured from surface water 
samples on the antibiotic media were often small and dry in initial appearance. Although colony isolates 
were frozen for later confirmation and characterization, isolates from surface water samples had poor 
revival rates, often requiring multiple subcultures before validation steps commenced.  
One potential reason for the high number of false positives as well as low isolate revival for E. coli 
is that the ESBL and KPC CHROMagar media rely on β-D-Glucuronidase (GLUC) activity to differentiate E. 
coli. All the CHROMagar products used in the study as well as Bio-Rad Rapid’E. coli 2 agar medium use β-
D-Galactosidase (GAL) specific chromogenic substrates and β-D-Glucuronidase (GLUC) specific 
chromogenic substrates to differentiate coliforms and E. coli, respectively86,97. When coliforms cleave the 
GAL substrate, a green precipitate is left behind as the enzyme hydrolysis product, allowing for positive 
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confirmation of coliforms. When E. coli cleave the GLUC substrate, a pink precipitate is left behind as the 
enzyme hydrolysis product, allowing for positive confirmation of E. coli 98. CHROMagar Orientation has an 
additional proprietary blend of other chromogenic substrates used for the detection of both Gram-positive 
and -negative organisms 86. A full listing can be found in Table 2.5. E. coli specific survival and 
disinfection studies have shown that loss in cultivability does not necessarily result in the loss of GLUC 
enzyme activity, resulting in false positives for uncultivable bacteria 95,99. Other false positives may be 
related to the production of GLUC and GAL by many organisms other than E. coli and coliforms, 
respectively. GLUC can be produced by Flavobacterium spp., Bacteroides spp., Staphylococcus spp. and 
Streptococcus spp. all of which were identified in presumptive E. coli isolate samples, especially when 
isolated on the CHROMagar KPC medium95. 
Limitations 
Funding and Confirmation of Bacteria Isolates  
Funding was the major limiting factor that hindered timely confirmation and characterization of 
presumptive colonies, possibly reducing the accuracy, precision and reliability of the subjective 
presumptive bacteria counts and concentration calculations. Confirmatory antimicrobial susceptibility 
testing and speciation should have been performed prior to freezing the initial isolates or much earlier in 
the project to better evaluate the performance of the media, the experimental protocol and the 
proficiency of the analysts involved. The antimicrobial resistance profile of an organism can change with 
stress, prolonged storage at sub-optimal conditions and repeated serial culturing 100. Repeated 
freeze/thaw and exposure to antibiotics during revival for further testing may damage bacterial cells and 
possibly increase or change initial susceptibility of the test isolate 100. Such changes from repeated isolate 
handling could bias the performance evaluation of the media using conventional antimicrobial 
susceptibility techniques.  
Analyst Training and Proficiency 
Successful performance of the proposed culture methods requires knowledge of culture-based, 
clinical-style microbial techniques that the analyst team initially lacked, as well as proper performance 
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and consistent incorporation of quality control measures. Prior to training at UNAN in the summer of 
2015, the team responsible for the evaluation of this method did not have the preferred level of training, 
skill and proficiency required for the reliable detection, enumeration and isolation of wild-strain resistant 
target organisms, many of which displayed an array of highly variable phenotypic characteristics.  
For instance, it may have been concluded that two blue colonies had the same presumptive 
identities. However, with in-service training and experience in getting results from speciation, one could 
discern that one apparent “colony” was a presumptive turquoise Enterococcus colony merging over the 
smaller pink E. coli colony, and the other apparent “colony” was a metallic blue Klebsiella-type colony 
covered in cream, pin-point Pseudomonas colonies. These are prototypical examples of several issues 
that can lead to poor bacteria isolation success and subsequent contamination of frozen isolates. It is also 
illustrative of the training and experience needed to successfully utilize and evaluate this, or a similar, 
culture-based method. 
Sample Comparisons and Size 
The sampling strategy lacked temporal consistency between the hospital and other sample types 
due to delays in the participation of the UNC hospital system. This delayed inclusion of hospital samples 
into the regime by five months hindered the simultaneous comparison of all sample types. Jordan Lake 
was also sampled less due to limited sample collection and analysis capacity. Power is based on the 
smallest sample size and our sampling limitations reduced the power of both the paired Wilcoxon Signed 
Rank and Kruskal Wallis analysis of some of the samples. The sample size for the hospital samples, while 
on the cusp of being too small, allowed for the Kruskal Wallis inter-sample comparison. A Kruskal Wallis 
analysis of Morgan Creek (upstream and downstream) with Jordan Lake was not done due to unequal 
sample sizes that would affect the homogeneity of variance assumption. Though a moderate departure 
from sample size is possible, it is not as rigorous, as the results are considerably less robust.  
Reliance on GAL and GLUC for differentiation of Coliforms and E. coli  
Beta-D-Galactosidase (GAL) has been found in numerous gram-negative bacteria strains 
belonging to Enterobacteriaceae and Pseudomonadaceae as well as in several gram-positive bacteria, 
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yeasts, protozoa, and fungi 95,101. Beta-D-Glucuronidase (GLUC) is produced by most E. coli strains and 
also by other members of Enterobacteriaceae, including some Citrobacter and Edwardsiella as well as by 
Flavobacterium spp., Bacteroides spp., Staphylococcus spp. and Streptococcus spp. 3,95.  
All the CHROMagar media and the Bio-Rad Rapid’E. coli 2 agar medium use β-D-Galactosidase 
(GAL) specific chromogenic substrates and β-D-Glucuronidase (GLUC) specific chromogenic substrates to 
differentiate and positively identify coliforms and E. coli colonies, respectively. Sole dependence on the 
green and pink colored precipitate as evidence for positive identification of coliforms and E. coli without 
use of other confirmatory methods may be in error, as production of GAL and GLUC can occur in other, 
non-target organisms, thereby creating false positives during the detection and enumeration of coliforms 
and E. coli in environmental matrices.  
Recommendations 
The expressed limitations of this study highlight the need for more funding, better test media and 
engagement of clinical and veterinary microbiologists for better evaluation. Though the proposed method 
is generally promising, culture-based methods can be onerous, time-consuming and prone to bias when 
compared to other available, more sensitive and rapid detection methods. PCR is a highly sensitive and 
specific method for the detection of AMR, but remains unavailable for use in many laboratories 19. A 
tiered approach that utilizes both molecular and phenotypic methods is needed. Using similar methods to 
the ones evaluated in this study would address capacity limitations and thereby be inclusive of a broad 
network of stakeholders required to fully implement the proposed global surveillance system.  
It is pragmatic and prudent to adhere in part to highly standardized, culture-based clinical 
methods for assessing antibiotic resistance, as their use would support, rather than hinder, the broad 
adoption and implementation of future surveillance efforts. Accordingly, building from culture-based 
methods already used in clinical laboratories around the world is a pragmatic and prudent strategy 
towards globally harmonized surveillance. More work should be done toward the development or 
selection of appropriate and effective culture-based media. If a harmonized, culture-based methodology 
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for the surveillance of AMR in representative waste and environmental samples is to be developed, 
serious consideration must be given to its availability, expense, infrastructure requirements, relative time 
burden, and the choice, availability and effective use of its culture media. Without the incorporation of 
recommendations outlined below, a globally coordinated AMR surveillance system will possibly never 
come to fruition. 
Initial and Iterative Performance Evaluation 
Determination of resistance profiles and bacterial identities of presumptive isolates should occur 
as soon as possible upon initial bacteria detection, enumeration and isolation from the samples. The 
resistance profile of an organism can change with stress or poor storage conditions. Repeated freeze / 
thaw and exposure to antibiotics during revival for future testing may damage bacterial cells, increasing 
or causing changes in the initial susceptibility of the test isolate, biasing the performance evaluation of 
the media using conventional antimicrobial susceptibility techniques102. Antimicrobial susceptibility testing 
in clinical laboratories is routine, expected and standardized. Future evaluation of this method should be 
done in clinical laboratories where the assays are routine, highly structured and more representative of 
the conditions in which the future AMR surveillance method would be adopted and encouraged.  
Bacteria Colony Color and Morphology Referencing Catalog  
A bacteria colony color and morphology referencing catalog should be developed at the 
beginning of the project and updated iteratively with continued confirmation of presumptive identities. 
Though perhaps challenging to the capacity of many labs, including this one, a series of control bacteria 
isolates or strains with similar resistance traits to the target organisms should be performed on the 
medium in question, with referencing of colony appearance using a Pantone international printing color 
chart. Another option would be to take high resolution photographs of the colonies on the resulting test 
plates for later comparison and then import them to a digital device (e.g. mobile phone or tablet) and / 
or obtain high quality, printed copies). This use of reference and positive control bacteria strains should 
also be done proactively with environmental bacterial isolates that will be immediately characterized. The 
colony photos would be linked to the bacterial identity and sample type and used to guide interpretation 
in future assays. If different morphological characteristics are attributed to the same bacteria species 
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after rigorous characterization, a photo and description would be added, creating an interpretation 
catalog for future use by the researchers as well as others.  
Cost and Availability of Indicator System 
Further evaluation of the CHROMagar agar media must be done before definitive statements can 
be made regarding their suitability for use in the discussed monitoring method of a surveillance system. 
CHROMagar Orientation, KPC and ESBL are very expensive and may create serious cost barriers for many 
laboratories in low-resource settings. CHROMagar Orientation is the base media for CHROMagar ESBL 
and KPC. Purchasing a five liter supply of both CHROMagar ESBL and KPC agar media with requisite 
antibiotic supplements costs approximately $800 USD, with CHROMagar ESBL agar costing $385 and 
CHROMagar KPC agar costing $443, respectively. A five liter supply of BioRad Rapid’E. coli 2 agar costs 
$412 USD. This does not include the cost of consumables or other evaluation and confirmation analyses. 
Other clinical candidate agar media are being identified for incorporation into this ongoing study. 
However, the fact remains that antibiotic supplements are very expensive and require refrigeration. 
Validating the proposed protocol requires three step-wise uses of the antibiotic containing medium: one 
for initial spread plating or membrane filtration and two additional purification streaks on agar media 
plates. This can become very costly and possibly impede consistent culture-based monitoring for 
surveillance.  
Many clinical laboratories, especially in low- and middle-income countries, are capable of 
overcoming the lack of availability and / or expense of bacteriologic culture media by preparing 
comparable media from “scratch” from listed, constituent ingredients. However, the antibiotics and 
chromogenic substrates in CHROMagar media are proprietary and unlisted. Due to the cost and 
proprietary nature of many antibiotic substrates, iterative plating, post-spreading or filtration, may not be 
economically feasible. Thus, it is recommended to find alternative agar media for the purification steps 
that is capable of differentiating target resistant species. For instance, MacConkey agar is the most widely 
used clinical medium in clinical laboratories for the differentiation and isolation of Gram-negative bacteria 
and has been shown to perform well in disk diffusion tests for the phenotypic evaluation of KPC 
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production65. It can be supplemented with known ESBL and KPC antimicrobials to select for and purify 
such bacteria isolates at lower initial cost. However, it does not allow direct and specific visual distinction 
of E. coli from other coliforms, unless a chromogenic or fluorogenic Beta-D-glucuronide substrate is 
incorporated into the medium.  Furthermore, the use of such culture media made from “scratch”, 
including the preparation and storage of the antimicrobials to be used with them, requires rigorous and 
regular quality control and quality assurance activities, which also adds cost, time and effort. 
Animal-free products 
  All of the agar media used in the project have animal-derived ingredients. Consequently, a 
global-scale harmonized methodology would exclude use in countries or cultures that practice strict 
vegetarianism or do not use pork-based or beef-based products, e.g. certain sects of Hinduism, 
Buddhism, Judaism, and Islam. To create an inclusive methodology, animal-free products should be 
identified and incorporated into the methodology or validated against the performance of animal-
containing products.  
Spread Plating vs. Membrane Filtration 
Inclusion of traditional approaches for isolation and quantification of microbial indicators will 
continue to be relevant. Spread plating on standard size plates of agar media supplemented with 
antibiotics at MIC is more appropriate for enumeration of AMR in wastewater samples that are expected 
to have higher bacterial concentrations. In membrane filtration on 60 mm diameter culture plates 
overgrowth of non-target organisms and biofilms was routinely observed during this project. Side 
experiments were done to evaluate the efficacy of spread plating and this method was found to 
unequivocally maximize the probability of obtaining distinct, isolated colonies when compared to 
membrane filtration. However, if surface water or other samples that are expected to be less 
contaminated are analyzed, the membrane filtration technique is still preferred to spread plates, as the 
latter requires analysis of larger volumes of water. In addition, more work should be done to develop and 
evaluate a liquid cultivation and quantitative method that utilizes multiple tube techniques and most 
probable number calculations. This would better contend with more turbid samples as well as allow for a 
more flexible and broad range of sample volumes.  
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Partners, Personnel, and Planning  
A One Health approach would involve multi-sector involvement in AMR monitoring for integrated 
surveillance, such as project partnership between clinical, veterinary-agricultural and environmental 
microbiology labs and researchers. Planning is requisite due to the infectious nature of domestic and 
hospital sewage samples, and differences in analytical techniques, and materials and methods. These 
differences should be identified and overcome early so as to identify harmonized methods in planning,  
training and implementation. A standard operating procedure must be developed prior to project initiation 
for sample collection, transport, storage, processing, analysis and enumeration and confirmation. All 
personnel involved must be fully trained prior to project initiation, both in the lab and in the field.  
The determination of sampling sites and collection strategies should be based on accessibility, 
consistency and institutional capacity. Composite sampling, or collection of multiple, discrete samples 
taken at a regular interval over a pre-determined time, can potentially provide better, more 
representative sampling of a waterbody or waste treatment facility when compared to grab samples. 
Composite or repeated samples better represent a system through repeated sample collection over time 
rather than at a single instant. However, composite sampling is much more capacity- and time-intensive. 
Grab samples, though less representative, are a less-intensive alternative to characterize water quality at 
the point and specific time of collection. It is important to consider that sampling waste and surface water 
frequently requires the direct involvement of, and coordination with, external parties, e.g. treatment plant 
or hospital facilities personnel for waste water samples and landowners for surface water samples. 
Establishing and finalizing the terms of external involvement is essential but may require more time than 
expected. It is also important to address potential administrative-related delays in project planning and 
implementation.  
Future Work 
There are several procedures that could be changed in order to create future improvements in 
the culture-based detection and enumeration of ESBL and KPC E. coli and coliforms in samples of 
wastewater and environmental surface water as an ongoing effort. More work is being done to create, 
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further evaluate and attempt to validate an accessible, final methodology for direct, culture based 
detection and enumeration of ESBL and KPC E. coli and coliforms in wastewater and environmental 
waste samples. A revised protocol is in review and will be made available for open distribution to 
present and future partners and other interested parties and stakeholders. Future work includes 
application of the revised methodology to matrices covered in One Health strategies, such as agricultural 
waste, manure, aquaponics and animal carcasses. 
Summary and Conclusion  
Modern antibiotics have changed the world by treating infectious diseases that were once fatal, 
saving millions of lives. However, in the seventy years since their introduction, antibiotics have been used 
excessively and indiscriminately in medical, agricultural, veterinary and domestic settings. This 
irresponsible and imprudent use has introduced antibiotic waste into the environment, creating massive 
reservoirs of ARB presence and complex systems of selective pressure that foster, sustain and spread 
AMR and ARG from bacteria to bacteria, person to person or animal, animal to animal or person, setting 
to setting and country to country. With the global spread of AMR, the world is facing a post-antibiotic era 
where even the simplest infections may become fatal18. Little is known about the actual magnitude of 
AMR because the resistome is vast and multi-faceted with pathogens and autochthonous bacteria 
harboring, transferring and acquiring AMR and ARG to the most sophisticated chemotherapies at rates 
rapidly exceeding pharmacological development of new antimicrobial agents.  
Continuous identification, evaluation and monitoring of AMR hotspots are incredibly important to 
combatting and preventing the spread of AMR. Hospital settings are often considered one of the most 
important reservoirs for the spread of AMR, and mitigation strategies such as antibiotic stewardship have 
been implemented. However, wastewater treatment systems are potentially as important as hospitals, 
and the efficacy of such treatment is of pressing concern. When fecal wastes from patients are conveyed 
to municipal wastewater treatment plants, the AMR pathogens contained within the wastes follow. 
Evaluating the magnitude of AMR in influent is a potential proxy for evaluating the magnitude of AMR in 
the community, analogous to obtaining a snapshot community-wide fecal sample. Evaluating the 
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presence of AMR in treated effluent and biosolids can also be used to evaluate the efficacy of treatment 
as well as the risk of emission of AMR into the environment. Focus on WWTP hotspots is not always 
appropriate, as many areas do not have safe wastewater containment, management or treatment. 
Surface and other environmental waters should also undergo surveillance, as it is estimated that 90% of 
wastewater is discharged untreated into the environment68. This is especially important if land application 
of human and animal waste is practiced. These unmitigated releases work to further increase and spread 
AMR and ARG, exacerbating the risk of exposure and potential burden of infectious disease.  
There are presently no internationally harmonized or enforced strategies, guidelines and standards in 
place that address AMR prevention and reduction in medical, domestic, agricultural, veterinary and food-
production settings. Consequently, there are no harmonized strategies for requisite evaluation, 
monitoring and control of AMR, creating multiple barriers to the institutionalization and maintenance of 
aforementioned policies, guidelines and standards. WHO and others have called for coordinated global 
action to combat AMR, emphasizing surveillance methods that are accessible and practicable across the 
world 1,12,18. Deterrents to the development of this surveillance method include disparate capacities of 
labs, the lack of standardized antimicrobial detection, quantification and susceptibility testing methods 
and differences regarding the use of target indicator organisms and target antimicrobial resistance traits 
to detect and possibly quantify.  
The primary goal of this Masters research was to advance a proof of concept indicator system 
proposed by the World Health Organization via performance evaluation of a prototype method for the 
direct, one-step, culture-based quantitative detection of ARB in representative waste waters and 
environmental samples of interest. The proposed method can be briefly characterized as a culture-based 
indicator system for the direct detection and quantification of Extended-spectrum-β-lactamase (ESBL) and 
carbapenemase (KPC) producing Enterobacteriaceae of the coliform group in exposure-relevant 
environmental matrices such as hospital and domestic sewage, treat sewage effluent, surface waters, 
and agricultural waste. The work was divided into four research objectives (Tables 1.1 – 1.4) that were 
executed in eighteen months over five different project phases (Figure 2.6). 
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The first objective was to assess the performance of CHROMagar Orientation – a chromogenic clinical 
diagnostic medium used for the isolation and differentiation of urinary tract pathogens – as the primary 
agar medium in the prototype method. CHROMagar Orientation medium was chosen above several other 
comparable media due to the availability of two corresponding product lines of bacteriologic culture 
media: CHROMagar ESBL for the detection of Gram-negative bacteria producing ESBL and CHROMagar 
KPC developed for the detection of Gram-negative bacteria with reduced susceptibility to most 
carbapenem agents. Both media were designed for use in the evaluation of urine and stool samples and 
are composed of CHROMagar Orientation as the base medium supplemented with a proprietary mixture 
of either extended-spectrum-β-lactam or carbapenem antibiotics.  
The performance assessment involved repeated, parallel assays of representative environmental and 
waste water samples using procedures of EPA Method 1604 for membrane filtration followed by culturing 
on CHROMagar Orientation and Bio-Rad Rapid’E. coli 2.  Bio-Rad Rapid’E. coli 2 is a chromogenic, culture-
based medium used for the detection and enumeration of E. coli and other coliform bacteria in food and 
waste waters and was used as the “gold standard” for performance. The resultant concentrations of 
presumptive E. coli and other coliforms from both media were paired by date, sample site and organism 
and compared using a Wilcoxon signed-rank tests, with a significance α = 0.05. Results suggest that: 
Objective 1 results: 
 The performance of the clinical medium was comparable to the gold standard for detection of E. 
coli, non-E. coli coliforms, and combined coliforms in hospital sewage and treated sewage 
effluent matrices (Tables 3.1 – 3.3), fulfilling the requirements for the proposed method 
associated with discrimination of target bacteria in mixed culture of environmental matrices.  
 
 The performance of the clinical medium was comparable to the gold standard for detection of 
non-E. coli coliforms and combined coliforms in raw sewage and surface water. (Tables 3.2 – 3.3) 
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 The performance of CHROMagar Orientation in raw sewage and surface water matrices for the 
detection of E. coli did not fulfill the needed requirements for the proposed method associated 
with discrimination of target bacteria in mixed culture of environmental matrices. (Table 3.1)  
The second objective was to determine the presence, concentration, and relative proportion of 
presumptive ESBL producing E. coli and other coliforms as well as presumptive carbapenemase producing 
E. coli and other coliforms in the same representative waste waters and environmental surface waters. 
During the aforementioned assays, the same samples were also plated on the CHROMagar ESBL and 
CHROMagar KPC media. The resulting concentration data was used to calculate a relative proportion of 
presumptive ESBL producing E. coli and coliforms as well as presumptive carbapenemase producing E. 
coli and other coliforms. This was done by pairing ESBL or KPC concentrations with Bio-Rad data from the 
same date, sample site and organism. Proportions for each resistance profile were then calculated using 
either the ESBL or KPC concentrations as the numerator and the Bio-Rad concentrations as the 
denominator.  
Objective 2 results: 
 
 ESBL and KPC E. coli and other coliforms are present in hospital sewage, domestic sewage, 
treated sewage effluent, and surface waters up and downstream from the effluent discharge 
point. 
 ESBL and KPC producing E. coli and other coliforms can be consistently detected and confirmed 
at high concentrations in hospital sewage and raw sewage 
 Lower, but still detectable concentrations of presumptive ESBL and KPC producing bacteria can 
be found in secondary effluent and surface water samples 
 Secondary treatment of the sewage does not completely eliminate ESBL and KPC producing 
bacteria.  
The third objective focused on validation of the CHROMagar ESBL agar medium via analysis and 
confirmation of frozen isolates of presumptive ESBL E. coli and non-E. coli coliforms collected during 
the aforementioned assays. Isolates were revived and subjected to VITEK 2 automated antimicrobial 
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susceptibility analysis in order to assess and confirm reduced susceptibility to extended-spectrum-β-
lactam antibiotics. MALDI-TOF MS was then performed to speciate the same isolates for further 
confirmation of identity as presumptive indicator E. coli or non-E. coli coliforms.  
The fourth objective centered on validation of the CHROMagar KPC agar medium via analysis and 
confirmation of frozen isolates of presumptive KPC producing E. coli and non-E. coli coliforms. 
Isolates were revived and subjected to Modified Hodge Testing for antimicrobial susceptibility analysis 
and to phenotypically evaluate resistance profiles, thereby confirming KPC production. MALDI-TOF 
MS was also used for speciation and identity confirmation.  
Objective 3 and 4 results: 
 The CHROMagar ESBL agar medium is capable of correctly detecting microorganisms with 
resistance to extended-spectrum-β-lactam antibiotics in all sampled environmental matrices 
(Tables 3.28 – 3.36) 
 For all sample matrices, several organisms isolated on CHROMagar ESBL medium demonstrated 
multiple resistance to both extended-spectrum-β-lactam and carbapenem antibiotics (Tables 3.28 
– 3.36).  
 CHROMagar KPC medium did not perform as well in the sampled environmental matrices for the 
detection of indicator organisms with reduced susceptibility to carbapenem. There was high 
confirmation of KPC production in raw sewage and secondary effluent, but, given study and 
methodological limitations, more analysis should be performed (Tables 3.37 – 3.55).  
 The performance of both CHROMagar ESBL and KPC media in environmental matrices for the 
correct detection of E. coli is unreliable due in part to the diversity and complexity of 
autochthonous organisms and reliance on Beta-D-Galactosidase and Beta-D-Glucuronidase for 
visual target colony differentiation and positive identification (Tables 3.28 – 3.55).  
 Both media also performed poorly in surface water sites, however, a complex resistome may 
exist in the autochthonous bacteria analyzed. Many harbored intrinsic resistance at MICs 
breakpoints, but were not species considered of clinical concern within the CLSI database. This 
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may merit future evaluation and inclusion, as holistic surveillance of hotspots will require the 
analysis of this potential reservoir. (Tables 3.51 – 3.55 and APPENDIX 4).  
 The use of a chromogenic substrate standard clinical agar medium for the direct detection and 
enumeration of E. coli and coliforms as fecal indicator bacteria in representative waste waters 
and surface waters is promising. However, given the limitations of the agar base CHROMagar 
Orientation, other candidate clinical media should be identified and evaluated for performance 
and suitability in the proposed method. 
In conclusion, the development of new antibiotic chemotherapies has lagged over the past decade, 
suggesting a tipping point in pharmaceutical innovation. If this is indeed true, we must look to other 
approaches for mitigation of AMR development and spread. If one critically evaluates the advent of 
modern public health, it is the development and employment of antimicrobials in concert with 
improvements in the quality of and access to water, sanitation, and hygiene as leading achievements and 
accomplishments. This study demonstrates that present waste management methods are not sufficient 
for the containment and treatment of AMR. The elevated concentrations of highly AMR bacteria in 
hospital and municipal sewage as well as treated effluent indicates the widespread presence in the 
population and their possible spread to others from exposure via environmental, food and person-to-
person transmission routes. More must be done to inform and support efforts to control and prevent the 
spread and release of antimicrobial agents, ARB, and ARG in human and animal waste into the 
environment. Coordination of surveillance efforts with documentation of antibiotic consumption provides 
a baseline for assessment efforts for future AMR mitigation strategies 103 
The global spread of ARB merits evaluation across other geographic regions in US and abroad 
using parallel, matching and harmonized methods to identify ARB threats and detect outbreaks. These 
media and methods have promise as a candidate indicator system to detect and quantify ARB of health 
concern in environmental media as a monitoring system to support environmental surveillance, thereby 
generating supporting evidence to inform and help shape future global action plans 
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The work performed during this study has implications for the development of future protocols for 
the analysis of AMR in the environment. To date, there are no published studies that evaluate the 
performance of CHROMagar ESBL agar and CHROMagar KPC agar for direct detection of presumptive 
ESBL and KPC positive E. coli and other coliforms in hospital sewage, municipal sewage, secondary 
effluent and surface waters by membrane filtration. There are also no published studies comparing the 
performance of the based agar medium, CHROMagar Orientation, to Bio-Rad Rapid’E. coli 2 agar as the 
“gold standard” agar medium for direct detection and enumeration of E. coli and coliforms in 
environmental matrices by membrane filtration. This study provides significant information that supports 
the development and improvement of future prototype methods as well as evidence to inform future 
recommendations on candidate methods for direct, culture-based environmental monitoring using a 
harmonized and ongoing surveillance system for specified AMR traits of E. coli and other coliforms in the 
environmental samples that are the same as or consistent with the methods used in clinical and 
agricultural/veterinary settings and samples.  
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APPENDIX 1 MEDIA PREPARATION  
Bacteriologic Agar Media 
All agar media will be prepared according to manufacturer’s instructions and plates were stored 
for no longer than 1 month at 4°C. CHROMagar ESBL and CHROMagar KPC antibiotic additives will be 
stored at 4°C and prepared according to manufacturer’s instructions.  
 
Bio Rad Rapid’ E. coli 2 agar medium – A 37g quantity of powdered media per 1 liter of 
deionized water was mixed in a container. The agar medium was dissolved by bringing to a boil on a 
magnetic hot plate at a moderate temperature and the use of a stir bar for frequent agitation. The 
molten medium was then autoclaved at 121°C for 15 minutes. After sterilization, agar medium was 
tempered in a 55°C water bath for approximately 30 minutes and then poured into the desired plate size. 
CHROMagar™ Orientation Medium – A 33 g quantity powder medium base in 1 liter of 
deionized water was mixed in container. The agar medium was dissolved bringing to a boil on a magnetic 
hot plate at a moderate temperature with a stir bar for frequent agitation. The molten medium was then 
autoclaved at 121°C for 15 minutes. After sterilization, the agar medium was tempered in a 55°C water 
bath for approximately 30 minutes and then poured into desired plate size.  
CHROMagar™ ESBL - ESBL antibiotic supplement was prepared by weighing 570 mg ESBL 
supplement to 10 mL of cooled, autoclaved deionized water. Agar medium was prepared by adding 
reconstituted supplement solution to cooled, molten CHROMAgar Orientation medium at a 1% volume 
ratio (i.e. 10 mLs antibiotic supplement solution to 1 liter of agar). Supplement was not stored and used 
the same day it was prepared. Plates were poured as for the other agar media. 
CHROMagar™ KPC – KPC antibiotic supplement was prepared by weighing 400mg KPC 
supplement to 10 mL of cooled, autoclaved deionized water. Agar medium was prepared by adding 
reconstituted supplement solution to cooled, molten CHROMAgar Orientation medium at a 1% volume 
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ratio (i.e. 10 mLs antibiotic supplement solution to 1 liter of agar) and plates were poured as for other 
media. Supplement was not stored and used the same day it was prepared.  
Tryptic Soy Agar (Difco™) – A 40g quantity of powder medium per 1 liter of deionized water 
was mixed in container. To dissolve it the agar medium was then brought to a boil on a magnetic hot 
plate at a moderate temperature with a stir bar for frequent agitation. The medium was then autoclaved 
at 121°C for 15 minutes. After sterilization, the agar medium was tempered in a 55°C water bath for 
approximately 30 minutes and then poured into the desired plate size. 
Mueller Hinton Agar (Remel™) – A 38g gram quantity of medium powder per 1 liter of 
deionized water was mixed in container. To dissolve it, the agar medium was then brought to a boil on a 
magnetic hot plate at a moderate temperature with a stir bar for frequent agitation. The medium was 
then autoclaved at 121°C for 15 minutes. After sterilization, agar medium was tempered in a 55°C water 
bath for approximately 30 minutes and then poured at 25 mL per 100 mm x 15 mm plate after the pH of 
agar medium was evaluated to ensure it was between 7.2 and 7.4 at room temperature. 
 
MacConkey (Remel™) – A 50g quantity of powder medium per 1 liter of deionized water 
was mixed in container. To dissolve it, the agar medium was then brought to a boil on a magnetic hot 
plate at a moderate temperature with a stir bar for frequent agitation. The agar medium was then 
autoclaved at 121°C for 15 minutes. After sterilization, the agar medium was tempered in a 55°C water 
bath for approximately 30 minutes and then poured into the desired plate size. 
Stock Solutions and Other Media 
Phosphate-buffered solution 81 To make phosphate buffer stock, dissolve 8.5 g KH2PO4, 21.75 
g K2HPO4, 33.4 g Na2HPO47H2O, and 1.7 g NH4Cl in 500 mL reagent grade water and dilute to 1L. To 
make phosphate buffer, 1.25 mL of concentrated stock phosphate buffer solution and 5.0mL MgCl2 
solution (81.1g MgCl2•H2O/L reagent grade water) was added to 1 L reagent grade water and then 
autoclaved for 15 mi at 121°C and stored in 4°C cold room until use, for no more than 3 weeks. 
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Buffered Peptone Water (BPW) 81 – Quantities of 10.0g peptone, 5.0 g NaCl, 3.5 g 
Na2HPO4, and 1.5 g KH2PO4 were dissolved in in 1 L reagent grade water. pH was adjusted to 7.2 + 0.5 
with 1N NaOH, and then the BPW was autoclaved for 15 mi at 121°C and stored in 4°C cold room until 
use, for no more than 3 weeks. 
 
1X Trypticase Soy Broth (TSB)- A 30 g quantity of powder medium was dissolved in 1 liter 
deionized water, mixed thoroughly, and then heated on a hotplate until completely dissolved. TSA was 
then autoclaved at 121°C for 15 minutes and stored in 4°C cold room until use, for no more than 3 
weeks.  
 
40% Glycerol Solution – A 4 part glycerol to 6 part deionized water solution was prepared, 
by volume, and autoclaved at 121°C for 15 minutes. The solution was stored in 4°C cold room until use, 
for no more than 3 weeks. 
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APPENDIX 2 CONCENTRATION AND PROPORTIONS 
 
Table 1.A -  Hospital 1 (GI MICU) E. coli Concentration (CFU / 100mL) by Media and Date 
Table 1.B - Hospital 1 (GI, MICU) Non- E. coli coliforms Concentration (CFU / 100mL) by Media and Date 
Table 1.C - Hospital 1 (GI, MICU) Total coliform Concentration (CFU / 100mL) by Media and Date 
      
Table 2.A – Hospital 2 (Burn, Lab, ICU) E. coli Concentration (CFU / 100mL) by Media and Date 
Table 2.B – Hospital 2 (Burn, Lab, ICU) Non- E. coli coliforms Concentration (CFU / 100mL) by Media Date 
Table 2.C – Hospital 2 (Burn, Lab, ICU) Total coliform Concentration (CFU / 100mL) by Media and Date 
      
Table 3.A – Hospital 3 (Heart, ICU) E. coli Concentration (CFU / 100mL) by Media and Date 
Table 3.B – Hospital 3 (Heart, ICU) Non- E. coli coliforms Concentration (CFU / 100mL) by Media and Date 
Table 3.C – Hospital 3 (Heart, ICU) Total coliform Concentration (CFU / 100mL) by Media and Date 
      
Table 4.A – Hospital 4 (ER, Neuro) E. coli Concentration (CFU / 100mL) by Media and Date 
Table 4.B – Hospital 4 (ER, Neuro) Non- E. coli coliforms Concentration (CFU / 100mL) by Media and Date 
Table 4.C – Hospital 4 (ER, Neuro) Total coliform Concentration (CFU / 100mL) by Media and Date 
      
Table 5.A – Raw Sewage E. coli Concentration  
Table 5.B – Raw Sewage Non- E. coli coliforms Concentration 
Table 5.C – Raw Sewage Total coliform Concentration  
      
Table 6.A – Secondary Effluent E. coli Concentration  
Table 6.B – Secondary Effluent Non- E. coli coliforms Concentration 
Table 6.C – Secondary Effluent Total coliform Concentration 
      
Table 7.A – Morgan Creek Upstream E. coli Concentration 
Table 7.B – Morgan Creek Upstream Non- E. coli coliforms Concentration 
Table 7.C – Morgan Creek Upstream Total coliform Concentration 
      
Table 8.A – Morgan Creek Downstream E. coli Concentration 
Table 8.B – Morgan Creek Downstream Non- E. coli coliforms Concentration 
Table 8.C – Morgan Creek Downstream Total coliform Concentration 
      
Table 9.A – Jordan Lake E. coli Concentration (CFU / 100mL) by Media and Date 
Table 9.B – Jordan Lake Non- E. coli coliforms Concentration (CFU / 100mL) by Media and Date 
Table 9.C – Jordan Lake Total coliform Concentration (CFU / 100mL) by Media and Date 
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Hospital 1 Sewage (Gastrointestinal and Medical Intensive Care Unit): 
Table 1.A – Hospital 1 (GI and MICU) E. coli Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad Rapid 
'E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL  % KPC  
5/11/2015 9 No BR 3.33E+06 5.67E+04 9.58E+04 1.70% 2.88% 
5/18/2015 10 1.00E+06 1.43E+06 2.00E+04 2.50E+04 1.40% 1.74% 
5/26/2015 11 2.15E+05 1.72E+06 1.35E+05 1.55E+04 7.83% 0.90% 
6/15/2015 12 6.48E+06 3.30E+07 6.00E+06 2.23E+06 18.18% 6.74% 
7/1/2015 13 1.40E+06 1.40E+06 8.00E+04 4.00E+03 5.71% 0.29% 
Average 2.27E+06 8.18E+06 1.26E+06 4.73E+05 6.97% 2.51% 
Standard Error 7.54E+02 1.28E+03 5.02E+02 3.08E+02 3.06% 1.14% 
95% Confidence ± 1.48E+03 2.51E+03 9.83E+02 6.03E+02 5.99% 2.24% 
 
Table 1.B – Hospital 1 (GI and MICU) Non- E. coli coliforms Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL  % KPC  
5/6/2015 8 1.44E+09 4.48E+08 1.66E+07 1.10E+07 3.70% 2.46% 
5/11/2015 9 No BR 3.33E+06 2.91E+06 2.52E+06 87.27% 75.48% 
5/18/2015 10 3.50E+06 2.33E+06 1.32E+06 1.75E+06 56.71% 75.14% 
5/26/2015 11 3.70E+06 2.54E+06 1.16E+06 8.75E+02 45.70% 0.03% 
6/15/2015 12 6.79E+07 8.02E+07 9.93E+06 2.65E+06 12.38% 3.31% 
7/1/2015 13 3.00E+05 3.40E+06 3.90E+05 5.20E+04 11.47% 1.53% 
Average 3.04E+08 8.99E+07 5.38E+06 3.00E+06 36.21% 26.33% 
Standard Error 7.80E+03 3.87E+03 9.47E+02 7.07E+02 13.36% 15.50% 
95% Confidence ± 1.53E+04 7.59E+03 1.86E+03 1.38E+03 26.18% 30.38% 
 
Table 1.C – Hospital 1 (GI and MICU) Total coliform Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL % KPC  
5/11/2015 9 No BR 6.67E+06 2.97E+06 2.61E+06 44.48% 39.18% 
5/18/2015 10 4.50E+06 3.77E+06 1.34E+06 1.78E+06 35.66% 47.21% 
5/26/2015 11 3.91E+06 4.27E+06 1.30E+06 1.64E+04 30.41% 0.38% 
6/15/2015 12 7.44E+07 1.13E+08 1.59E+07 4.88E+06 14.07% 4.31% 
7/1/2015 13 1.70E+06 4.80E+06 4.70E+05 5.60E+04 9.79% 1.17% 
Average 2.11E+07 2.65E+07 4.40E+06 1.87E+06 26.88% 18.45% 
Standard Error 2.30E+03 2.30E+03 9.38E+02 6.11E+02 6.54% 10.20% 
95% Confidence ± 4.50E+03 4.51E+03 1.84E+03 1.20E+03 12.82% 20.00% 
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Hospital 2 Sewage (Burn Unit, Laboratory, Intensive Care Unit): 
Table 2.A – Hospital 2 (Burn, Lab, ICU) E. coli Concentration (CFU / 100mL)  
Date Week 
Bio-Rad 
Rapid'E. coli 2 
Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL % KPC  
5/11/2015 9 No BR 2.33E+04 4.83E+02 2.00E+02 2.07% 0.86% 
5/18/2015 10 1.00E+04 2.40E+05 1.01E+04 9.61E+03 4.19% 4.00% 
5/26/2015 11 2.33E+05 3.73E+05 1.98E+03 1.70E+03 0.53% 0.46% 
6/15/2015 12 1.28E+06 1.43E+06 1.34E+05 3.00E+04 9.33% 2.09% 
7/1/2015 13 0.00E+00 1.00E+04 0.00E+00 0.00E+00 0.00% 0.00% 
Average 3.79E+05 4.16E+05 2.93E+04 8.30E+03 3.22% 1.48% 
Standard Error 3.08E+02 2.88E+02 7.65E+01 4.07E+01 1.69% 0.72% 
95% Confidence ± 6.04E+02 5.65E+02 1.50E+02 7.99E+01 3.32% 1.41% 
 
Table 2.B – Hospital 2 (Burn, Lab, ICU) Non- E. coli coliforms Concentration (CFU / 100mL 
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL  % KPC  
5/6/2015 8 3.33E+05 1.00E+06 3.33E+05 0.00E+00 33.33% 0.00% 
5/11/2015 9 No BR 1.67E+04 4.17E+02 7.67E+02 2.50% 4.60% 
5/18/2015 10 7.45E+05 1.08E+05 6.97E+04 5.83E+04 64.69% 54.07% 
5/26/2015 11 2.65E+04 1.90E+04 2.65E+02 9.50E+01 1.39% 0.50% 
6/15/2015 12 1.72E+06 2.00E+06 5.70E+05 1.28E+05 28.51% 6.39% 
7/1/2015 13 3.00E+04 5.00E+04 0.00E+00 5.00E+04 0.00% 100.00% 
Average 5.70E+05 5.32E+05 1.62E+05 3.95E+04 21.74% 27.59% 
Standard Error 3.38E+02 2.98E+02 1.64E+02 8.11E+01 10.46% 16.75% 
95% Confidence ± 6.62E+02 5.84E+02 3.22E+02 1.59E+02 20.50% 32.83% 
 
Table 2.C – Hospital 2 (Burn, Lab, ICU) Total coliform Concentration (CFU / 100mL)  
Date Week 
Bio-Rad 
Rapid'E. coli 2 
Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL  % KPC  
5/11/2015 9 No BR 4.00E+04 9.00E+02 9.67E+02 2.25% 2.42% 
5/18/2015 10 7.55E+05 3.48E+05 7.98E+04 6.79E+04 22.94% 19.52% 
5/26/2015 11 2.59E+05 3.92E+05 2.24E+03 1.80E+03 0.57% 0.46% 
6/15/2015 12 2.99E+06 3.43E+06 7.04E+05 1.58E+05 20.50% 4.59% 
7/1/2015 13 3.00E+04 6.00E+04 0.00E+00 5.00E+04 0.00% 83.33% 
Average 1.01E+06 8.55E+05 1.57E+05 5.57E+04 9.25% 22.06% 
Standard Error 5.02E+02 4.13E+02 1.77E+02 1.06E+02 5.12% 15.68% 
95% Confidence ± 9.84E+02 8.10E+02 3.48E+02 2.07E+02 10.03% 30.74% 
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Hospital 3 Sewage (Cardiovascular Unit, Intensive Care Unit): 
Table 3.A – Hospital 3 (Heart, ICU) E. coli Concentration (CFU / 100mL)  
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL  % KPC  
5/11/2015 9 No BR 2.22E+04 1.32E+04 6.50E+02 59.60% 2.93% 
5/18/2015 10 2.50E+03 7.00E+04 3.83E+04 1.83E+04 54.76% 26.19% 
5/26/2015 11 2.15E+07 4.55E+07 1.53E+03 1.55E+03 0.00% 0.00% 
6/15/2015 12 1.70E+06 2.25E+06 1.24E+05 7.58E+05 5.52% 33.67% 
7/1/2015 13 - - 1.00E+03 0.00E+00 1.04% 6.33% 
Average 7.73E+06 1.20E+07 3.57E+04 1.56E+05 24.19% 13.82% 
Standard Error 1.61E+03 1.73E+03 8.45E+01 1.76E+02 13.52% 6.75% 
95% Confidence ± 3.15E+03 3.39E+03 1.66E+02 3.46E+02 26.51% 13.24% 
*The average Bio-Rad concentration was used for these weeks, due to issues with dilutions, supplies availability, or 
swarming by protists. These concentrations previously were at zero or counts were not possible 
Table 3.B – Hospital 3 (Heart, ICU) Non- E. coli coliforms Concentration (CFU / 100mL)  
Date Week 
Bio-Rad Rapid’ 
E. coli 2 Agar 
CHROMagar 
Orientation 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL  % KPC  
5/6/2015 8 3.33E+05 6.67E+05 3.33E+05 3.33E+05 50.00% 50.00% 
5/11/2015 9 No BR 3.50E+04 2.42E+04 8.10E+03 69.21% 23.14% 
5/18/2015 10 2.05E+05 1.03E+05 1.71E+05 1.93E+05 165.95% 187.89% 
5/26/2015 11 1.30E+06 1.90E+06 8.05E+02 1.25E+03 0.04% 0.07% 
6/15/2015 12 1.40E+07 7.55E+06 2.83E+05 1.38E+06 3.74% 18.21% 
7/1/2015 13 0.00E+00 7.00E+04 5.00E+03 0.00E+00 7.14% 0.00% 
Average 3.16E+06 1.72E+06 1.36E+05 3.18E+05 49.35% 46.55% 
Standard Error 7.95E+02 5.36E+02 1.51E+02 2.30E+02 26.00% 29.25% 
95% Confidence ± 1.56E+03 1.05E+03 2.95E+02 4.52E+02 50.96% 57.33% 
 
Table 3.C – Hospital 3 (Heart, ICU) Total coliform Concentration (CFU / 100mL 
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL  % KPC  
5/11/2015 9 No BR 5.72E+04 3.75E+04 8.75E+03 65.48% 15.29% 
5/18/2015 10 2.07E+05 1.73E+05 2.09E+05 2.11E+05 120.90% 122.38% 
5/26/2015 11 2.28E+07 4.74E+07 2.33E+03 2.80E+03 0.00% 0.01% 
6/15/2015 12 1.57E+07 9.80E+06 4.07E+05 2.13E+06 4.15% 21.76% 
7/1/2015 13 0.00E+00 7.00E+04 6.00E+03 0.00E+00 8.57% 0.00% 
Average 9.67E+06 1.15E+07 1.32E+05 4.71E+05 39.82% 31.89% 
Standard Error 1.55E+03 1.52E+03 1.63E+02 3.07E+02 23.52% 23.02% 
95% Confidence ± 3.05E+03 2.97E+03 3.19E+02 6.02E+02 46.10% 45.12% 
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Hospital 4 Sewage (Emergency Room and Neurological Unit): 
Table 4.A – Hospital 4 (ER, Neuro) E. coli Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL  % KPC  
5/6/2015 8 2.88E+07 3.97E+07 2.67E+06 3.33E+05 6.72% 0.84% 
5/11/2015 9 No BR 5.11E+05 5.63E+04 2.31E+03 11.02% 0.45% 
5/18/2015 10 5.00E+03 3.33E+04 2.75E+04 5.58E+02 82.50% 1.68% 
5/26/2015 11 4.95E+05 2.28E+03 5.10E+03 1.00E+02 224.18% 4.40% 
6/15/2015 12 5.58E+06 6.73E+06 5.95E+05 6.75E+04 8.85% 1.00% 
7/1/2015 13 5.00E+04 1.10E+05 4.00E+04 5.00E+03 36.36% 4.55% 
Average 6.98E+06 7.84E+06 5.65E+05 6.81E+04 61.61% 2.15% 
Standard Error 1.18E+03 1.14E+03 3.07E+02 1.07E+02 34.57% 0.75% 
95% Confidence ± 2.32E+03 2.24E+03 6.02E+02 2.09E+02 67.76% 1.47% 
 
Table 4.B – Hospital 4 (ER, Neuro) Non- E. coli coliforms Concentration (CFU / 100mL)  
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL % KPC  
5/6/2015 8 3.17E+06 3.00E+06 3.33E+06 1.00E+06 111.11% 33.33% 
5/11/2015 9 No BR 3.00E+05 3.64E+05 3.02E+04 121.30% 10.07% 
5/18/2015 10 2.50E+05 1.00E+05 1.24E+05 2.10E+04 124.44% 20.97% 
5/26/2015 11 6.13E+05 4.43E+03 7.50E+02 5.02E+02 16.95% 11.34% 
6/15/2015 12 4.40E+06 4.57E+07 7.28E+05 1.46E+05 1.59% 0.32% 
7/1/2015 13 2.10E+05 6.40E+05 2.90E+05 1.70E+04 45.31% 2.66% 
Average 1.73E+06 8.28E+06 8.07E+05 2.02E+05 70.12% 13.11% 
Standard Error 5.88E+02 1.29E+03 3.67E+02 1.84E+02 22.65% 5.02% 
95% Confidence ± 1.15E+03 2.52E+03 7.19E+02 3.60E+02 44.39% 9.84% 
 
Table 4.C – Hospital 4 (ER, Neuro) Total coliform Concentration (CFU / 100mL)  
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL  % KPC  
5/6/2015 8 3.19E+07 4.27E+07 6.00E+06 1.33E+06 14.06% 3.13% 
5/11/2015 9 No BR 8.11E+05 4.20E+05 3.25E+04 51.81% 4.01% 
5/18/2015 10 2.55E+05 1.33E+05 1.52E+05 2.15E+04 113.96% 16.15% 
5/26/2015 11 1.11E+06 6.70E+03 5.85E+03 6.02E+02 87.31% 8.98% 
6/15/2015 12 9.98E+06 5.24E+07 1.32E+06 2.14E+05 2.53% 0.41% 
7/1/2015 13 2.60E+05 7.50E+05 3.30E+05 2.20E+04 44.00% 2.93% 
Average 8.71E+06 1.61E+07 1.37E+06 2.71E+05 52.28% 5.93% 
Standard Error 1.32E+03 1.64E+03 4.78E+02 2.12E+02 17.36% 2.34% 
95% Confidence ± 2.59E+03 3.21E+03 9.37E+02 4.16E+02 34.02% 4.59% 
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Raw Sewage: 
Table 5.A - Raw Sewage E. coli Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
2/9/2015 W1 1.89E+06 6.67E+06 7.81E+04 5.56E+03 4.14% 0.29% 
2/16/2015 W2 8.33E+05 - 1.50E+05 1.51E+04 18.00% 1.81% 
3/2/2015 W3 - - 8.33E+03 7.25E+03 0.32% 0.28% 
3/17/2015 W4 - - 5.00E+04 7.92E+03 1.94% 0.31% 
3/23/2015 W5 3.33E+05 2.67E+06 1.33E+04 8.83E+03 4.00% 2.65% 
3/31/2015 W6 1.25E+06 7.92E+06 6.48E+04 4.43E+04 5.18% 3.54% 
4/9/2015 W7 2.33E+06 1.52E+07 1.73E+06 3.23E+05 74.29% 13.86% 
5/26/2015 W11 5.50E+06 9.00E+06 1.12E+05 1.28E+05 2.03% 2.32% 
6/15/2015 W12 3.50E+06 4.00E+07 2.53E+05 5.53E+04 7.21% 1.58% 
7/1/2015 W13 5.00E+06 3.00E+06 2.40E+05 4.80E+04 4.80% 0.96% 
Average  2.58E+06 1.21E+07 2.70E+05 6.43E+04 12.19% 2.76% 
Standard Error 5.68E+02 1.31E+03 1.64E+02 8.02E+01 7.10% 1.30% 
95% Confidence ± 1.11E+03 2.57E+03 3.22E+02 1.57E+02 13.90% 2.50% 
*The average Bio-Rad concentration was used for these weeks, due to issues with dilutions, supplies availability, or swarming by 
protists. These concentrations previously were at zero or counts were not possible 
 
Table 5.B - Raw Sewage Non- E. coli coliforms Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation 
CHROMagar 
ESBL 
CHROMagar 
KPC 
% ESBL % KPC 
2/9/2015 W1 2.13E+07 4.00E+07 7.48E+05 1.30E+05 3.52% 0.61% 
2/16/2015 W2 2.50E+07 2.17E+07 7.08E+05 2.87E+05 2.83% 1.15% 
3/2/2015 W3 3.33E+06 6.67E+06 5.25E+05 1.20E+05 15.75% 3.59% 
3/17/2015 W4 1.42E+07 3.58E+07 2.83E+05 1.96E+05 2.00% 1.38% 
3/23/2015 W5 7.42E+06 1.23E+07 7.42E+04 3.68E+04 1.00% 0.50% 
3/31/2015 W6 2.95E+07 2.14E+07 6.88E+05 1.92E+05 2.33% 0.65% 
4/9/2015 W7 6.27E+07 1.75E+07 3.72E+06 8.20E+05 5.93% 1.31% 
5/26/2015 W11 1.10E+07 1.38E+07 5.38E+05 4.00E+04 4.89% 0.36% 
6/15/2015 W12 9.80E+07 3.75E+07 2.32E+06 3.48E+05 2.37% 0.36% 
7/1/2015 W13 6.20E+07 4.20E+07 2.11E+06 1.97E+05 3.40% 0.32% 
Average  3.34E+07 2.49E+07 1.17E+06 2.37E+05 4.40% 1.02% 
Standard Error 1.83E+03 1.58E+03 3.42E+02 1.54E+02 1.3% 0.3% 
95% Confidence ± 3.58E+03 3.09E+03 6.71E+02 3.02E+02 2.6% 0.6% 
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Table 5.C - Raw Sewage Total coliform Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL  % KPC  
2/9/2015 W1 2.32E+07 4.67E+07 8.26E+05 1.36E+05 3.57% 0.59% 
2/16/2015 W2 2.58E+07  - 8.58E+05 3.02E+05 3.32% 1.17% 
3/2/2015 W3  -  - 5.33E+05 1.27E+05 1.26% 0.30% 
3/17/2015 W4  -  - 3.33E+05 2.04E+05 0.79% 0.48% 
3/23/2015 W5 7.75E+06 1.50E+07 8.75E+04 4.56E+04 1.13% 0.59% 
3/31/2015 W6 3.08E+07 2.93E+07 7.52E+05 2.37E+05 2.45% 0.77% 
4/9/2015 W7 6.50E+07 3.27E+07 5.45E+06 1.14E+06 8.38% 1.76% 
5/26/2015 W11 1.65E+07 2.28E+07 6.50E+05 1.68E+05 3.94% 1.02% 
6/15/2015 W12 1.02E+08 7.75E+07 2.58E+06 4.03E+05 2.54% 0.40% 
7/1/2015 W13 6.70E+07 4.50E+07 2.35E+06 2.45E+05 3.51% 0.37% 
Average  4.22E+07 3.84E+07 1.44E+06 3.01E+05 3.09% 0.74% 
Standard Error 2.30E+03 2.34E+03 3.80E+02 1.73E+02 0.7% 0.1% 
95% Confidence ± 4.50E+03 4.59E+03 7.44E+02 3.40E+02 1.3% 0.3% 
 
Secondary Effluent: 
 
Table 6.A – Secondary Effluent E. coli Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL  % KPC  
2/9/2015 W1 2.11E+03 2.06E+04 7.52E+01 1.44E+01 3.56% 0.68% 
2/16/2015 W2 1.25E+04 2.50E+04 8.33E+01 7.50E+01 0.67% 0.60% 
3/2/2015 W3 6.67E+03 3.33E+04 1.17E+02 2.92E+01 1.75% 0.44% 
3/17/2015 W4 1.67E+03 0.00E+00 3.33E+01 1.50E+01 2.00% 0.90% 
3/23/2015 W5 1.42E+03 4.25E+03 4.67E+01 2.33E+01 3.29% 1.65% 
3/31/2015 W6 7.50E+04 7.42E+04 2.97E+02 1.23E+02 0.40% 0.16% 
4/9/2015 W7 6.67E+03 1.03E+05 9.50E+02 2.67E+02 14.25% 4.00% 
5/26/2015 W11 2.55E+05 1.98E+03 4.00E+01 0.00E+00 0.02% 0.00% 
6/15/2015 W12 2.15E+04 4.53E+04 6.53E+02 8.75E+01 3.03% 0.41% 
7/1/2015 W13 1.00E+04 3.00E+04 6.00E+02 9.00E+02 6.00% 9.00% 
Average  3.93E+04 3.38E+04 2.89E+02 1.53E+02 3.50% 1.78% 
Standard Error 6.27E+01 5.81E+01 5.38E+00 3.92E+00 1.3% 0.9% 
95% Confidence ± 1.23E+02 1.14E+02 1.05E+01 7.68E+00 2.6% 1.7% 
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Table 6.B – Secondary Effluent Non- E. coli coliforms Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL % KPC  
2/9/2015 1 3.28E+04 9.33E+04 2.72E+02 3.67E+02 0.83% 1.12% 
2/16/2015 2 7.08E+04 1.46E+05 0.00E+00 9.50E+02 0.00% 1.34% 
3/2/2015 3 1.25E+04 2.67E+05 3.83E+02 5.65E+02 3.07% 4.52% 
3/17/2015 4 1.08E+04 2.67E+04 2.83E+02 1.61E+02 2.62% 1.48% 
3/23/2015 5 2.01E+04 1.95E+04 2.55E+02 2.01E+02 1.27% 1.00% 
3/31/2015 6 1.39E+05 1.31E+05 1.88E+03 1.42E+03 1.35% 1.02% 
4/9/2015 7 2.18E+05 9.00E+04 4.88E+03 3.28E+03 2.24% 1.50% 
5/26/2015 11 2.05E+03 9.25E+02 6.75E+01 3.50E+01 3.29% 1.71% 
6/15/2015 12 2.22E+05 1.10E+05 1.53E+03 5.65E+02 0.69% 0.25% 
7/1/2015 13 2.30E+05 1.40E+05 1.50E+03 3.50E+03 0.65% 1.52% 
Average 9.58E+04 1.02E+05 1.11E+03 1.10E+03 1.60% 1.55% 
Standard Error 9.79E+01 1.01E+02 1.05E+01 1.05E+01 0.4% 0.4% 
95% Confidence ± 1.92E+02 1.98E+02 2.06E+01 2.06E+01 0.7% 0.7% 
 
Table 6.C – Secondary Effluent Total coliform Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL % KPC  
2/9/2015 1 3.49E+04 1.14E+05 3.47E+02 3.81E+02 1.00% 1.09% 
2/16/2015 2 8.33E+04 1.71E+05 8.33E+01 1.03E+03 0.10% 1.23% 
3/2/2015 3 1.92E+04 3.00E+05 5.00E+02 5.94E+02 2.61% 3.10% 
3/17/2015 4 1.25E+04 2.67E+04 3.17E+02 1.76E+02 2.53% 1.41% 
3/23/2015 5 2.15E+04 2.38E+04 3.02E+02 2.24E+02 1.40% 1.04% 
3/31/2015 6 2.14E+05 2.05E+05 2.18E+03 1.54E+03 1.02% 0.72% 
4/9/2015 7 2.25E+05 1.93E+05 5.83E+03 3.55E+03 2.59% 1.58% 
5/26/2015 11 2.57E+05 2.90E+03 1.08E+02 3.50E+01 0.04% 0.01% 
6/15/2015 12 2.43E+05 1.56E+05 2.18E+03 6.53E+02 0.90% 0.27% 
7/1/2015 13 2.40E+05 1.70E+05 2.10E+03 4.40E+03 0.88% 1.83% 
Average 1.35E+05 1.36E+05 1.39E+03 1.26E+03 1.31% 1.23% 
Standard Error 1.16E+02 1.17E+02 1.18E+01 1.12E+01 0.3% 0.3% 
95% Confidence ± 2.28E+02 2.29E+02 2.31E+01 2.20E+01 0.6% 0.5% 
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Morgan Creek Upstream: 
Table 7.A – Morgan Creek Upstream E. coli Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL % KPC  
2/9/2015 1 1.94E+02 6.11E+02 0.00E+00 0.00E+00 0.00% 0.00% 
2/16/2015 2 0.00E+00 3.33E+02 0.00E+00 0.00E+00 0.00% 0.00% 
3/2/2015 3 8.25E+01 6.33E+02 3.33E+00 8.33E+00 0.53% 1.32% 
3/17/2015 4 1.83E+02 3.33E+01 5.00E+00 0.00E+00 15.00% 0.00% 
3/23/2015 5 1.00E+02 2.50E+02 1.67E+00 0.00E+00 0.67% 0.00% 
3/31/2015 6 1.17E+02 7.08E+03 0.00E+00 0.00E+00 0.00% 0.00% 
4/9/2015 7 3.33E+01 4.00E+02 3.33E+01 0.00E+00 8.33% 0.00% 
5/26/2015 11 1.38E+02 2.90E+02 0.00E+00 0.00E+00 0.00% 0.00% 
6/15/2015 12 1.73E+02 8.50E+02 5.00E+00 5.00E+00 0.59% 0.59% 
7/1/2015 13 3.00E+03 3.00E+03 2.00E+02 9.00E+02 6.67% 30.00% 
Average 4.02E+02 1.35E+03 2.48E+01 9.13E+01 3.18% 3.19% 
Standard Error 6.34E+00 1.16E+01 1.58E+00 3.02E+00 1.6% 3.0% 
95% Confidence ± 1.24E+01 2.28E+01 3.09E+00 5.92E+00 3.2% 5.8% 
 
 
Table 7.B – Morgan Creek Upstream Non- E. coli coliforms Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL 
coliforms 
% KPC 
coliform 
2/9/2015 1 9.15E+02 1.44E+03 2.00E+01 0.00E+00 2.19% 0.00% 
2/16/2015 2 2.33E+03 9.25E+03 3.33E+00 5.83E+00 0.14% 0.25% 
3/2/2015 3 4.03E+02 7.25E+02 4.83E+01 2.33E+01 11.98% 5.79% 
3/17/2015 4 1.46E+03 1.03E+03 4.17E+01 5.00E+00 2.86% 0.34% 
3/23/2015 5 2.37E+03 1.04E+03 2.17E+01 5.00E+01 0.92% 2.11% 
3/31/2015 6 4.03E+03 1.14E+04 3.33E+00 1.33E+01 0.08% 0.33% 
4/9/2015 7 6.82E+03 3.00E+02 1.00E+02 0.00E+00 1.47% 0.00% 
5/26/2015 11 1.23E+02 3.90E+02 0.00E+00 0.00E+00 0.00% 0.00% 
6/15/2015 12 1.12E+04 6.60E+03 3.00E+01 2.95E+02 0.27% 2.63% 
7/1/2015 13 1.22E+05 4.40E+04 1.50E+03 3.50E+03 1.23% 2.87% 
Average 1.52E+04 7.62E+03 1.77E+02 3.89E+02 2.11% 1.43% 
Standard Error 3.89E+01 2.76E+01 4.21E+00 6.24E+00 1.1% 0.6% 
95% Confidence ± 7.63E+01 5.41E+01 8.24E+00 1.22E+01 2.2% 1.2% 
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Table 7.C – Morgan Creek Upstream Total coliform Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL % KPC  
2/9/2015 1 1.11E+03 2.06E+03 2.00E+01 0.00E+00 1.80% 0.00% 
2/16/2015 2 2.33E+03 9.58E+03 3.33E+00 5.83E+00 0.14% 0.25% 
3/2/2015 3 4.86E+02 1.36E+03 5.17E+01 3.17E+01 10.63% 6.52% 
3/17/2015 4 1.64E+03 1.07E+03 4.67E+01 5.00E+00 2.84% 0.30% 
3/23/2015 5 2.47E+03 1.29E+03 2.33E+01 5.00E+01 0.95% 2.03% 
3/31/2015 6 4.14E+03 1.85E+04 3.33E+00 1.33E+01 0.08% 0.32% 
4/9/2015 7 6.85E+03 7.00E+02 1.33E+02 0.00E+00 1.95% 0.00% 
5/26/2015 11 2.60E+02 6.80E+02 0.00E+00 0.00E+00 0.00% 0.00% 
6/15/2015 12 1.14E+04 7.45E+03 3.50E+01 3.00E+02 0.31% 2.63% 
7/1/2015 13 1.25E+05 4.70E+04 1.70E+03 4.40E+03 1.36% 3.52% 
Average 1.56E+04 8.97E+03 2.02E+02 4.81E+02 2.01% 1.56% 
Standard Error 3.95E+01 2.99E+01 4.49E+00 6.93E+00 1.0% 0.7% 
95% Confidence ± 7.73E+01 5.87E+01 8.80E+00 1.36E+01 2.0% 1.3% 
 
Morgan Creek Downstream: 
Table 8.A – Morgan Creek Downstream E. coli Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL % KPC  
2/9/2015 1 8.06E+01 1.33E+03 7.78E+00 0.00E+00 9.66% 0.00% 
2/16/2015 2 1.67E+02 1.08E+03 3.33E+00 0.00E+00 2.00% 0.00% 
3/2/2015 3 9.00E+03 6.25E+04 5.00E+00 0.00E+00 0.06% 0.00% 
3/17/2015 4 6.67E+01 0.00E+00 3.33E+00 0.00E+00 5.00% 0.00% 
3/23/2015 5 6.67E+01 4.08E+02 6.67E+00 1.67E+00 10.00% 2.50% 
3/31/2015 6 8.33E+01 6.67E+03 0.00E+00 0.00E+00 0.00% 0.00% 
4/9/2015 7 1.00E+02 1.27E+03 6.67E+01 0.00E+00 66.67% 0.00% 
5/26/2015 11 1.45E+02 1.73E+02 0.00E+00 0.00E+00 0.00% 0.00% 
6/15/2015 12 1.83E+02 1.25E+03 1.00E+01 3.00E+01 5.48% 16.44% 
7/1/2015 13 3.00E+03 4.00E+03 5.00E+02 0.00E+00 16.67% 0.00% 
Average 1.29E+03 7.87E+03 6.03E+01 3.17E+00 11.55% 1.89% 
Standard Error 1.14E+01 2.81E+01 2.46E+00 5.63E-01 6.4% 1.6% 
95% Confidence ± 2.23E+01 5.50E+01 4.81E+00 1.10E+00 12.5% 3.2% 
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Table 8.B – Morgan Creek Downstream Non- E. coli coliforms Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad 
Rapid'E. coli 2 
Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL  % KPC  
2/9/2015 1 8.61E+02 8.89E+02 3.11E+01 0.00E+00 3.61% 0.00% 
2/16/2015 2 1.17E+03 9.50E+03 5.00E+00 1.33E+01 0.43% 1.14% 
3/2/2015 3 2.31E+05 7.08E+04 4.92E+01 9.17E+01 0.02% 0.04% 
3/17/2015 4 1.54E+03 7.67E+02 3.75E+01 1.17E+01 2.43% 0.76% 
3/23/2015 5 3.23E+03 1.83E+03 9.58E+01 1.00E+01 2.96% 0.31% 
3/31/2015 6 3.08E+03 8.83E+03 3.33E+00 1.00E+01 0.11% 0.33% 
4/9/2015 7 6.78E+03 3.47E+03 2.33E+02 1.67E+01 3.44% 0.25% 
5/26/2015 11 1.55E+02 5.53E+02 0.00E+00 0.00E+00 0.00% 0.00% 
6/15/2015 12 8.60E+03 8.45E+03 4.50E+01 3.65E+02 0.52% 4.24% 
7/1/2015 13 5.60E+04 4.50E+04 3.20E+03 9.00E+02 5.71% 1.61% 
Average 3.12E+04 1.50E+04 3.70E+02 1.42E+02 1.92% 0.87% 
Standard Error 5.59E+01 3.87E+01 6.08E+00 3.77E+00 0.63% 0.41% 
95% Confidence ± 1.10E+02 7.59E+01 1.19E+01 7.38E+00 1.23% 0.81% 
 
 
Table 8.C – Morgan Creek Downstream Total coliform Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad 
Rapid'E. coli 2 
Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL  % KPC  
2/9/2015 1 9.42E+02 2.22E+03 3.89E+01 0.00E+00 4.13% 0.00% 
2/16/2015 2 1.33E+03 1.06E+04 8.33E+00 1.33E+01 0.63% 1.00% 
3/2/2015 3 2.40E+05 1.33E+05 5.42E+01 9.17E+01 0.02% 0.04% 
3/17/2015 4 1.61E+03 7.67E+02 4.08E+01 1.17E+01 2.54% 0.73% 
3/23/2015 5 3.30E+03 2.24E+03 1.03E+02 1.17E+01 3.11% 0.35% 
3/31/2015 6 3.16E+03 1.55E+04 3.33E+00 1.00E+01 0.11% 0.32% 
4/9/2015 7 6.88E+03 4.73E+03 3.00E+02 1.67E+01 4.36% 0.24% 
5/26/2015 11 3.00E+02 7.25E+02 0.00E+00 0.00E+00 0.00% 0.00% 
6/15/2015 12 8.78E+03 9.70E+03 5.50E+01 3.95E+02 0.63% 4.50% 
7/1/2015 13 5.90E+04 4.90E+04 3.70E+03 9.00E+02 6.27% 1.53% 
Average 3.25E+04 2.29E+04 4.30E+02 1.45E+02 2.18% 0.87% 
Standard Error 5.70E+01 4.78E+01 6.56E+00 3.81E+00 0.71% 0.43% 
95% Confidence ± 1.12E+02 9.38E+01 1.29E+01 7.46E+00 1.38% 0.85% 
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Jordan Lake: 
Table 9.A – Jordan Lake E. coli Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL  % KPC  
5/26/2015 11 0 82.5 0 1.67 0.00% 2.02% 
6/15/2015 12 425 750 5   0.67% 0.00% 
7/1/2015 13 0 13000 100 0 0.77% 0.00% 
Average 1.42E+02 4.61E+03 3.50E+01 8.33E-01 0.48% 0.67% 
Standard Error 6.87E+00 3.92E+01 3.42E+00 6.45E-01 0.2% 0.7% 
95% Confidence ± 1.35E+01 7.68E+01 6.69E+00 1.27E+00 0.5% 1.3% 
 
Table 9.B – Jordan Lake Non- E. coli coliforms Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad 
Rapid' E. coli 2 
Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL  % KPC  
5/26/2015 11 15 132.5 0 503.75 0.00% 380.19% 
6/15/2015 12 24500 22175 5   0.02% 0.00% 
7/1/2015 13 50000 48000 1200 600 2.50% 1.25% 
Average 2.48E+04 2.34E+04 4.02E+02 5.52E+02 0.84% 127.15% 
Standard Error 9.10E+01 8.84E+01 1.16E+01 1.66E+01 0.8% 126.5% 
95% Confidence ± 1.78E+02 1.73E+02 2.27E+01 3.26E+01 1.6% 248.0% 
 
Table 9.C – Jordan Lake Total coliform Concentration (CFU / 100mL) by Media and Date 
Date Week 
Bio-Rad Rapid' 
E. coli 2 Agar 
CHROMagar 
Orientation  
CHROMagar 
ESBL  
CHROMagar 
KPC  
% ESBL  % KPC  
5/26/2015 11 15 215 0 505.42 0.00% 235.08% 
6/15/2015 12 24925 22925 10   0.04% 0.00% 
7/1/2015 13 50000 61000 1300 600 2.13% 0.98% 
Average 2.50E+04 2.80E+04 4.37E+02 5.53E+02 0.72% 78.69% 
Standard Error 9.13E+01 9.67E+01 1.21E+01 1.66E+01 0.7% 78.2% 
95% Confidence ± 1.79E+02 1.90E+02 2.36E+01 3.26E+01 1.4% 153.3% 
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APPENDIX 3 – ESBL MALDI-TOF MS AND VITEK 2 RESULTS 
S = Susceptible  I = Intermediate  R = Resistant based on MIC  R* = Resistant based on other phenotypic properties (VITEK Software Determined) 
Pos = Positive ESBL Production   Neg = Negative for ESBL Production     (.) = Not applicable 
ESBL 
Code 
Week Site ESBL ID 
MALDI
-TOF 
MALDI TOF Result 
NCSU 
VITEK 2 
Cefpodoxime ESBL Imipenem 
MIC S/I/R MIC MIC S/I/R 
AE09 3 Raw Sewage ECOLI 1 Klebsiella oxytoca 1 >=8 R POS 4 R* 
AE10 3 Raw Sewage ECOLI 1 Klebsiella oxytoca 1 >=8 R POS 8 R* 
AE12 4 Raw Sewage ECOLI 1 Escherichia coli 0 . . . . . 
AE16 5 Raw Sewage ECOLI 1 
Stenotrophomonas 
maltophilia 
1 Not clinically significant 
AE18 6 Raw Sewage ECOLI 1 Streptococcus cristatus 0 . . . . . 
AE19 6 Raw Sewage ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
AE20 6 Raw Sewage ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
AE23 7 Raw Sewage ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
AE24 7 Raw Sewage ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
AE25 7 Raw Sewage ECOLI 1 
Staphylococcus 
saprophyticus 
0 . . . . . 
AE26 11 Raw Sewage ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
AE27 11 Raw Sewage ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
AE28 11 Raw Sewage ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
AE29 12 Raw Sewage ECOLI 1 Escherichia coli 1 >=8 R NEG <=1 S 
AE31 12 Raw Sewage ECOLI 1 Citrobacter freundii 1 >=8 R  4 R* 
AE32 12 Raw Sewage ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
AE33 12 Raw Sewage ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
AE34 13 Raw Sewage ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
AE36 13 Raw Sewage ECOLI 1 Escherichia coli 1 >=8 R NEG <=1 R* 
AE37 13 Raw Sewage ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
AT09 3 Raw Sewage KLEBSIELLA 1 Klebsiella oxytoca 1 >=8 R POS 4 R* 
AT10 3 Raw Sewage KLEBSIELLA 1 Citrobacter werkmanii 1 >=8 R  8 I 
AT11 3 Raw Sewage KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
1 >=8 R  8 I 
AT13 4 Raw Sewage KLEBSIELLA 1 Serratia marcescens 1    2 S 
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ESBL 
Code 
Week Site ESBL ID 
MALDI
-TOF 
MALDI TOF Result 
NCSU 
VITEK 2 
Cefpodoxime ESBL Imipenem 
MIC S/I/R MIC MIC S/I/R 
AT15 4 Raw Sewage KLEBSIELLA 1 
Aeromonas hydrophila / 
caviae 
1 >=8 R  8 I 
AT16 4 Raw Sewage KLEBSIELLA 1 Citrobacter farmeri 1 >=8 R  <=1 S 
AT17 5 Raw Sewage KLEBSIELLA 1 
Raoultella planticola / 
ornithinolytica 
1 >=8 R  <=1 S 
AT18 5 Raw Sewage KLEBSIELLA 1 
Aeromonas hydrophila / 
caviae 
1 >=8 R  8 I 
AT20 5 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
AT21 5 Raw Sewage KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
1 >=8 R  8 I 
AT22 6 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R NEG 4 R* 
AT23 6 Raw Sewage KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
1 >=8 R  2 S 
AT24 6 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 4 R* 
AT25 6 Raw Sewage KLEBSIELLA 1 
Raoultella planticola / 
ornithinolytica 
1 2 S  <=1 S 
AT27 7 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 4 R* 
AT28 7 Raw Sewage KLEBSIELLA 1 
Raoultella planticola / 
ornithinolytica 
1 2 S  <=1 S 
AT29 7 Raw Sewage KLEBSIELLA 1 Pseudomonas putida 1 >=8 R  <=1 S 
AT31 7 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R NEG 4 R* 
AT32 11 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
AT32 
- 
Turq 
11 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 4 R* 
AT33 11 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
AT34 11 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
AT34
-Turq 
11 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
AT35 11 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
AT36 11 Raw Sewage KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
1 >=8 R  8 I 
AT37 11 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R NEG >=16 R 
AT38 11 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
AT39 12 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R NEG 2 R* 
AT40 12 Raw Sewage KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
1 4 I  2 S 
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ESBL 
Code 
Week Site ESBL ID 
MALDI
-TOF 
MALDI TOF Result 
NCSU 
VITEK 2 
Cefpodoxime ESBL Imipenem 
MIC S/I/R MIC MIC S/I/R 
AT41 12 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS <=1 R* 
AT42 12 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
AT42 
- 
Turq 
12 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
AT43 12 Raw Sewage KLEBSIELLA 1 Pseudomonas aeruginosa 1 >=8 R  <=1 S 
AT44 12 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
AT44 
pink 
(A) 
12 Raw Sewage KLEBSIELLA 1 Escherichia coli 1 >=8 R POS <=1 R* 
AT45 13 Raw Sewage KLEBSIELLA 1 Raoultella planticola 1 >=8 R  4 S 
AT46 13 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 4 R* 
AT47 13 Raw Sewage KLEBSIELLA 1 
Aeromonas hydrophila / 
caviae 
1 >=8 R  8 I 
AT48 13 Raw Sewage KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
1 >=8 R  8 I 
AT49 
- 
Small 
13 Raw Sewage KLEBSIELLA 1 
Aeromonas hydrophila / 
caviae 
1 >=8 R  >=16 R 
AT49 
large 
13 Raw Sewage KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
1 >=8 R  8 R 
BE07 3 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE08 3 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE09 3 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE10 
- turq 
4 
Secondary 
Effluent 
ECOLI 1 
Aeromonas hydrophila / 
caviae 
1 >=8 R  8 I 
BE11 5 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE12 5 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE13 5 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE14 5 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE15 5 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE16 6 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
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ESBL 
Code 
Week Site ESBL ID 
MALDI
-TOF 
MALDI TOF Result 
NCSU 
VITEK 2 
Cefpodoxime ESBL Imipenem 
MIC S/I/R MIC MIC S/I/R 
BE17 6 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE18 6 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE19 6 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE20 6 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE21 7 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE22 7 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE23 7 
Secondary 
Effluent 
ECOLI 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
BE23 
- 
TURQ 
7 
Secondary 
Effluent 
ECOLI 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
BE24 7 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE25 7 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE26 11 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE27 11 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE29 12 
Secondary 
Effluent 
ECOLI 1 
Stenotrophomonas 
maltophilia 
1  Not clinically significant   
BE30 12 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE31 12 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE32 12 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BE33 13 
Secondary 
Effluent 
ECOLI 1 Citrobacter freundii 1 >=8 R  <=1 S 
BE34 13 
Secondary 
Effluent 
ECOLI 1 
Streptococcus 
parasanguinis 
0 . . . . . 
BE35 13 
Secondary 
Effluent 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
BT11 3 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 4 R* 
BT11 
- 
Turq 
3 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 4 R* 
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ESBL 
Code 
Week Site ESBL ID 
MALDI
-TOF 
MALDI TOF Result 
NCSU 
VITEK 2 
Cefpodoxime ESBL Imipenem 
MIC S/I/R MIC MIC S/I/R 
BT12 3 
Secondary 
Effluent 
KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
1 >=8 R  8 I 
BT13 3 
Secondary 
Effluent 
KLEBSIELLA 1 
Serratia 
odorifera/fonticola 
1    <=1 S 
BT13 
- dup 
3 
Secondary 
Effluent 
KLEBSIELLA 1 
Serratia 
odorifera/fonticola 
0 . . . . . 
BT16 4 
Secondary 
Effluent 
KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
1 >=8 R  4 S 
BT17 4 
Secondary 
Effluent 
KLEBSIELLA 1 Serratia marcescens 1    >=16 R 
BT18 4 
Secondary 
Effluent 
KLEBSIELLA 1 
Citrobacter freundii / 
werkmanii 
1 >=8 R  8 I 
BT19 4 
Secondary 
Effluent 
KLEBSIELLA 1 
Aeromonas hydrophila / 
caviae 
1 >=8 R  8 I 
BT20 4 
Secondary 
Effluent 
KLEBSIELLA 1 
Aeromonas sobria / 
hydrophila / caviae 
1 >=8 R  <=1 S 
BT21 5 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS <=1 R* 
BT22 5 
Secondary 
Effluent 
KLEBSIELLA 1 Escherichia coli 1 >=8 R POS <=1 R* 
BT23 5 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R NEG 8 R* 
BT24 5 
Secondary 
Effluent 
KLEBSIELLA 1 
Aeromonas hydrophila / 
caviae 
1 >=8 R  2 S 
BT26 6 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS <=1 R* 
BT27 6 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS <=1 R* 
BT28 6 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
BT28 
- 
Turq 
6 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
BT29 7 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS <=1 R* 
BT30 7 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 4 R* 
BT31 7 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
BT32 7 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS <=1 R* 
BT33 11 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
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ESBL 
Code 
Week Site ESBL ID 
MALDI
-TOF 
MALDI TOF Result 
NCSU 
VITEK 2 
Cefpodoxime ESBL Imipenem 
MIC S/I/R MIC MIC S/I/R 
BT34 11 
Secondary 
Effluent 
KLEBSIELLA 1 Cronobacter sakazakii 1 >=8 R  4 S 
BT35 11 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
BT36 11 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS 8 R* 
BT37 11 
Secondary 
Effluent 
KLEBSIELLA 1 Cronobacter sakazakii 1 >=8 R  >=16 R 
BT38 11 
Secondary 
Effluent 
KLEBSIELLA 1 Citrobacter freundii 1 4 R*  8 R* 
BT40 12 
Secondary 
Effluent 
KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
1 4 I  4 S 
BT41 12 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R NEG 8 R* 
BT42 12 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 4 R* POS <=1 R* 
BT43 12 
Secondary 
Effluent 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS <=1 R* 
BT45 13 
Secondary 
Effluent 
KLEBSIELLA 1 Serratia fonticola 1    <=1 S 
BT46 13 
Secondary 
Effluent 
KLEBSIELLA 1 
Aeromonas hydrophila / 
caviae 
1 >=8 R  8 I 
BT47 13 
Secondary 
Effluent 
KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
0 . . . . . 
CE01 3 
Morgan Creek 
Upstream 
ECOLI 1 Serratia fonticola 0 . . . . . 
CE02 5 
Morgan Creek 
Upstream 
ECOLI 1 Serratia fonticola 0 . . . . . 
CE03 6 
Morgan Creek 
Upstream 
ECOLI 1 Citrobacter freundii 0 . . . . . 
FE04 9 H1 GI + MICU ECOLI 1 
Citrobacter freundii / 
braaki 
0 . . . . . 
FE06 9 H1 GI + MICU ECOLI 1 
Citrobacter farmeri / 
amalonaticus 
0 . . . . . 
FE07 9 H1 GI + MICU ECOLI 1 
Aeromonas sobria / 
hydrophila / caviae 
0 . . . . . 
FE08 10 H1 GI + MICU ECOLI 1 Ochrobactrum anthropi 0 . . . . . 
FE09 10 H1 GI + MICU ECOLI 1 Citrobacter freundii 0 . . . . . 
FE10 13 H1 GI + MICU ECOLI 1 Citrobacter freundii 0 . . . . . 
FE12 13 H1 GI + MICU ECOLI 1 
Citrobacter freundii / 
braaki 
0 . . . . . 
FE13 13 H1 GI + MICU ECOLI 1 Citrobacter freundii 0 . . . . . 
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ESBL 
Code 
Week Site ESBL ID 
MALDI
-TOF 
MALDI TOF Result 
NCSU 
VITEK 2 
Cefpodoxime ESBL Imipenem 
MIC S/I/R MIC MIC S/I/R 
FT01 8 H1 GI + MICU KLEBSIELLA 1 Klebsiella oxytoca 0 . . . . . 
FT02 8 H1 GI + MICU KLEBSIELLA 1 Citrobacter werkmanii 0 . . . . . 
FT03 8 H1 GI + MICU KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
0 . . . . . 
FT04 8 H1 GI + MICU KLEBSIELLA 1 
Raoultella planticola / 
ornithinolytica 
0 . . . . . 
FT05 8 H1 GI + MICU KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
0 . . . . . 
FT06 8 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT07 8 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT08 9 H1 GI + MICU KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
0 . . . . . 
FT09 9 H1 GI + MICU KLEBSIELLA 1 
Citrobacter freundii / 
werkmanii 
0 . . . . . 
FT10 9 H1 GI + MICU KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
0 . . . . . 
FT11 9 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT12 9 H1 GI + MICU KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
0 . . . . . 
FT13 10 H1 GI + MICU KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
0 . . . . . 
FT14 10 H1 GI + MICU KLEBSIELLA 1 
Citrobacter youngae / 
farmeri 
0 . . . . . 
FT15 10 H1 GI + MICU KLEBSIELLA 1 Citrobacter freundii 0 . . . . . 
FT16 10 H1 GI + MICU KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
0 . . . . . 
FT18 10 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT19 10 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT20 10 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT21 11 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT22 11 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT23 11 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT24 11 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT25 11 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT26 11 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT27 11 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
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ESBL 
Code 
Week Site ESBL ID 
MALDI
-TOF 
MALDI TOF Result 
NCSU 
VITEK 2 
Cefpodoxime ESBL Imipenem 
MIC S/I/R MIC MIC S/I/R 
FT28 11 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT29 11 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT30 11 H1 GI + MICU KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
0 . . . . . 
FT32 12 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT33 12 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT34 12 H1 GI + MICU KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
0 . . . . . 
FT35 12 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT36 12 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT37 13 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT38 13 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT39 13 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT40 13 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
FT41 13 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 0 . . . . . 
GE04 10 
H2 Burn + 
Lab + ICU 
ECOLI 1 Ochrobactrum anthropi 0 . . . . . 
GE05 10 
H2 Burn + 
Lab + ICU 
ECOLI 1 Ochrobactrum anthropi 0 . . . . . 
GE06 10 
H2 Burn + 
Lab + ICU 
ECOLI 1 Citrobacter youngae 0 . . . . . 
GE08 12 
H2 Burn + 
Lab + ICU 
ECOLI 1 Pseudomonas putida 0 . . . . . 
GE10 13 
H2 Burn + 
Lab + ICU 
ECOLI 1 
Serratia rubidaea / 
marcescens 
0 . . . . . 
HE04 9 
H3 Heart + 
ICU 
ECOLI 1 Citrobacter freundii 0 . . . . . 
HE05 9 
H3 Heart + 
ICU 
ECOLI 1 Citrobacter freundii 0 . . . . . 
HE06 10 
H3 Heart + 
ICU 
ECOLI 1 Ochrobactrum anthropi 0 . . . . . 
HE10 10 
H3 Heart + 
ICU 
ECOLI 1 Ochrobactrum anthropi 0 . . . . . 
HE12 11 
H3 Heart + 
ICU 
ECOLI 1 Escherichia coli 0 . . . . . 
HE13 12 
H3 Heart + 
ICU 
ECOLI 1 Citrobacter amalonaticus 0 . . . . . 
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Code 
Week Site ESBL ID 
MALDI
-TOF 
MALDI TOF Result 
NCSU 
VITEK 2 
Cefpodoxime ESBL Imipenem 
MIC S/I/R MIC MIC S/I/R 
HE14 12 
H3 Heart + 
ICU 
ECOLI 1 
Citrobacter youngae / 
farmeri 
0 . . . . . 
HT01 8 
H3 Heart + 
ICU 
KLEBSIELLA 1 Raoultella ornithinolytica 1 >=8 R  <=1 S 
HT02 8 
H3 Heart + 
ICU 
KLEBSIELLA 1 Klebsiella oxytoca 1 >=8 R POS <=1 R* 
HT03 9 
H3 Heart + 
ICU 
KLEBSIELLA 1 Klebsiella oxytoca 1 >=8 R POS <=1 R* 
IE01 8 
H4 ER + 
Neuro 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
IE05 8 
H4 ER + 
Neuro 
ECOLI 1 
Citrobacter braakii / 
werkmanii 
1 TRM   8 R* 
IE06 9 
H4 ER + 
Neuro 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
IE07 9 
H4 ER + 
Neuro 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
IE09 10 
H4 ER + 
Neuro 
ECOLI 1 Citrobacter freundii 1 >=8 R  <=1 S 
IE10 10 
H4 ER + 
Neuro 
ECOLI 1 
Citrobacter freundii / 
werkmanii 
1 >=8 R  >=16 R 
IE11 10 
H4 ER + 
Neuro 
ECOLI 1 Citrobacter freundii 1 >=8 R  2 S 
IE12 10 
H4 ER + 
Neuro 
ECOLI 1 Citrobacter freundii 1 >=8 R  8 R* 
IE13 10 
H4 ER + 
Neuro 
ECOLI 1 Citrobacter freundii 1 >=8 R  8 R* 
IE15 12 
H4 ER + 
Neuro 
ECOLI 1 Citrobacter freundii 1 >=8 R  2 S 
IE16 12 
H4 ER + 
Neuro 
ECOLI 1 Citrobacter freundii 1 >=8 R  8 R* 
IE17 12 
H4 ER + 
Neuro 
ECOLI 1 Citrobacter freundii 1 >=8 R  4 R* 
IE18 12 
H4 ER + 
Neuro 
ECOLI 1 Citrobacter freundii 1 >=8 R  <=1 S 
IE21 13 
H4 ER + 
Neuro 
ECOLI 1 Escherichia coli 1 >=8 R POS <=1 R* 
IE23 13 
H4 ER + 
Neuro 
ECOLI 1 Citrobacter freundii 1 >=8 R  8 R* 
IT01 8 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R NEG 4 R* 
IT02 8 
H4 ER + 
Neuro 
KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
0 . . . . . 
IT03 8 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R  8 R* 
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ESBL 
Code 
Week Site ESBL ID 
MALDI
-TOF 
MALDI TOF Result 
NCSU 
VITEK 2 
Cefpodoxime ESBL Imipenem 
MIC S/I/R MIC MIC S/I/R 
IT04 8 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella oxytoca 1 1 R* POS <=1 S 
IT05 8 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella oxytoca 1 >=8 R NEG 8 R* 
IT06 9 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella oxytoca 1 >=8 R NEG >=16 R 
IT07 9 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS <=1 S 
IT08 9 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella oxytoca 1 >=8 R POS <=1 S 
IT09 9 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella oxytoca 1 2 S NEG <=1 S 
IT12 9 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella oxytoca 1 2 R* POS <=1 S 
IT14 9 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella oxytoca 1 2 S NEG <=1 S 
IT17 10 
H4 ER + 
Neuro 
KLEBSIELLA 1 Raoultella ornithinolytica 1 >=8 R  8 I 
IT18 10 
H4 ER + 
Neuro 
KLEBSIELLA 1 Citrobacter farmeri 1 >=8 R  4 S 
IT19 11 
H4 ER + 
Neuro 
KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
1 >=8 R  8 I 
IT20 11 
H4 ER + 
Neuro 
KLEBSIELLA 1 
Enterobacter cloacae / 
asburiae 
1 >=8 R  >=16 R 
IT21 11 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS <=1 S 
IT22 12 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella pneumoniae 1 2 R* POS <=1 S 
IT23 12 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS <=1 S 
IT23
A 
12 
H4 ER + 
Neuro 
KLEBSIELLA 1 Serratia marcescens 1    >=16 R 
IT24 12 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS <=1 S 
IT26 12 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella pneumoniae 1 >=8 R POS <=1 S 
IT27 13 
H4 ER + 
Neuro 
KLEBSIELLA 1 Citrobacter amalonaticus 1 >=8 R  8 I 
IT28 13 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella oxytoca 1 >=8 R POS <=1 R* 
IT29 13 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella oxytoca 1 >=8 R POS <=1 R* 
IT30 13 
H4 ER + 
Neuro 
KLEBSIELLA 1 Citrobacter amalonaticus 1 >=8 R  <=1 S 
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Cefpodoxime ESBL Imipenem 
MIC S/I/R MIC MIC S/I/R 
IT30-
MALD
I 
extra 
13 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella pneumoniae 1 2 R* POS <=1 S 
IT31 13 
H4 ER + 
Neuro 
KLEBSIELLA 1 Klebsiella pneumoniae 1 2 R* POS <=1 S 
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APPENDIX 4 – KPC MALDI-TOF MS AND MODIFIED HODGE TEST ISOLATE RESULTS 
KPC(+) = Positive KPC Production   KPC(R-) = “Intermediate” KPC production   KPC(-) = Negative for KPC Production     (.) = Not applicable 
KPC 
Code 
Week Site KPC ID 
MALDI 
– TOF 
MALDI-TOF Result 
Modified 
Hodge Test  
KPC (+) 
Producer 
KPC(-R) 
Intermediate 
KPC (-) 
Negative 
JE11 3 Raw Sewage ECOLI 1 Enterobacter cloacae / asburiae 1 1 0 0 
JE12 3 Raw Sewage ECOLI 1 Klebsiella pneumoniae 1 1 0 0 
JE13 3 Raw Sewage ECOLI 0 NO MALDI 1 0 1 0 
JE14 3 Raw Sewage ECOLI 1 Enterobacter cloacae / asburiae 1 1 0 0 
JE16 4 Raw Sewage ECOLI 1 Enterococcus faecium 1 0 0 1 
JE17 4 Raw Sewage ECOLI 1 Citrobacter freundii 1 1 0 0 
JE19 5 Raw Sewage ECOLI 1 Enterobacter cloacae / asburiae 1 1 0 0 
JE20 5 Raw Sewage ECOLI 1 Citrobacter freundii 1 1 0 0 
JE21 6 Raw Sewage ECOLI 1 Stenotrophomonas maltophilia  1 0 1 0 
JE26 12 Raw Sewage ECOLI 1 Serratia marcescens 1 0 1 0 
JE27 12 Raw Sewage ECOLI 1 Citrobacter freundii 1 1 0 0 
JE28 12 Raw Sewage ECOLI 0 NO MALDI 1 1 0 0 
JE29 12 Raw Sewage ECOLI 1 Pseudomonas aeruginosa 1 0 1 0 
JE30 13 Raw Sewage ECOLI 0 NO MALDI 1 1 0 0 
JE31 13 Raw Sewage ECOLI 0 NO MALDI 1 1 0 0 
JE32 13 Raw Sewage ECOLI 1 Stenotrophomonas maltophilia  1 0 1 0 
JT11 3 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT12 3 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT13 3 Raw Sewage KLEBSIELLA 1 Klebsiella oxytoca 1 1 0 0 
JT14 3 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT15 3 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT17 4 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT18 4 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT19 4 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT19B 4 Raw Sewage KLEBSIELLA 1 
Raoultella planticola / 
ornithinolytica 
1 1 0 0 
JT20 4 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 0 1 0 
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KPC 
Code 
Week Site KPC ID 
MALDI 
– TOF 
MALDI-TOF Result 
Modified 
Hodge Test  
KPC (+) 
Producer 
KPC(-R) 
Intermediate 
KPC (-) 
Negative 
JT22 4 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT23 5 Raw Sewage KLEBSIELLA 1 Serratia marcescens 1 0 0 1 
JT24 5 Raw Sewage KLEBSIELLA 1 Serratia marcescens 1 0 1 0 
JT25 5 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT26 5 Raw Sewage KLEBSIELLA 1 Serratia marcescens 1 0 0 1 
JT27 5 Raw Sewage KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 1 0 0 
JT28 5 Raw Sewage KLEBSIELLA 1 Klebsiella oxytoca 1 1 0 0 
JT29 5 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT30 5 Raw Sewage KLEBSIELLA 1 Klebsiella oxytoca 1 0 1 0 
JT31 6 Raw Sewage KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 1 0 0 
JT32 6 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT33 6 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT34 6 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT35 6 Raw Sewage KLEBSIELLA 1 Stenotrophomonas maltophilia  1 0 0 1 
JT36 11 Raw Sewage KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 1 0 0 
JT37 11 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 0 1 0 
JT38 11 Raw Sewage KLEBSIELLA 1 Cronobacter sakazakii 1 1 0 0 
JT39 11 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT40 11 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT41 11 Raw Sewage KLEBSIELLA 1 Cronobacter sakazakii 1 1 0 0 
JT42 11 Raw Sewage KLEBSIELLA 1 Cronobacter sakazakii 1 1 0 0 
JT43 11 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT44 12 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT45 12 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT46 12 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT47 12 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT48 12 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT49 12 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT50 13 Raw Sewage KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 1 0 0 
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KPC 
Code 
Week Site KPC ID 
MALDI 
– TOF 
MALDI-TOF Result 
Modified 
Hodge Test  
KPC (+) 
Producer 
KPC(-R) 
Intermediate 
KPC (-) 
Negative 
JT51 13 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 0 0 1 
JT52 13 Raw Sewage KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
JT53 13 Raw Sewage KLEBSIELLA 1 Aeromonas hydrophila / caviae 1 1 0 0 
KE09 3 Secondary Effluent ECOLI 1 Citrobacter werkmanii 1 1 0 0 
KE11 3 Secondary Effluent ECOLI 1 Citrobacter freundii 1 1 0 0 
KE12 3 Secondary Effluent ECOLI 1 Citrobacter farmeri 1 1 0 0 
KE14 4 Secondary Effluent ECOLI 1 Citrobacter freundii 1 1 0 0 
KE16 4 Secondary Effluent ECOLI 0 NO MALDI 1 1 0 0 
KE17A 4 Secondary Effluent ECOLI 1 Citrobacter freundii 1 1 0 0 
KE17B 4 Secondary Effluent ECOLI 1 Citrobacter freundii 1 1 0 0 
KE21 5 Secondary Effluent ECOLI 1 Citrobacter freundii 1 1 0 0 
KE22 5 Secondary Effluent ECOLI 1 Pseudomonas putida 1 1 0 0 
KE23 6 Secondary Effluent ECOLI 1 Klebsiella pneumoniae 1 0 1 0 
KE24 6 Secondary Effluent ECOLI 1 Aeromonas hydrophila / caviae 1 1 0 0 
KE25 6 Secondary Effluent ECOLI 1 Stenotrophomonas maltophilia 1 1 0 0 
KE26 6 Secondary Effluent ECOLI 1 Citrobacter freundii 1 1 0 0 
KE27 12 Secondary Effluent ECOLI 1 Stenotrophomonas maltophilia 1 0 1 0 
KE29 13 Secondary Effluent ECOLI 1 Enterobacter cloacae / asburiae 1 1 0 0 
KE30 13 Secondary Effluent ECOLI 1 Stenotrophomonas maltophilia 1 0 1 0 
KE31 13 Secondary Effluent ECOLI 1 Stenotrophomonas maltophilia 1 0 1 0 
KT11 3 Secondary Effluent KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
KT12 3 Secondary Effluent KLEBSIELLA 0 NO MALDI 1 1 0 0 
KT13 3 Secondary Effluent KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
KT14 3 Secondary Effluent KLEBSIELLA 1 Pantoea aggiomerans 1 1 0 0 
KT15 4 Secondary Effluent KLEBSIELLA 0 NO MALDI 1 1 0 0 
KT16 4 Secondary Effluent KLEBSIELLA 1 Escherichia coli 1 0 0 1 
KT17 4 Secondary Effluent KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
KT19 4 Secondary Effluent KLEBSIELLA 0 NO MALDI 1 0 0 1 
KT20 5 Secondary Effluent KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 1 0 0 
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KPC 
Code 
Week Site KPC ID 
MALDI 
– TOF 
MALDI-TOF Result 
Modified 
Hodge Test  
KPC (+) 
Producer 
KPC(-R) 
Intermediate 
KPC (-) 
Negative 
KT21 5 Secondary Effluent KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 1 0 0 
KT22 5 Secondary Effluent KLEBSIELLA 0 NO MALDI 1 1 0 0 
KT23 5 Secondary Effluent KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
KT24 5 Secondary Effluent KLEBSIELLA 1 Klebsiella pneumoniae 1 0 1 0 
KT25 5 Secondary Effluent KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
KT26 6 Secondary Effluent KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
KT27 6 Secondary Effluent KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
KT28 6 Secondary Effluent KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
KT29 6 Secondary Effluent KLEBSIELLA 0 NO MALDI 1 1 0 0 
KT30 6 Secondary Effluent KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
KT31 6 Secondary Effluent KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
KT32 6 Secondary Effluent KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
KT33 12 Secondary Effluent KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
KT34 12 Secondary Effluent KLEBSIELLA 1 Klebsiella oxytoca 1 0 1 0 
KT35 12 Secondary Effluent KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 0 1 0 
KT35A 12 Secondary Effluent KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 0 1 0 
KT36 12 Secondary Effluent KLEBSIELLA 1 Klebsiella oxytoca 1 0 1 0 
KT37 12 Secondary Effluent KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 1 0 0 
KT40 12 Secondary Effluent KLEBSIELLA 0 NO MALDI 1 1 0 0 
KT41 13 Secondary Effluent KLEBSIELLA 0 NO MALDI 1 1 0 0 
KT42 13 Secondary Effluent KLEBSIELLA 0 NO MALDI 1 0 0 1 
KT43 13 Secondary Effluent KLEBSIELLA 0 NO MALDI 1 0 0 1 
KT45 13 Secondary Effluent KLEBSIELLA 0 NO MALDI 1 1 0 0 
LT02 5 
Morgan Creek 
Upstream 
KLEBSIELLA 1 Ochrobactrum anthropi 1 0 1 0 
LT03 6 
Morgan Creek 
Upstream 
KLEBSIELLA 1 Ochrobactrum anthropi 0 . . . 
LT04 6 
Morgan Creek 
Upstream 
KLEBSIELLA 1 Ochrobactrum anthropi 1 0 1 0 
LT05 6 
Morgan Creek 
Upstream 
KLEBSIELLA 1 Ochrobactrum anthropi 1 0 1 0 
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KPC 
Code 
Week Site KPC ID 
MALDI 
– TOF 
MALDI-TOF Result 
Modified 
Hodge Test  
KPC (+) 
Producer 
KPC(-R) 
Intermediate 
KPC (-) 
Negative 
LT06 7 
Morgan Creek 
Upstream 
KLEBSIELLA 1 Bacillus cereus / thuringiensis 1 0 1 0 
LT07 7 
Morgan Creek 
Upstream 
KLEBSIELLA 1 Ochrobactrum anthropi 1 0 1 0 
LT09 7 
Morgan Creek 
Upstream 
KLEBSIELLA 1  Staphlycoccus waneri 1 0 0 1 
LT10 12 
Morgan Creek 
Upstream 
KLEBSIELLA 1 Sphingobacterium multivorum 1 0 0 1 
LT11 11 
Morgan Creek 
Upstream 
KLEBSIELLA 1 Sphingobacterium multivorum 1 0 1 0 
MT04 3 
Morgan Creek 
Downstream 
KLEBSIELLA 1 
Pseudomonas chororaphis / 
fluorescens 
1 0 1 0 
MT05 3 
Morgan Creek 
Downstream 
KLEBSIELLA 1 Ochrobactrum anthropi 1 0 0 1 
MT06 3 
Morgan Creek 
Downstream 
KLEBSIELLA 1 Ochrobactrum anthropi 1 0 1 0 
MT07 3 
Morgan Creek 
Downstream 
KLEBSIELLA 1 Ochrobactrum anthropi 1 0 0 1 
MT08 4 
Morgan Creek 
Downstream 
KLEBSIELLA 1 Stenotrophomonas maltophilia 1 0 1 0 
MT09 6 
Morgan Creek 
Downstream 
KLEBSIELLA 1 Ochrobactrum anthropi 1 0 0 1 
MT10 7 
Morgan Creek 
Downstream 
KLEBSIELLA 1 Ochrobactrum anthropi 1 0 1 0 
MT11 12 
Morgan Creek 
Downstream 
KLEBSIELLA 1 Elizabethkingia meningoseptica 1 0 1 0 
MT12 12 
Morgan Creek 
Downstream 
KLEBSIELLA 1 Stenotrophomonas maltophilia 1 0 1 0 
MT13 12 
Morgan Creek 
Downstream 
KLEBSIELLA 1 Sphingobacterium multivorum 1 0 1 0 
MT14 13 
Morgan Creek 
Downstream 
KLEBSIELLA 1 Sphingobacterium multivorum 1 0 1 0 
NT01 12 Jordan Lake KLEBSIELLA 1 Stenotrophomonas maltophilia 1 0 1 0 
NT02 12 Jordan Lake KLEBSIELLA 1 Sphingobacterium multivorum 1 0 1 0 
NT03 12 Jordan Lake KLEBSIELLA 1 Stenotrophomonas maltophilia 1 0 1 0 
NT04 12 Jordan Lake KLEBSIELLA 1 Stenotrophomonas maltophilia 1 0 0 1 
NT05 12 Jordan Lake KLEBSIELLA 1 Sphingobacterium multivorum 1 0 1 0 
NT06 13 Jordan Lake KLEBSIELLA 1 Ochrobactrum anthropi 1 0 0 1 
NT07 13 Jordan Lake KLEBSIELLA 1 Ralstonia insidosa 1 0 0 1 
NT08 13 Jordan Lake KLEBSIELLA 1 Stenotrophomonas maltophilia 1 0 1 0 
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KPC 
Code 
Week Site KPC ID 
MALDI 
– TOF 
MALDI-TOF Result 
Modified 
Hodge Test  
KPC (+) 
Producer 
KPC(-R) 
Intermediate 
KPC (-) 
Negative 
OE02 8 H1 GI + MICU ECOLI 0 NO MALDI 1 0 1 0 
OE03 8 H1 GI + MICU ECOLI 0 NO MALDI 1 1 0 0 
OE04 9 H1 GI + MICU ECOLI 0 NO MALDI 1 1 0 0 
OE05 9 H1 GI + MICU ECOLI 0 NO MALDI 1 0 0 1 
OE06 10 H1 GI + MICU ECOLI 0 NO MALDI 1 1 0 0 
OE07 10 H1 GI + MICU ECOLI 0 NO MALDI 1 1 0 0 
OE08 10 H1 GI + MICU ECOLI 0 NO MALDI 1 0 1 0 
OE09 10 H1 GI + MICU ECOLI 0 NO MALDI 1 1 0 0 
OE11 13 H1 GI + MICU ECOLI 0 NO MALDI 1 1 0 0 
OT01 8 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT02 8 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT02 - 
TURQ 
8 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT03 8 H1 GI + MICU KLEBSIELLA 1 Ochrobactrum anthropi 1 0 1 0 
OT04 8 H1 GI + MICU KLEBSIELLA 1 Citrobacter freundii 1 1 0 0 
OT05 8 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT06 8 H1 GI + MICU KLEBSIELLA 1 Klebsiella oxytoca 1 1 0 0 
OT07 8 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT08 9 H1 GI + MICU KLEBSIELLA 1 Citrobacter freundii / werkmanii 1 1 0 0 
OT09 9 H1 GI + MICU KLEBSIELLA 1 Serratia marcescens 1 1 0 0 
OT10 9 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT11 9 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT12 9 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT13 10 H1 GI + MICU KLEBSIELLA 1 Citrobacter freundii 1 1 0 0 
OT14 10 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT14 - 
Turq 
10 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT15 10 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT16 10 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT16 - 
TURQ 
10 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
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KPC 
Code 
Week Site KPC ID 
MALDI 
– TOF 
MALDI-TOF Result 
Modified 
Hodge Test  
KPC (+) 
Producer 
KPC(-R) 
Intermediate 
KPC (-) 
Negative 
OT17 10 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT17 - 
TURQ 
10 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT18 11 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT19 12 H1 GI + MICU KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 1 0 0 
OT20 12 H1 GI + MICU KLEBSIELLA 1 Citrobacter freundii 1 1 0 0 
OT21 12 H1 GI + MICU KLEBSIELLA 1 Citrobacter freundii 1 1 0 0 
OT22 12 H1 GI + MICU KLEBSIELLA 1 Citrobacter freundii 1 1 0 0 
OT23 12 H1 GI + MICU KLEBSIELLA 1 Citrobacter amalonaticus 1 1 0 0 
OT23 - 
PINK 
12 H1 GI + MICU KLEBSIELLA 1 Citrobacter amalonaticus 1 1 0 0 
OT24 12 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT24 - 
TURQ 
12 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT25 12 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT25 - 
TURQ 
12 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT26 12 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT27 12 H1 GI + MICU KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 1 0 0 
OT28 13 H1 GI + MICU KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 0 0 1 
OT28 - 
PINK 
13 H1 GI + MICU KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 1 0 0 
OT29 13 H1 GI + MICU KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 0 1 0 
OT30 13 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT31 13 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT31 - 
TURQ 
13 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT32 13 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT32 - 
TURQ 
13 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT33 13 H1 GI + MICU KLEBSIELLA 1 Citrobacter freundii 1 1 0 0 
OT34 13 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
OT34 - 
turq 
13 H1 GI + MICU KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
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KPC 
Code 
Week Site KPC ID 
MALDI 
– TOF 
MALDI-TOF Result 
Modified 
Hodge Test  
KPC (+) 
Producer 
KPC(-R) 
Intermediate 
KPC (-) 
Negative 
PE01 8 
H2 Burn + Lab + 
ICU 
ECOLI 1 Escherichia coli 1 0 1 0 
PE02 9 
H2 Burn + Lab + 
ICU 
ECOLI 0 NO MALDI 1 1 0 0 
PE03 9 
H2 Burn + Lab + 
ICU 
ECOLI 0 NO MALDI 1 0 1 0 
PE04 9 
H2 Burn + Lab + 
ICU 
ECOLI 0 NO MALDI 1 0 1 0 
PE05 9 
H2 Burn + Lab + 
ICU 
ECOLI 0 NO MALDI 1 0 1 0 
PE06 9 
H2 Burn + Lab + 
ICU 
ECOLI 0 NO MALDI 1 0 1 0 
PE07 9 
H2 Burn + Lab + 
ICU 
ECOLI 1 Stenotrophomonas maltophilia 1 0 1 0 
PE08 10 
H2 Burn + Lab + 
ICU 
ECOLI 0 NO MALDI 1 0 0 1 
PE09 10 
H2 Burn + Lab + 
ICU 
ECOLI 0 NO MALDI 1 0 1 0 
PE10 10 
H2 Burn + Lab + 
ICU 
ECOLI 0 NO MALDI 1 0 1 0 
PE11 10 
H2 Burn + Lab + 
ICU 
ECOLI 0 NO MALDI 1 0 1 0 
PE12 10 
H2 Burn + Lab + 
ICU 
ECOLI 0 NO MALDI 1 0 1 0 
PE13 11 
H2 Burn + Lab + 
ICU 
ECOLI 0 NO MALDI 1 0 0 1 
PE14 11 
H2 Burn + Lab + 
ICU 
ECOLI 0 NO MALDI 1 0 0 1 
PE15 11 
H2 Burn + Lab + 
ICU 
ECOLI 1 Klebsiella pneumoniae 1 0 1 0 
PE16 11 
H2 Burn + Lab + 
ICU 
ECOLI 0 NO MALDI 1 0 1 0 
PE17 12 
H2 Burn + Lab + 
ICU 
ECOLI 1 Klebsiella pneumoniae 1 0 1 0 
PT01 8 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Serratia marcescens 1 0 1 0 
PT02 9 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Serratia marcescens / odifera 1 0 1 0 
PT03 9 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Serratia marcescens / odifera 1 0 1 0 
PT03A 9 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Serratia marcescens / odifera 1 0 1 0 
PT06 10 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Klebsiella oxytoca 1 0 0 1 
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KPC 
Code 
Week Site KPC ID 
MALDI 
– TOF 
MALDI-TOF Result 
Modified 
Hodge Test  
KPC (+) 
Producer 
KPC(-R) 
Intermediate 
KPC (-) 
Negative 
PT07 10 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Serratia marcescens / odifera 1 0 1 0 
PT07A
/NF 
10 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Serratia marcescens / odifera 1 1 0 0 
PT08 10 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 0 NO MALDI 1 0 0 1 
PT09 10 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 0 NO MALDI 1 0 1 0 
PT10 10 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Serratia marcescens 1 0 0 1 
PT11 11 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
PT11/
NF 
11 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
PT12 11 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
PT13 11 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
PT14 11 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
PT15 11 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
PT16 12 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Serratia marcescens / odifera 1 0 1 0 
PT17 12 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Klebsiella pneumoniae 1 0 1 0 
PT18 12 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Klebsiella pneumoniae 1 1 0 0 
PT19 12 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Citrobacter amalonaticus 1 0 0 1 
PT20 12 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Cronobacter turicensis 1 0 0 1 
PT21 12 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Citrobacter amalonaticus 1 0 0 1 
PT22 12 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Citrobacter amalonaticus / farmeri 1 0 0 1 
PT23 13 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 1 0 0 
PT24 13 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Serratia marcescens 1 0 0 0 
PT25 13 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Serratia marcescens / odifera 0 0 0 0 
PT26 13 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Serratia marcescens 1 0 1 0 
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KPC 
Code 
Week Site KPC ID 
MALDI 
– TOF 
MALDI-TOF Result 
Modified 
Hodge Test  
KPC (+) 
Producer 
KPC(-R) 
Intermediate 
KPC (-) 
Negative 
PT27 13 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Serratia marcescens 1 0 1 0 
PT28 13 
H2 Burn + Lab + 
ICU 
KLEBSIELLA 1 Serratia marcescens / odifera 0 0 0 0 
QE01 8 H3 Heart + ICU ECOLI 0 NO MALDI 1 0 1 0 
QE02 8 H3 Heart + ICU ECOLI 0 NO MALDI 1 0 1 0 
QE03 8 H3 Heart + ICU ECOLI 0 NO MALDI 1 0 1 0 
QE04 9 H3 Heart + ICU ECOLI 0 NO MALDI 1 0 0 1 
QE06 10 H3 Heart + ICU ECOLI 0 NO MALDI 1 0 0 1 
QE08 10 H3 Heart + ICU ECOLI 0 NO MALDI 1 0 0 1 
QE10 10 H3 Heart + ICU ECOLI 0 NO MALDI 1 0 1 0 
QE12 10 H3 Heart + ICU ECOLI 0 NO MALDI 1 0 1 0 
QE14 12 H3 Heart + ICU ECOLI 0 NO MALDI 1 0 1 0 
QE15 12 H3 Heart + ICU ECOLI 0 NO MALDI 1 0 1 0 
QE17 12 H3 Heart + ICU ECOLI 0 NO MALDI 1 0 1 0 
QT01 9 H3 Heart + ICU KLEBSIELLA 1 Serratia marcescens 1 0 1 0 
QT02 9 H3 Heart + ICU KLEBSIELLA 0 NO MALDI 1 1 0 0 
QT02A 9 H3 Heart + ICU KLEBSIELLA 0 NO MALDI 1 1 0 0 
QT03 9 H3 Heart + ICU KLEBSIELLA 1 Serratia marcescens 1 0 1 0 
QT04 9 H3 Heart + ICU KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 0 1 0 
QT05 9 H3 Heart + ICU KLEBSIELLA 1 Serratia marcescens / odifera 1 1 0 0 
QT06 9 H3 Heart + ICU KLEBSIELLA 1 Serratia marcescens / odifera 1 1 0 0 
QT07 9 H3 Heart + ICU KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 1 0 0 
QT08 9 H3 Heart + ICU KLEBSIELLA 1 Staphylococcus epidermidis 1 0 1 0 
QT09 9 H3 Heart + ICU KLEBSIELLA 1 Serratia marcescens / odifera 1 0 1 0 
QT10 10 H3 Heart + ICU KLEBSIELLA 1 Serratia marcescens 1 0 0 1 
QT11 10 H3 Heart + ICU KLEBSIELLA 1 Serratia marcescens 1 0 1 0 
QT13 12 H3 Heart + ICU KLEBSIELLA 0 NO MALDI 1 0 1 0 
QT14 12 H3 Heart + ICU KLEBSIELLA 1 Stenotrophomonas maltophilia 1 0 1 0 
QT15 12 H3 Heart + ICU KLEBSIELLA 1 Pseudomonas putida 1 0 1 0 
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KPC 
Code 
Week Site KPC ID 
MALDI 
– TOF 
MALDI-TOF Result 
Modified 
Hodge Test  
KPC (+) 
Producer 
KPC(-R) 
Intermediate 
KPC (-) 
Negative 
QT16 12 H3 Heart + ICU KLEBSIELLA 0 NO MALDI 1 0 1 0 
RE02 8 H4 ER + Neuro ECOLI 1 Aeromonas hydrophila / caviae 1 1 0 0 
RE03 9 H4 ER + Neuro ECOLI 1 Serratia marcescens 1 0 0 1 
RE04 9 H4 ER + Neuro ECOLI 1 Ralstonia mannitolityca 1 1 0 0 
RE05 9 H4 ER + Neuro ECOLI 1 Citrobacter braakii / werkmanii 1 1 0 0 
RE06 9 H4 ER + Neuro ECOLI 0 NO MALDI 1 0 1 0 
RE07 9 H4 ER + Neuro ECOLI 1 Citrobacter amalonaticus 1 0 1 0 
RE08 10 H4 ER + Neuro ECOLI 1 Stenotrophomonas maltophilia 1 0 1 0 
RE09 10 H4 ER + Neuro ECOLI 1 Stenotrophomonas maltophilia 1 0 1 0 
RE11 10 H4 ER + Neuro ECOLI 1 Ochrobactrum anthropi 1 0 1 0 
RE13 12 H4 ER + Neuro ECOLI 1 Enterobacter cloacae / asburiae 1 1 0 0 
RE14 12 H4 ER + Neuro ECOLI 0 NO MALDI 1 0 1 0 
RE15 13 H4 ER + Neuro ECOLI 1 Citrobacter freundii 1 1 0 0 
RE16 13 H4 ER + Neuro ECOLI 1 Stenotrophomonas maltophilia 1 0 1 0 
RE17 13 H4 ER + Neuro ECOLI 1 Citrobacter werkmanii 1 0 0 1 
RE18 13 H4 ER + Neuro ECOLI 0 NO MALDI 1 0 1 0 
RT01 8 H4 ER + Neuro KLEBSIELLA 0 NO MALDI 1 0 1 0 
RT03 8 H4 ER + Neuro KLEBSIELLA 0 NO MALDI 1 1 0 0 
RT04 8 H4 ER + Neuro KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 0 0 1 
RT05 9 H4 ER + Neuro KLEBSIELLA 0 NO MALDI 1 1 0 0 
RT06 9 H4 ER + Neuro KLEBSIELLA 0 NO MALDI 1 1 0 0 
RT07 9 H4 ER + Neuro KLEBSIELLA 1 
Raoultella planticola / 
ornithinolytica 
1 0 0 1 
RT08 9 H4 ER + Neuro KLEBSIELLA 0 NO MALDI 1 1 0 0 
RT09 9 H4 ER + Neuro KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 1 0 0 
RT10 9 H4 ER + Neuro KLEBSIELLA 1 
Raoultella planticola / 
ornithinolytica 
1 0 0 1 
RT11 10 H4 ER + Neuro KLEBSIELLA 0 NO MALDI 1 0 1 0 
RT12 10 H4 ER + Neuro KLEBSIELLA 0 NO MALDI 1 1 0 0 
RT13 10 H4 ER + Neuro KLEBSIELLA 0 NO MALDI 1 0 0 1 
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KPC 
Code 
Week Site KPC ID 
MALDI 
– TOF 
MALDI-TOF Result 
Modified 
Hodge Test  
KPC (+) 
Producer 
KPC(-R) 
Intermediate 
KPC (-) 
Negative 
RT14 10 H4 ER + Neuro KLEBSIELLA 0 NO MALDI 1 0 0 1 
RT15 10 H4 ER + Neuro KLEBSIELLA 0 NO MALDI 1 0 1 0 
RT17 12 H4 ER + Neuro KLEBSIELLA 1 Serratia marcescens / odifera 1 0 1 0 
RT18 12 H4 ER + Neuro KLEBSIELLA 1 Citrobacter amalonaticus 1 0 0 1 
RT19 12 H4 ER + Neuro KLEBSIELLA 1 Serratia marcescens 1 0 1 0 
RT20 12 H4 ER + Neuro KLEBSIELLA 0 NO MALDI 1 0 1 0 
RT21 12 H4 ER + Neuro KLEBSIELLA 1 Klebsiella oxytoca 1 1 0 0 
RT22 13 H4 ER + Neuro KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 1 0 0 
RT23 13 H4 ER + Neuro KLEBSIELLA 0 NO MALDI 1 1 0 0 
RT24 13 H4 ER + Neuro KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 1 0 0 
RT25 13 H4 ER + Neuro KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 1 0 0 
RT26 13 H4 ER + Neuro KLEBSIELLA 1 Enterobacter cloacae / asburiae 1 1 0 0 
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APPENDIX 5 – KPC MALDI-TOF MS AND VITEK 2 RESULTS 
S = Susceptible  I = Intermediate  R = Resistant based on MIC  R* = Resistant based on other phenotypic properties (VITEK Software Determined) 
KPC(+) = Positive KPC Production   KPC(R-) = “Intermediate” KPC production   KPC(-) = Negative for KPC Production     (.) = Not applicable 
KPC Code Site MALDI-TOF Result 
Cefpodoxime  Imipenem  
Hodge Results 
MIC S/I/R MIC S/I/R 
KT16 Secondary Effluent Escherichia coli <=0.25 S 2* S KPC(-) 
KT24 Secondary Effluent Klebsiella pneumoniae 2 R* 4 R* KPC(-R) 
KT35A Secondary Effluent Enterobacter cloacae / asburiae >=8 R 8 I KPC(-R) 
KT35B Secondary Effluent Enterobacter cloacae / asburiae >=8 R 8 I KPC(-R) 
LT02 Morgan Creek Upstream Ochrobactrum anthropi >=8 R 4 S KPC(-R) 
LT04 Morgan Creek Upstream Ochrobactrum anthropi >=8 R 4 S KPC(-R) 
LT05 Morgan Creek Upstream Ochrobactrum anthropi 4 I 2 S KPC(-R) 
LT07 Morgan Creek Upstream Ochrobactrum anthropi >=8 R 4 S KPC(-R) 
LT10 Morgan Creek Upstream Sphingobacterium multivorum >=8 R >=16 R KPC(-) 
LT11 Morgan Creek Upstream Sphingobacterium multivorum >=8 R >=16 R KPC(-R) 
MT04 Morgan Creek Downstream Pseudomonas chororaphis / fluorescens >=8 R >=16 R KPC(-R) 
MT05 Morgan Creek Downstream Ochrobactrum anthropi >=8 R 2 S KPC(-) 
MT06 Morgan Creek Downstream Ochrobactrum anthropi >=8 R 2 S KPC(-R) 
MT07 Morgan Creek Downstream Ochrobactrum anthropi >=8 R 2 S KPC(-) 
MT08 Morgan Creek Downstream Stenotrophomonas maltophilia Not of clinical significance KPC(-R) 
MT09 Morgan Creek Downstream Ochrobactrum anthropi >=8 R 2 S KPC(-) 
MT11 Morgan Creek Downstream Elizabethkingia meningoseptica >=8 R >=16 R KPC(-R) 
MT12 Morgan Creek Downstream Stenotrophomonas maltophilia Not of clinical significance KPC(-R) 
MT13 Morgan Creek Downstream Sphingobacterium multivorum 4 I >=16 R KPC(-R) 
NT01 Jordan Lake Stenotrophomonas maltophilia Not of clinical significance KPC(-R) 
NT02 Jordan Lake Sphingobacterium multivorum >=8 R >=16 R KPC(-R) 
NT03 Jordan Lake Stenotrophomonas maltophilia Not of clinical significance KPC(-R) 
NT05 Jordan Lake Sphingobacterium multivorum >=8 R >=16 R KPC(-R) 
NT06 Jordan Lake Ochrobactrum anthropi 1 S <=1 S KPC(-) 
NT07 Jordan Lake Ralstonia insidiosa 4 I 4 S KPC(-) 
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KPC Code Site MALDI-TOF Result 
Cefpodoxime  Imipenem  
Hodge Results 
MIC S/I/R MIC S/I/R 
NT08 Jordan Lake Stenotrophomonas maltophilia Not of clinical significance KPC(-R) 
RT04 H4 ER + Neuro Enterobacter cloacae/asburiae 4 I 4 S KPC(-) 
RT07 H4 ER + Neuro Raoultella planticola/ornithinolytica >=8 R 8 I KPC(-) 
RT10 H4 ER + Neuro Raoultella planticola/ornithinolytica >=8 R 4 S KPC(-) 
RT18 H4 ER + Neuro Citrobacter amalonaticus >=8 R 4 S KPC(-) 
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